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ABSTRACT 
 
Type 1 Diabetic Heart: Examination of Mitochondrial structure and microRNAS 
     Dharendra Thapa 
 
 Cardiac complications such as diabetic cardiomyopathy are the leading cause of 
morbidity and mortality in patients with diabetes mellitus.  Dysfunctional mitochondria, an effect 
associated with cardiomyopathy, are central in the pathogenesis of type 1 diabetes mellitus. 
Cardiac mitochondria are comprised of two spatially located mitochondria including 
mitochondria located beneath the sarcolemma, termed subsarcolemmal mitochondria (SSM) and 
those located in between myofibrils, termed interfibrillar mitochondria (IFM). Mitochondrial 
subpopulations have been shown to respond differently to pathological and physiological stimuli 
as reported in a review published by our laboratory. IFM mitochondria are most impacted in a 
type 1 diabetic setting. Proteomic alterations in cardiac mitochondria during a diabetic insult 
reveal impact primarily on IFM on nuclear-encoded mitochondrial proteins, a finding that has 
been previously reported by our laboratory. Alterations of proteins encoded by the mitochondrial 
genome have not been observed in our proteomics. Further, regulation of nuclear-encoded 
proteins by microRNAs (miRNAs) has been previously reported by our laboratory. MiRNAs are 
22 nucleotide long post-transcriptional regulators with a 7 nucleotide seeding region specific to 
complementary sequences in the mRNA.  More than 30% of all proteins are regulated by 
miRNAs and one miRNA has the potential to regulate the expression of multiple proteins. The 
potential regulation of mitochondrial genome encoded proteins by miRNAs has yet to be 
investigated in mitochondrial subpopulations during diabetes. Among the altered nuclear 
encoded proteins in type 1 diabetic IFM is structural protein known as mitofilin. Mitofilin is an 
inner mitochondrial membrane structural protein, well established for its role in maintaining 
cristae morphology and structure. It is a central component of the mitochondrial contact site and 
cristae organizing system (MICOS) complex. Interactions of mitofilin with outer and inner 
membrane proteins have been reported to be crucial for mitochondrial membrane organization, 
cristae integrity and inner membrane architecture. Moreover, MICOS has been shown to function 
in concert with ATP synthase dimers. However, association of mitofilin with ATP synthase 
subunits is not known. Moreover, literature examining association of mitofilin and regulation of 
mitochondrial genome by miRNAs in type 1 diabetic insult is sparse. Also, the impact of 
diabetes mellitus on mitofilin protein interactions, mitochondrial structure and function are 
currently unclear. It is specifically unknown whether overexpression of mitofilin aids in 
alleviating complications associated with diabetic cardiomyopathy. The goal of the present 
studies was to determine novel association of mitofilin and the impact of mitofilin 
overexpression upon mitochondrial structure and function. Further, regulation of mitochondrial 
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genome by mitochondrial miRNAs (mitomiRs) has been investigated. The overall hypothesis of 
this application is that alterations of cristae morphology, inner membrane organization and 
mitochondrial dysfunction observed during type 1 diabetic insult are associated with decrements 
in mitofilin content as well as translational regulation of mitochondrial encoded proteins due to 
altered levels of mitochondrial miRNAs (mitomiRs). Type 1 diabetes mellitus was induced in 
five weeks old mice with multiple low dose injections of streptozotocin (STZ) for five 
consecutive days. Five weeks post hyperglycemic onset, hearts were excised and mitochondrial 
subpopulations isolated for further studies. Using a gel based technique, mitochondrial proteins 
immunoprecipitated with mitofilin were subjected to LC-ESI-MS analysis. Proteins from all 
electron transport chain complexes, structural proteins and proteins involved in protein import 
were identified in an immunoprecipitated complex. Association of mitofilin with F0 -ATP 
synthase subunit b (ATP5F1) was decreased in the diabetic IFM when compared with control. 
Moreover, interaction of mitofilin with coiled-coil-helix coiled-coil-helix domain 3 (CHCHD3) 
trended towards decreased in diabetic IFM. A transgenic mouse line overexpressing mitofilin 
was generated and utilized to investigate the role of mitofilin overexpression in mitochondrial 
structure and function. Restoration of ejection fraction and fractional shortening was observed in 
mitofilin diabetic mice as compared to wild-type controls (P<0.05 for both). Decrements 
observed in electron transport chain (ETC) complexes I, III, IV and V activities, state 3 
respiration, lipid peroxidation as well as mitochondria membrane potential in type 1 diabetic 
IFM were restored in mitofilin diabetic mice (P<0.05 for all). Qualitative analyses of electron 
micrographs revealed restoration of mitochondrial cristae structure in mitofilin diabetic mice as 
compared to wild-type controls. Furthermore measurement of mitochondrial internal complexity 
using flow cytometry displayed significant reduction in internal complexity in diabetic IFM 
which was restored in mitofilin diabetic IFM (P<0.05). No significant changes in mitochondrial 
dynamic regulating proteins or mitochondrial DNA content were observed. Examination of 
mitochondrial miRNAs was performed using microarray technology coupled with cross-linking 
immunoprecipitation and next generation sequencing, we identified a functional pool of 
mitochondrial microRNAs, termed mitomiRs that are redistributed in spatially-distinct 
mitochondrial subpopulations in an inverse manner following diabetic insult.  Redistributed 
mitomiRs displayed distinct interactions with the mitochondrial genome requiring specific 
stoichiometric associations with RISC constituents argonaute-2 (Ago2) and fragile X mental 
retardation–related protein 1 (FXR1) for translational regulation.  In the presence of Ago2 and 
FXR1, redistribution of mitomiR-378 to the IFM following diabetic insult led to down regulation 
of mitochondrially-encoded F0 component (ATP6). Next generation sequencing analyses 
identified specific transcriptome and mitomiR sequences associated with ATP6 regulation.  
Overexpression of mitomiR-378 in HL-1 cells resulted in its accumulation in the mitochondrion 
and down-regulation of functional ATP6 protein, while antagomir blockade restored functional 
ATP6 protein and contractile function. The results reveal the requirement of RISC constituents in 
the mitochondrion for functional mitomiR translational regulation and provide a connecting link 
between diabetic insult and ATP synthase function. Taken together, the studies highlighted 
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above show that mitochondrial dysfunction observed during type 1 diabetic insult could be due 
to multiple reasons including decrements in mitofilin content and dysregulation of mitomiRs in 
IFM subpopulations. Overexpression of mitofilin targeted to restore mitochondrial structure and 
utilization of anatogomir target at mitomiR-378 both restored mitochondrial functionality and 
cardiac contractile function during type 1 diabetic insult.  
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SPECIFIC AIMS 
Diabetic cardiomyopathy, characterized by contractile dysfunction, independent of 
atherosclerosis, is the leading cause of heart failure in patients with diabetes mellitus (5). 
Dysfunctional mitochondria are central to the pathogenesis of diabetes mellitus (4, 11, 12). The 
inner mitochondrial membrane (IMM) is comprised of the inner boundary membrane and cristae 
membranes (9, 15). Mitofilin, a relatively unstudied inner mitochondrial membrane structural 
protein controls cristae morphology and is a central component of the mitochondrial inner 
membrane organizing system or mitochondrial organizing structure (MitOS)  (7, 8, 13) more 
recently named as mitochondrial contact site and cristae organizing system (MICOS) (10). 
Moreover, interactions of mitofilin with outer and inner membrane proteins have been reported 
to be crucial for membrane organization and protein biogenesis (1, 6, 13, 14). MICOS has also 
been shown to function in concert with ATP synthase dimers (7) and results from our laboratory 
reveal novel interactions of mitofilin with ATP synthase F0 subunits. Study of mitochondria in 
cardiac tissue is complicated by the presence of two spatially distinct subpopulations, 
subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM). Proteomic studies 
show a significant decrease of mitofilin in diabetic IFM (2) and other key proteins in the electron 
transport chain complexes (ETC). MicroRNAs (miRNAs) have been shown to regulate nuclear 
encoded proteins (3)  but translational regulation of mitochondrial-genome encoded proteins 
have not been examined yet. There is a gap in knowledge as to examining the mitochondrial 
mechanisms affected by loss of mitofilin and regulation of mitochondrially-encoded proteins by 
miRNAs. Moreover, literature examining these mechanisms in type 1 diabetic insult is sparse. 
Also, the impact of diabetes mellitus on mitofilin protein interactions, mitochondrial structure 
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and function are currently unclear. It is specifically unknown whether overexpression of 
mitofilin aids in alleviating complications associated with diabetic cardiomyopathy.  
Our long term goal is to better understand the mechanisms involved in the pathogenesis 
of diabetes mellitus for developing therapeutic interventions to protect against diabetic 
cardiomyopathy.  The objectives of this application are: (1) to determine the impact of type 1 
diabetes mellitus on mitofilin interactions with MINOS components and investigate novel 
associations of mitofilin with ATP synthase F0 subunits in mitochondrial subpopulations, (2) to 
determine the novel therapeutic benefit of mitofilin overexpression in mitochondrial morphology 
and cardiac function during a diabetic insult, and (3) examine and investigate mitochondrial 
miRNAs and their potential roles in translational regulation of the mitochondrial genome-
encoded proteins during type 1 diabetes mellitus.  
The central hypothesis of this application is that alterations of cristae morphology, inner 
membrane organization and mitochondrial dysfunction observed during type 1 diabetic insult are 
associated with decrements in mitofilin content as well as translational regulation of 
mitochondrial encoded proteins due to altered levels of mitochondrial miRNAs (mitomiRs). 
These effects are more pronounced in the diabetic IFM and influences cardiac contractile 
processes. Our rationale for the proposed research is based on the absolute importance of 
preserving IMM morphology and mitochondrial genome encoded proteins to attenuate 
mitochondrial dysfunction observed during type 1 diabetic insult. We anticipate being able to 
identify morphological and functional alterations in mitochondrial subpopulations and 
investigate areas at risk. The outcomes of this research application will provide insight in 
understanding the importance of preserved mitochondrial structure as well as potential roles of 
mitomiRs in regulating mitochondrial genome during diabetic cardiomyopathy, thus, further 
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aiding in the development of therapeutic interventions geared towards mitochondrial 
subpopulations at risk during type 1 diabetes mellitus. The objectives and central hypothesis of 
this application will be tested by pursuing the following specific aims: 
Specific Aim I: Determine the impact of type 1 diabetes mellitus on interaction of mitofilin 
with the MINOS components and investigate novel associations of mitofilin with ATP 
synthase F0 subunits.
In order to address Specific aim I, we will utilize immunoprecipitation in conjunction 
with mass spectrometry to identify novel proteins pulled down with mitofilin. Our working 
hypothesis is that type 1 diabetes mellitus will decrease mitofilin content resulting in damaged 
mitochondrial structure and decreased ATP synthase activity as a result of decreased association 
of mitofilin with MINOS components and ATP synthase F0 subunits respectively. The effects 
will be more pronounced in IFM. 
  
So as to address this aim, we will utilize a novel mitofilin over expression transgenic 
animal generated in our laboratory. Further, we will examine mitochondrial morphology, 
dynamics, DNA content, functionality and ultimately cardiac contractile function during type 1 
diabetic insult. Our working hypothesis is that overexpression of mitofilin will preserve 
mitochondrial and cardiac function through improved cristae morphology, and mitochondrial 
function during type 1 diabetes mellitus, particularly in the IFM. 
Specific Aim II: Evaluate the therapeutic benefit of mitofilin overexpression in 
mitochondrial morphology, function and cardiac function, following a type 1 diabetic 
insult. Further, determine if the effect is subpopulation specific.  
xx 
 
Specific Aim III: 
 Regulation of nuclear encoded genome proteins by miRNAs have been previously 
studied and reported by our laboratory. However, examination and presence of miRNAs in the 
mitochondrial subpopulations and their potential role in regulating mitochondrial genome-
encoded proteins have not been studied. In order to assess this Specific Aim III, we will conduct 
microarrays experiments in control and diabetic cardiac subpopulations and analyze the miRNAs 
that are altered in type 1 diabetic phenotype. Our working hypothesis is that the miRNA profile 
will be altered in the diabetic IFM (subpopulation more affected by the disease phenotype) which 
will lead to decrements in mitochondrially-encoded proteins and hence function. Further, 
targeting of altered miRNAs by anatgomir treatment will lead to restoration of protein and 
associated mitochondrial functionality. 
Examine and investigate mitochondrial miRNAs and their potential roles 
in translational regulation of the mitochondrial genome-encoded proteins during type 1 
diabetes mellitus.  
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1.1 Diabetes Mellitus 
Diabetes Mellitus (DM) is a pathological condition characterized by lack of insulin (Type 
1 DM) or resistance to insulin (Type 2 DM) production. Type 1 DM accounts for 10% of all 
cases and type 2 DM is the more prevalent form accounting for 90% of all cases (141). DM is 
characterized by chronic hyperglycemia which is associated with damage and failure of different 
organs including the heart, eyes, kidney and blood vessels. If left untreated, both types of DM 
manifest various complications and ultimately result in death.  Lesser known types of DM 
constitute gestational diabetes that occurs during pregnancies and DM resulting from genetic 
defects, surgeries, medicine as well as other pancreatic diseases. A fasting blood glucose level 
over 126 mg/dl suggests impaired glucose tolerance and is the criterion used to diagnose DM 
(155). 
 
1.1a Type 1 DM 
Type 1 DM (T1DM) also referred to as insulin dependent DM is caused by an absolute 
deficiency of insulin as a result of autoimmune destruction of pancreatic beta cells (81). Because 
of its majority of diagnoses occurring in children and young adults (19) it is also known as 
juvenile-onset diabetes. In addition to genetic predisposition, other environmental factors like 
viral infections, low birth weight, parental age and nutritional factors have also been associated 
with the development of T1DM (2). The main course of treatment used for T1DM is to monitor 
blood glucose level regularly and inject with artificial insulin prior to eating. Insulin deficiency 
as observed during T1DM increases ketone bodies in the liver and causes diabetic ketoacidosis, a 
metabolic complication characterized by hyperglycemia, ketosis and acidosis (48) which is fatal 
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if left untreated (32). Patients with T1DM are also prone to other autoimmune disorders like 
Graves’ disease, Addison’s disease, vitiligo, autoimmune hepatitis and pernicious anemia (1). 
All these manifestations observed during T1DM are associated with hyperglycemic environment 
observed during DM and there is no known prevention of T1DM. 
 
1.1b Significance            
Cardiac failure is the leading cause of mortality in patients with diabetes mellitus in the 
United States (63). In 2000, over 171 million people worldwide were suffering from diabetes 
mellitus, with an estimate of 366 million by the year 2030 (172). Over 40% of the population 20 
years or older in United States are hyperglycemic (35). According to the National Diabetes 
Statistics Report, as of 2012, 29.1 million Americans are diabetic and the total direct and indirect 
cost of diagnosed DM is $245 billion. These staggering statistics implicate the necessity for 
investigating potential therapeutic interventions and vindicates the importance of studying 
diabetic cardiomyopathy, an increasingly prevalent diagnosis in heart failure (13). Moreover, 
mitochondrial dysfunction is central in the pathogenesis of diabetic cardiomyopathy due to its 
role in ATP production for cardiac contractile processes and electrolytes transport.  
 
1.2 Diabetic Cardiomyopathy 
Diabetic cardiomyopathy, characterized by contractile dysfunction independent of 
atherosclerosis, is the leading cause of heart failure in patients with diabetes mellitus (27). A 
number of clinical, epidemiological, pathological and animal studies have examined and 
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suggested the existence of diabetic heart disease irrespective of hypertension and coronary artery 
disease (CAD) (68, 113, 132, 137). In a clinical setting, Rubler et. al (137) was the first to 
examine and acknowledge the presence of diabetic cardiomyopathy in diabetic patients with 
congestive heart failure without  coronary atherosclerosis and hypertension. Existence of diabetic 
cardiomyopathy was further strengthened by a study examining four diabetic patients without 
CAD that showed an increase left ventricle (LV) end diastolic pressure (EDP), decreased LV 
compliance and decreased ejection fraction (EF) (132). Furthermore, studies utilizing type 1 
diabetic rat models resistant to atherosclerosis showed decreased contractile performance 
implicating diabetic cardiomyopathy (84, 159). Hence, these studies present diabetic 
cardiomyopathy as a distinct clinical entity that is solely associated with ventricular dysfunction 
in the absence of hypertension or CAD. Further characterization of diabetic cardiomyopathy 
reveals several dysfunctions in the diabetic heart including contractile dysfunction, cardiac 
structural changes, and oxidative stress (51, 141). 
 
1.2a Cardiac contractile dysfunction          
Assessment of diastolic dysfunction relies on doppler studies of transmitral inflow that 
measures mitral inflow velocities, deceleration time, and isovolumic relaxation time, and 
assessing flow patterns (51). Diastolic dysfunction has been widely reported in both diabetic 
animals (62, 140) and patients (129, 130) without any other factors contributing to heart disease. 
A study examining influence of diabetes on contractile performance of rat myocardium show 
diastolic dysfunction characterized by prolongation of relaxation and considerable slowing in 
relaxation velocity (21). Similarly, perfused diabetic rat hearts showed prolonged isovolumic 
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relaxation time and increases in later mitral inflow velocity and LV EDP (85). Assessment of 
diastolic function in thirty diabetic male rats in comparison with control showed significant 
decrements in early to late diastolic mitral inflow velocity ratio and isovolumic relaxation time 
(44). The authors suggest that the presence of diastolic dysfunction in diabetic hearts might relate 
to uncoupling of the contractile apparatus without increments in chamber thickness. A study 
comprising eighty seven young T1DM patients without known cardiac disease displayed reduced 
early peak mitral velocity, increased late peak mitral velocity, and prolonged deceleration time 
and isovolumic relaxation time compared to controls (138).  
 DM has been associated with systolic dysfunction comprising reduction in heart rate, 
systolic blood pressure, and fractional shortening (70, 74, 85, 174). Also, reduction in systolic 
LV pressure has been observed in papillary muscle isolated from type 1 diabetic mouse hearts 
(156). However, association of LV systolic dysfunction with DM has not been uniformly 
reported (58, 110, 129). Although diastolic dysfunction is observed during DM, reports of 
systolic dysfunction are varied. This discrepancy could be due to less sensitive techniques 
utilized to assess systolic dysfunction. Advancements or more sensitive techniques for systolic 
assessment such as strain, strain rate, and myocardial tissue Doppler velocity can indeed detect 
systolic abnormalities in diabetic patients (52). 
   
1.2b Structural changes in diabetes          
Structural changes, focusing on fibrosis, have been reported in both animals (78, 154) and 
humans (96, 118, 152) in parallel with functional changes of diabetic heart disease, in the 
absence of hypertension and CAD. Extracellular fibrosis and abundant TGF-β1 receptor II in LV 
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myocytes were observed in 15 wk old diabetic rats compared with control suggesting LV fibrosis 
in the early stage of the disease (113). In an autopsy study comprising 9 diabetic hearts, six with 
heart failure, Regan et al. reported increased interstitial fibrosis in diabetic hearts (132). Similar 
morphological alterations were observed by Nunoda et al. who reported a higher percentage of 
interstitial fibrosis in diabetic patients without hypertension or CAD (121). Mechanisms involved 
in fibrosis accumulation in the diabetic heart are not entirely elucidated. However, increased 
levels of plasma endothelian-1 (ET-1) have been associated with fibroblast accumulation in 
diabetic hearts (171). Further, enhanced levels of protein kinase C beta-1 activation have also 
been observed with increased fibrosis in streptozotocin (STZ) diabetic hearts (168). Hence, 
fibrosis plays a crucial role in the manifestation of diabetes induced cardiac dysfunction in both 
animals and humans.  
 
1.2c Oxidative stress            
Oxidative stress can be defined as an imbalance between reactive oxygen species (ROS) 
generation and antioxidant defense. Activation of renin-angiotensin system has been implicated 
in increased oxidative damage and development of diabetic cardiomyopathy during DM (45, 51, 
59).  Hyperglycemia is the primary cause of diabetic cardiomyopathy. Increased ROS production 
has been implicated to augment hyperglycemia induced activation of protein kinase C isoforms, 
formation of advanced glycation end products as well as increased flux of glucose through the 
aldose reductase pathways (22, 91) contributing to the development of cardiac complications in 
DM. Moreover, hyperglycemia has been suggested to decrease antioxidant levels in the diabetic 
hearts making it prone to ROS damage (135). Furthermore, cardiac overexpression of 
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mitochondrial superoxide dismutase (Sod2) in the type 1 diabetic heart has been shown to 
reverse altered mitochondrial structure and function (142).  Mitochondria are the major source of 
ROS production in the cardiomyocytes. Previous work from our laboratory have shown 
increased level of ROS production and oxidative damage in STZ induced T1DM (38).  
 
1.3 STZ mouse model of diabetic cardiomyopathy 
Utilization of rodent models for investigating diabetic cardiomyopathy is beneficial 
because of their resistance to atherosclerosis. This allows investigator to examine diabetic 
cardiomyopathy dysfunction without the confounding effects of atherosclerosis. STZ, a 
glucosamine-nitrosourea was first utilized for destruction of cancerous pancreatic β-cells and 
then for induction of diabetes in rodent models (3).  Because of its similarities to glucose, it is 
taken up by GLUT2 glucose transporter which is abundantly found in β-cells, causing DNA 
alkylation (139, 167). The DNA damage further leads to activation of poly ADP-ribosylation that 
causes diminished cellular NAD+ and ATP.  Further, STZ induced enhanced ATP 
dephosphorylation offers substrate for xanthine oxidase to form superoxide radical. Finally, this 
increased expression of ROS causes necrosis of β-cells diminishing insulin production (139). 
Our laboratory utilizes the protocol established by the Animal Model of Diabetic Complications 
Consortium (AMDCC). AMDCC recommends multiple low-dose (50mg/kg) of STZ injection 
over five consecutive days. Generally, mice will develop fasting hyperglycemia 7-14 days after 
the first injection of STZ (23). Our laboratory and others have reported induction of diabetic 
cardiomyopathy, including systolic and diastolic dysfunction after STZ treatment (8, 38, 119, 
151). STZ model is widely used because of the ability to induce diabetes in any rodent strains. 
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Also, diabetes can be induced at any age allowing the investigation of diabetic heart at various 
stages in the life cycle of the organism (23).  
1.4 Mitochondrial subpopulations          
With the advent of advanced imaging techniques, insight into cellular and organellar 
structure of the cardiomyocyte has provided a wealth of information for the cardiovascular 
researcher. Among these insights has been the recognition that in cardiac muscle, mitochondria 
exist in a number of different subcellular locales. This phenomenon has been corroborated in 
numerous mammalian species including mouse, rat, muskrat, guinea pig, hamster, rabbit, dog, 
pig, monkey, cow and human (39, 60, 73, 100, 112, 114, 144, 145, 147, 157).  This phenomenon 
is consistent with the evaluation of other non-cardiac cells such as neurons where functional 
heterogeneity between dendritic, somatic, axonal, and presynaptic segments due to variations in 
energy demands and calcium (Ca2+) signaling dynamics are associated with structural and 
biochemical differences in mitochondria situated in a particular neuronal region. Ultimately, this 
heterogeneity may dictate differences in pathophysiological response of various neuronal regions 
(89). As with neuronal tissue studies suggest that mitochondrial spatial location within the 
myocyte may be associated with a particular response to physiological and pathological stimuli 
(67, 87, 94, 111, 153). With the pioneering development of mitochondrial isolation techniques 
designed to sequentially fraction spatially-distinct subpopulations of mitochondria utilizing both 
mechanical and enzymatic procedures (125), efforts to define their individual roles in various 
pathological conditions has been actively pursued. Using ultrastructure analyses several 
mitochondrial subpopulations have been identified in the cardiomyocyte, including those 
residing below the sarcolemma termed subsarcolemmal mitochondria (SSM) and those residing 
between the myofibril contractile apparatus termed interfibrillar mitochondria (IFM) (Figure 1.1) 
9 
 
(75). Additionally, a specific population of mitochondria, isolated as IFM, resides in the 
perinuclear region.   
 
 
 
 
 
 
Figure 1.1 Electron micrograph depicting SSM and IFM subpopulations. 
 
1.4a Structural Differences 
Structural alterations between mitochondria located in different sub-cellular locales have 
been reported using a number of diverse experimental techniques.  Using thin sections from left 
ventricular tissue of Japanese Monkeys (Macaca fuscata), scanning electron microscopy and 
transmission electron microscopy revealed distinct populations of mitochondria including 
perinuclear mitochondria, IFM and SSM (144). Perinuclear mitochondria were clustered at the 
nuclear poles and mostly spherical in shape with lengths ranging from 0.8-1.4 μm. These 
mitochondria contained well-developed curved cristae with relatively little matrix area.  In 
addition, IFM were identified and observed in longitudinal rows between the myofibrils, 
occupying the entire space between Z-lines (54) and bookended by the junctional sarcoplasmic 
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reticulum (104)(Figure 1B). IFM were elongated in shape with usually one mitochondrion 
existing per sarcomere. IFM were approximately 1.5-2.0 μm in length and their cristae structures 
also displayed curved configurations.  Finally, SSM were located beneath the sarcolemma 
(plasma membrane) and were somewhat more variable in length (0.4-3.0 μm), possessing closely 
packed cristae. Overall, perinuclear mitochondria were smaller than IFM were in size and 
possessed a more rounded shape (104), while SSM were varied in size and shape displaying 
oval, spherical, polygonal and horse-shoe patterns (144). Others have reported similar 
ultrastructural patterns using confocal imaging of HL-1 cells in the perinuclear region, which 
contain mitochondria clustered around the nucleus (95). En bloc staining of human papillary 
muscle revealed differences in staining patterns between SSM, IFM and perinuclear 
mitochondria suggesting differences in chemical properties and metabolic activities  (41).  These 
findings are consistent with flow cytometric analyses which employ membrane-dependent dyes 
(i.e. MitoTracker Deep Red 633) coupled with flow cytometry size calibration microspheres to 
determine absolute mitochondrial size and internal granulation in both SSM and IFM (37-39, 
173). Insight into subcellular mitochondrial distribution has also been afforded by probability 
density analyses. Using a 3-D modeling approach coupled with MitoTracker Red staining 
enabling probability density and distribution, isolated rat cardiomyocytes revealed a highly 
ordered crystal-like pattern in which IFM were arranged in longitudinal rows in clefts between 
myofibrils (18). In contrast, similar analyses on rainbow trout (Oncorhynchus mykiss) 
cardiomyocytes revealed one single cylinder-shaped layer of myofibrils situated beneath the 
sarcolemma in which the mitochondrial arrangement was random and chaotic (18). Thus, species 
differences may be associated with differential mitochondrial spatial patterns in a comparative 
physiological context.  
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To gain insight into structural differences in cristae morphology, Riva and colleagues 
utilized high resolution scanning electron microscopy to examine left ventricular tissue from rat. 
SSM and IFM displayed distinct morphological patterns in terms of cristae structure with SSM 
containing primarily (77%) lamelliform cristae which are broad and flat. In contrast, IFM cristae 
morphology was somewhat mixed and variable with some mitochondria (55%) possessing only 
tubular cristae while others (24%) possessing some lamelliform cristae mixed with tubular 
cristae. Further, 21% of IFM possessed only lamelliform cristae. These authors concluded that 
most of the cristae structure in SSM were lamelliform with occasional tubular cristae, while IFM 
possessed a reciprocal pattern in which some lamelliform cristae exist despite an abundance of 
tubular cristae. These authors speculate that the individual cristae morphological patterns may 
contribute to the functional differences observed between the two subpopulations, including a 
reduction in intracristal space of tubular cristae. Further, these authors speculate that a reduction 
of intracristal space could lead to a higher concentration of protons within the structure and 
enhance ATP synthase activity, which is consistent with IFM functional differences (134). In 
addition, biochemical composition of the two cristae structures may differ in terms of lipid or 
protein contents which could ultimately influence structure (134). Indeed, examination of the 
sphingolipid pool in cardiac SSM and IFM have revealed differences in the content of ceramide, 
which was higher in the SSM (115). 
 
1.4b Functional Differences 
 In conjunction with structural differences between spatially-distinct mitochondrial 
subpopulations, numerous reports have indicated that SSM and IFM possess distinct functional 
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differences which may result from their particular subcellular locales. Mitochondria residing in 
the perinuclear region of the cell have been suggested to generate ATP that drives mitochondrial 
metabolism close to the nucleus.  In contrast, it has been hypothesized that IFM supply ATP for 
contraction, whereas SSM are involved primarily in the provision of ATP for active transport of 
electrolytes and metabolites across the sarcolemma (116, 125, 136, 144). Though these 
postulations have not been definitively determined experimentally, they are consistent with the 
concept that the spatial location of a given mitochondrion is reflective of the processes in which 
it supplies ATP and the given locale in which it resides. 
 
1.5 Pathological influence on mitochondrial subpopulations 
 Mitochondrial subpopulations residing in different sub cellular locale are differentially 
influenced during pathological insult (75).  Ischemia studies in canines show structural 
alterations in the SSM subpopulations, including decrease in membrane fluidity (145). When 
examining a rat model of chronic hypoxia (11% oxygen exposure for 14 days), Heather et al. 
observed effects in both SSM and IFM subpopulations as displayed by decreased state 3 
respiration rates (71).  Because of its crucial role in cellular processes including ROS formation, 
mitochondrial dysfunction has been implicated as a central contributor in the development of 
aged heart (40). Fannin et al. observed decreased oxidative phoshporylation (OXPHOS) rates 
and cytochrome oxidase enzyme activities in the IFM subpopulations of aged rat model when 
compared to a young model (53). Myocardial infarction studies in rats subjected to coronary 
artery ligation treatment reveal decrements in respiration rates, electron transport chain (ETC) 
complex III protein contents and activities in addition to decreased mitochondrial cytochrome c 
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levels in both SSM and IFM subpopulations (71). Ischemia and reperfusion (I/R) studies display 
mitochondrial dysfunction in both subpopulations as evidenced by decreased OXPHOS and 
ADP/ATP translocase activity in rat models undergoing 20 min of ischemia and 30 minutes of 
reperfusion (46). Studies examining exercise training and its effects on cardiac mitochondrial 
subpopulations are sparse. Aged C57BL/6J mice subjected to treadmill training protocol 
displayed increased IFM hypertrophy and loss of matrix and cristae, as well as formation of giant 
mitochondria (33). However, Fischer 344 rats subjected to long-term voluntary wheel running 
coupled with caloric restriction showed a reduction in H2O2 production and lower manganese 
superoxide dismutase (MnSOD) activities in both SSM and IFM subpopulations. Interestingly, 
these authors observed a significant increase in protein carbonylation in SSM, which was not 
observed in IFM (88). These authors suggest that the increased protein carbonylation observed in 
SSM may be related to the decreased MnSOD activity in this subpopulation. In contrast, because 
IFM possess higher antioxidant enzyme activities, a resultant increase in protein carbonylation 
was not observed despite also displaying decreased MnSOD activities (88). Numerous groups 
have investigated the effects of specific drugs on cardiac mitochondrial subpopulations. In a 
study by Duan et al. investigating the effects of verapamil in rat cardiac mitochondrial 
subpopulations, the authors report significant reversal of oxidative phosphorylation depression in 
SSM, which was induced by treatment with phosphate (47).  
 
1.5a Pathological Influence: T1DM          
Studies have examined cardiac mitochondrial subpopulations in different metabolic 
diseases including DM. Cardiovascular complications and heart disease are the leading cause of 
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morbidity and mortality in patients with DM (63). Diabetic cardiomyopathy, characterized by 
contractile dysfunction independent of atherosclerosis, is the leading cause of heart failure in 
patients with DM (76, 141, 182). DM can be characterized by lack of insulin production (T1DM) 
or resistance to insulin (T2DM).  
 We have previously shown that IFM subpopulations isolated from Swiss-Webster mice 
rendered diabetic by multi low-dose STZ injections display decreases in size and internal 
complexity as well as decrements in ETC complex I and III function. Moreover, superoxide 
production and oxidative damage to proteins and lipids are significantly higher in the type 1 
diabetic IFM (38). Indeed, we have observed decreases in cardiolipin content of type 1 diabetic 
IFM (36, 38) which was associated with decrements in cardiolipin biosynthetic pathway 
constituent cardiolipin synthase, as reflected by decreased protein and enzymatic activity in the 
IFM (36). Further, we have observed enhanced apoptotic propensity in type 1 diabetic IFM 
which was associated with increased caspase-3 and 9 activities, mPTP opening, Bax and 
cyclophilin D protein contents, with decrements in mitochondrial cytochrome c content and Bcl-
2 levels (173). Proteomic approaches utilizing isobaric tags for relative and absolute quantitation 
and two-dimensional-differential in-gel electrophoresis reveal a greater impact in IFM proteomic 
make-up during type 1 diabetic insult characterized by a decreased abundance of fatty acid 
oxidation and electron transport chain proteins. Furthermore, mitochondrial protein import is 
compromised in type 1 diabetic IFM providing a potential mechanism accounting for proteomic 
dysregulation associated with the content of nuclear-encoded mitochondrial proteins (9). 
Overexpression of mPHGPx has been shown to increase ETC complex function, attenuate H2O2 
production and lipid peroxidation in type 1 diabetic IFM. Moreover, reversal of protein import 
dysfunction and lessened proteomic loss in type 1 diabetic IFM was observed with preservation 
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of oxidative phosphorylation, tricarboxylic acid cycle and fatty acid oxidation processes as 
indicated by Ingenuity Pathway Analysis (7). Slc25a3, an inner membrane protein transporter 
involved in the provision of inorganic phosphate to the mitochondrial matrix, is decreased 
specifically in type 1 diabetic IFM, which is associated with decreased ATP synthase activity 
and ATP production (11). Fancher et al., investigating the effects of type 1 diabetes mellitus on 
the function and expression of ATP-dependent K+ channels in FVB mice, observed a decrease in 
pore forming subunit Kir6.1 in both subpopulations whereas diazoxide-sensitive sulphonylurea 
receptor SUR1 was only decreased in IFM (50). In summary, the majority of studies indicate that 
type 1 diabetes mellitus primarily affects the IFM. It is unclear as to why this phenomenon 
occurs but may be related to higher respiration rates, membrane potential and inherent protein 
import rates in the IFM subpopulation.  
 
1.6 Mitochondrial dysfunction          
Mitochondrial dysfunction has been shown to be central to the pathogenesis of T1DM. 
Cardiac abnormalities observed in diabetic cardiomyopathy has been related to mitochondrial 
dysfunction including but not limited to enhanced oxidative stress, improper calcium handling, 
and mitochondrial morphology and number. 
1.6a Mitochondrial dysfunction and oxidative stress        
Mitochondrial respiratory chain is the major source of ROS production. ROS generation 
is mainly due to electrons leakage from complexes I and III of the ETC chain thus generating 
incompletely reduced forms of oxygen (20, 150). Approximately 90% of basal cellular ROS is 
produced by the mitochondrion in the cardiomyocytes (34). Mitochondrial ROS can cause 
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cellular damage by oxidation of proteins, conversion of lipids to form lipid peroxidation 
products. Moreover, ROS can increase intracellular nitration by generating peroxynitrate (158) 
and are also involved in damage to mitochondrial DNA(166). Increased ROS generation from 
cardiac mitochondria has been examined in different T1DM animal models (38, 146, 158). 
Proteomic study examining cardiac mitochondrial proteins in alloxan-induced type 1 diabetic 
rats provided evidence of tyrosine nitration (158). Further, overexpression of metallothionein, an 
antioxidant protein have shown  reduction in nitrosative damage in STZ-treated mice (28)   as 
well as restoration of normalized levels of oxidized glutathione in OVE26 mouse model (179). 
Other studies utilizing overexpression of catalase and MnSOD display preservation of 
myocardial function and mitochondrial morphology (142, 178). Diabetic IFM subpopulations 
displayed enhanced superoxide as well as nitrotyrosine content and lipid peroxidation in STZ 
induced T1DM study by our laboratory (38). Overexpression of mPHGPx attenuated H2O2 
production and lipid peroxidation in the IFM subpopulations of STZ induced T1DM (7). 
 
1.6b Mitochondrial dysfunction and calcium handling       
Adequate amount and intricate interactions of Ca2+ and ATP is required for 
cardiomyocyte contraction. Mitochondria aid in restoration and emission of Ca2+ to regulate 
excitation-contraction coupling within the heart (83). In addition to coupling within the heart 
Ca2+ also regulates energy metabolism i.e. ATP production as well as activation of apoptosis 
through mPTP opening (66).  Indeed, in STZ induced T1DM model, lower rates of 
mitochondrial Ca2+ uptake have been observed, which is associated with development of 
hyperglycemia (56). In another study, although it was observed that calcium uptake was similar 
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in control versus diabetic animals; diabetic mitochondria were unable to retain the accumulated 
calcium uptake due to increased opening of the mPTP.  This phenomenon was absent in the 
presence of mPTP inhibitor cyclosporin (123). Similar to these findings, we have observed 
increased rates of mPTP opening as well as decreased mitochondrial cytochrome c content in 
IFM subpopulations isolated from STZ treated type 1 diabetic mice (173). Hence, Ca2+ handling 
is impaired in diabetes thus resulting in contractile abnormalities, compromised energy 
metabolism as well as enhanced mitochondria derived cellular apoptosis.  
   
1.6c Mitochondrial dysfunction and mitochondrial morphology      
Alterations of mitochondrial morphology have been observed in T1DM. Examination of 
skeletal muscle mitochondria from STZ induced diabetic rats showed a loss of cristae when 
compared to control rats (31). Morphological alterations including mitochondrial cristae 
structure, number, membranes have been examined in different models of type 1 DM. A study by 
marinara et al. examining alloxan induced diabetic rats revealed mitochondrial swelling, 
disrupted membranes and cristae structure in addition to decrements in mitochondrial number in 
heart and liver (108). Further, Shen et al. upon examination of OVE26 mouse model of type 1 
diabetes observed increased focal regions with severe mitochondrial damage in diabetic hearts 
(143). A more recent study utilizing electon microscopy to examine mitochondrial structure in 
akita mouse model of type 1 diabetes revealed decrements in mitochondrial cristae density in 
cardiac mitochondria (25). Another study by the same group showed gross mitochondrial 
structure accompanied by reduced cristae density in cardiac mitochondria (24). Interestingly, 
studies by our laboratory have shown decreases in size and internal complexity of IFM 
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subpopulations isolated form STZ induced type 1 diabetes mouse model (38). Hence, studies 
examining mitochondrial structure of type 1 diabetes mouse models show gross mitochondrial 
structure including reduced cristae structure and density suggesting structural damage to the 
inner mitochondrial membrane. 
 
1.7 Inner Mitochondrial Membrane         
The inner mitochondrial membrane (IMM)  houses the ETC complexes, OXPHOS 
machinery, metabolite carriers and enzymes of mitochondrial metabolism. IMM and the proteins 
residing in it are thus particularly susceptible to ROS damage. 
1.7a IMM sub domains                 
The IMM is composed of two morphologically distinct sub domains, the inner boundary 
membrane and the cristae membrane (107, 186). These two subdomains have been indicated as 
distinct compartments of the inner mitochondria, largely due to their asymmetric protein 
distribution (164, 175, 186). The inner boundary membrane is in close proximity to the outer 
membrane whereas the cristae membrane is composed of large tubular invaginations that 
protrude into the matrix space and is the major site for ATP production by OXPHOS (65, 164, 
175). Morphological characterization by electron microscopy reveal that the region between the 
inner boundary membrane and cristae membrane consist of narrow tubular openings with a 
distinct diameter, length and high membrane curvature known as crista junctions (107, 128, 133, 
186). A single section through 3D tomogram of mitochondrion depicts structural features along 
with the dimensions of the mitochondria (57) (Figure 1.2). A key protein residing in the inner 
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mitochondrial membrane is structural protein mitofilin, which has been well established for its 
role in cristae morphology (86). 
 
 
 
 
 
 
 
Figure 1.2 3D tomogram of the mitochondrion (57). 
 
1.8 Mitofilin  
 One of the key findings towards understanding the IMM architecture along with cristae 
morphology was the identification of mitofilin. Because of its abundance in the human heart it 
was originally termed as heart muscle protein by Icho et al. (82). Later studies identified 
mitofilin as an integral membrane protein anchored in the inner mitochondrial membrane with an 
amino-terminal transmembrane domain (64, 122). It is localized in the cristae junction (90) and 
plays a role in maintaining cristae morphology (86). Deletion of mitofilin results in altered 
cristae morphology, loss of cristae junctions as well as mitochondrial DNA (86, 128). Moreover, 
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mitofilin is a critical component of a large multi-protein complex known as mitochondrial 
contact site and cristae organizing system (MICOS) (127), which functions as a central organizer 
of mitochondrial architecture, cristae junctions and determines cristae morphology. MICOS is 
comprised of Mio10, Aim5, CHCHD3, MOMA-1 and mitofilin (4, 69, 77, 165). Interactions of 
mitofilin with outer and inner membrane proteins are crucial for mitochondrial function, protein 
biogenesis, and membrane organization (4, 25, 42, 90, 165, 176, 184). Different interaction 
complexes of mitofilin have been reported (77, 165, 169, 184). A decrease in mitofilin level has 
been observed in many human diseases such as Down syndrome (15, 117), Parkinson’s disease 
(26, 160, 161), cancer (25, 106) and diabetic cardiomyopathy (10). Proteomic studies from our 
laboratory have shown a significant decrease of mitofilin content in IFM subpopulations isolated 
from STZ induced type 1 diabetic mice (9). Interaction of mitofilin with other proteins in 
MICOS complex is crucial for mitochondrial morphology and function. With downregulation of 
mitofilin in IFM of type 1 diabetes mellitus, studies investigating mitofilin and its potential 
interaction with other novel proteins, as well as over expression of mitofilin in restoring 
mitochondrial structure and function are crucial to understand the pathological manifestations of 
type 1 diabetes mellitus. 
 
1.9 Micro-RNA (miRNA)           
 miRNAs are endogeneous 22-23nt RNAs that play a significant role in gene expression 
in animals and plants by targeting mRNAs of protein-coding genes for posttranscriptional 
regulation or translational repression. miRNAs are critical to cell physiology, development and 
have been implicated in pathological processes such as autoimmune diseases, viral infections, 
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cancer and diabetes (11, 80, 92, 124, 126, 180). miRNAs were first identified during larval 
development of C. elegans in 1993 (97). 
 The biogenesis of matured miRNA initiates in the nucleus, with RNA Polymerase II 
transcribing miRNAs to produce pri-miRNA transcript that has a hairpin loop, capped 5’ end and 
polyadenylated tail which can be thousands of base pairs in length. The nuclear cleavage of pri-
miRNA by Drosha RNaase III endonuclease (98) liberates a 60-70nt stem loop intermediate 
known as pre-miRNA (99, 183). This pre-miRNA is then actively transported from the 
cytoplasm to the nucleus by Ran-GTP and export receptor Exportin-5 (105, 181). Nuclear cut by 
Drosha identifies one matured end of the miRNA whereas the other end is processed by the 
RNAse III endonuclease cytoplasm enzyme called Dicer (98). Dicer first recognizes the double 
stranded portion of the pre-miRNAs and at about two helical turns away from the base of the 
stem loop, it cuts both strands of the duplex. This produces an imperfect duplex that comprises 
the mature miRNA and similar sized fragment derived from opposing arm of the pre-miRNA. 
The final stage of miRNA biogenesis involves the formation of RNA induced silencing complex 
(RISC). Dicer unravels the miRNA from its complementary sequence and leaves the single 
stranded functional miRNA. Then, along with cofactors transactivating response RNA binding 
protein and other protein activator of interferon induced protein kinase, Dicer helps to bring 
miRNA to a member of the argonuate family (AGO), thus forming the RISC complex (131). 
When bound to the mRNA 3’ untranslated region, AGO proteins functions in miRNA repression 
by the inhibition of protein synthesis (55). After the formation of RISC, miRNAs particularly 
target AGO in RISC, to a specific mRNA for binding and subsequent inhibition. Thus, assembly 
of RISC and binding of miRNA with mRNA in the presence of AGO proteins are mandatory for 
miRNA regulated repression. As for the binding of miRNA to the mRNA there is a presence of 
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2-7 nt seeding region. Once bound to this seeding region, miRNAs can cause translational 
repression, deadenylation, endonucleolytic cleavage ultimately causing mRNA degradation 
(103). The figure below represents the biogenesis of miRNA with the RISC component (6). 
 
 
 
 
 
 
       
      
 
 
 
       
    
Figure 1.3 Biogenesis of a miRNA (6). 
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1.9a miRNAs in physiology  
 miRNAs have been found to regulate cellular functions including but not limited to cell 
growth, proliferation, differentiation and apoptosis. Because of their role in differentiation, 
miRNAs are thought to play role in specifying tissue identity and thus expression profile of 
miRNAs in a specific cell type can be used as a marker for cell type identification (185). 
Furthermore, miRNAs regulating cell differentiation required for tooth patterning, size, and 
shape and number destination have been identified (30). miRNAs have been investigated for 
their potential role in controlling the fate and behavior of stem cells. A study by Gangaraju et al. 
showed that miRNA-296 promoted embryonic cell differentiation whereas miRNA-22 inhibited 
the process. In addition to this, they showed that self-renewal of stem cells is promoted by the 
miR-290-295 cluster which has been shown to silence OCT4 (61). Similarly, studies examining 
miR-26a and miRNA-138 show that they modulate osteogenic differentiation of stem cells by 
targeting the SMAD1 transcription factor (49, 61). Hence, miRNAs have been examined for their 
role in physiology and development. 
 
1.9b miRNAs in pathologies 
Involvement of miRNAs in human pathologies were first identified in humans with 
mutations in fragile (a RISC cofactor) or DGCR 8 (a Drosha cofactor) suffering from mental 
retardation and DiGeorge syndrome respectively. Almost 50 % of human miRNA genes have 
been found in genetic loci that have been associated in cancers (14). Upon examination of 
miRNAs profile in head and neck squamous cell carcinomas (HNSCCs), miRNA-451 was 
identified as a potential prognostic marker with miRNAs 375 and 106b-25 clusters shown to 
24 
 
mediate development and progression of HNSCC (80). Furthermore, a study by Henson et al. 
found that downregulation of miR-100 and miR-125b are observed in oral squamous cell 
carcinoma and could be the potential reasoning behind low sensitivity to ionizing radiation (72). 
With advent in technologies, increased miRNA profiling in pathologies are being investigated. 
Characterization of miRNAs expression changes in acute cardioprotection by ischemic pre and 
post conditioning in rat hearts revealed a total of 18 miRNAs altered by pre and post 
conditioning or both (163). A similar study be Welten et al. investigating inhibition of miRNAs 
329, 487b, 494, and 495 showed increased neovascularization and blood flow recovery after 
ischemia (170). Hence, a lot of studies have reported altered miRNA profiles as well as role of 
specific miRNAs in different pathologies. 
 
1.9c miRNAs within the heart 
 miRNA expression analyses through microarray have demonstrated distinct cellular and 
tissue specific expression patterns of multiple miRNAs (12, 102). Although most miRNAs are 
ubiquitously expressed, several miRNAs are enriched within the heart. miRNAs 208a and 208b 
are cardiac specific miRNAs that are co-expressed, have identical seed sequences and are 
suggested to regulate same set of genes at different stages of development (29, 162). In addition 
to these, miRNAs 1, 133, 499 are also highly expressed in the heart (16). Because of spatial 
presence of specific miRNAs in the heart, role of miRNAs in regulation of cardiac functions 
including cardiomyocyte differentiation, cardiac development and ventricular hypertrophy have 
been elaborately studied (5). Furthermore, structural characteristics and mechanisms of miRNAs 
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have been studied to examine their effects upon development of heart failure, hypertrophy as 
well as treatment of heart failure (177).  
 High density microarrays analyses of human atrial tissue in patients with atrial fibrillation 
undergoing cardiac surgery revealed an elevated expression of miRNA-21. The authors show 
that expression of miRNA-21 is related to atrial fibrosis and might affect its occurrence and can 
be used as a biomarker for cardiac surgery management (120). Similarly, an analysis of global 
expression of miRNAs in physiological left ventricular hypertrophy model revealed a set of 
miRNAs (-26b, -150, -27a, -143) that can potentially modulate hypertrophy (109). A study by 
Huang et al. investigating miRNA-34a provided evidence that miRNA-34a plays a critical role in 
progression of cardiac fibrosis through its targeting of Smad4. Further, the authors conclude that 
inhibition of miRNA-34a could potentially be a promising strategy in the treatment of cardiac 
fibrosis (79). Similarly, study examining miRNA-30d revealed its role in regulating 
cardiomyocyte pyroptosis by targeting foxo3a in diabetic cardiomyopathy. The authors suggest 
that miRNA-30d could be a promising therapeutic target for management of diabetic 
cardiomyopathy (101). In conclusion, an array of miRNAs in the heart has been studied for their 
potential role as therapeutic target and strategy for the treatment of many cardiac diseases. 
 
1.9d miRNAs within the mitochondrion 
 Mitochondrion plays a critical role in many cellular processes, metabolic pathways which 
require and utilize proteins encoded from both nuclear and mitochondrial genome. Regulations 
of proteins in the mitochondria are crucial for its proper functioning. An appropriate balance of 
mRNA and protein levels is essential for cell survival. Presence of miRNAs in the mitochondria 
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and their potential roles in regulation of mRNA and proteins are being investigated in both 
physiological and pathological conditions (149). Recently, miRNAs have been found to be 
present in mouse and rat liver mitochondria and their roles have been associated with likely 
regulation of apoptosis, cell proliferation, and differentiation (17, 93). A study by Das et al. 
examining translocations of nuclear miRNAs into the mitochondria revealed that miRNA-181c 
was indeed present in the mitochondria and regulated mitochondrial function by targeting 
cytochrome c oxidase subunit 1 (mt-COX1) mRNA of the mitochondrial genome (43). Further, a 
study by Sripada et al. utilized deep sequencing approach to characterize the presence of 
miRNAs in pure fractions of mitochondria isolated from HEK293 and HeLa cells. 428 known 
and 196 putative novel miRNAs were present in mitochondria of HEK293 cells with 327 known 
and 13 novel in HeLa cells. Additional analyses of the identified miRNAs showed their potential 
association with critical cellular processes like RNA turnover, apoptosis, cell cycle and 
nucleotide metabolism (148). Taken together these findings suggest that further investigation of 
miRNAs in the mitochondria could potentially help us understand mitochondrial dynamics as 
well as the role of miRNA in mitochondrial dysfunction. Moreover, presence of differential 
profile of miRNAs in mitochondrial subpopulations could lend insight upon structural and 
functional differences observed within spatially distinct SSM and IFM mitochondria. 
 
1.10 Summary 
 Almost 40 % of populations over 20 years of age in the United Sates are hyperglycemic. 
As of 2012, 29.1 million Americans were suffering from diabetes and the total direct and indirect 
cost of the disease was at a staggering 245 billion dollars. Research endeavors geared towards 
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understanding the etiology and mechanism of DM is absolutely necessary for better diagnoses as 
well as therapeutic developments. Morphological alterations of the mitochondrial structure as 
well as regulation of the mitochondrial genome by miRNAs are associated with mitochondrial 
dysfunction and diabetic cardiomyopathy. Hence, the goal of this dissertation was to examine the 
role of mitochondrial structural as well as alterations in mitochondrial miRNA profile in the 
development of diabetic cardiomyopathy during type 1 DM. Further, a transgenic mouse model 
overexpressing mitofilin, an inner mitochondrial membrane structural protein was utilized to 
examine the beneficial effects of mitochondrial structural restoration during type 1 DM. 
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Abstract 
Mitofilin is an inner mitochondrial membrane structural protein, well established for its role in 
maintaining cristae morphology and structure. It is a central component of the mitochondrial 
contact site and cristae organizing system (MICOS) complex. Interactions of mitofilin with outer 
and inner membrane proteins have been reported to be crucial for mitochondrial membrane 
organization, cristae integrity and inner membrane architecture. Moreover, MICOS has been 
shown to function in concert with ATP synthase dimers. However, association of mitofilin with 
ATP synthase subunits is not known. The goal of this study was to investigate known and 
potential interactions of mitofilin with ATP synthase subunits in cardiac mitochondrial 
subpopulations during a type 1 diabetic insult. Cardiac mitochondria are comprised of two 
spatially located mitochondria, subsarcolemmal mitochondria (SSM) and interfibrillar 
mitochondria (IFM). Using a gel based technique, mitochondrial proteins immunoprecipitated 
with mitofilin were subjected to LC-ESI-MS analysis. Proteins from all electron transport chain 
complexes, structural proteins and proteins involved in protein import were identified in an 
immunoprecipitated complex. Association of mitofilin with F0 -ATP synthase subunit b 
(ATP5F1) was decreased in the diabetic IFM when compared with control. Moreover, interaction 
of mitofilin with coiled-coil-helix coiled-coil-helix domain 3 (CHCHD3) was trending towards 
decrements in diabetic IFM. Together these results suggest that mitofilin associates with 
ATP5F1 which is decreased in type 1 diabetic IFM potentially leading to morphological and 
ATP synthase dysfunction observed during diabetes. 
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Introduction 
 Mitochondria are comprised of two membranes, the outer membrane and the inner 
membrane. The inner membrane of the mitochondria further constitutes an inner boundary 
membrane and cristae membrane (22, 40). The inner mitochondrial membrane houses the 
proteins required for oxidative phosphorylation, electron transport chain complexes, metabolite 
carriers, and metabolic enzymes required for metabolism and are hence indispensable for proper 
mitochondrial functioning (13, 15, 36). Prior findings have suggested that proper integrity of 
mitochondrial cristae morphology is crucial for mitochondrial structure and function (12, 17, 23, 
26).  
Recently, various independent studies have led to the identification of a large inner 
membrane protein complex which is critical for inner membrane architecture, mitochondrial 
function, cristae organization, formation of contact sites as well as protein biogenesis (1, 5, 16, 
18, 33, 34, 38). This protein complex has been named mitochondrial contact site and cristae 
organizing system (MICOS) (28). Mitofilin, an inner membrane structural protein, has been 
identified as a critical component of the MICOS complex where it interacts with Mio10, Aim5, 
CHCHD3 and MOMA-1 to form the complex (39). The role of mitofilin in regulation of cristae 
morphology, mitochondrial membrane organization and formation of crista junctions has been 
well established (19, 20, 34). Further, interactions of mitofilin with Sam50 and CHCHD3 to form 
the mitochondrial intermembrane space bridging (MIB) complex for biogenesis of respiratory 
complexes (24), metaxins 1 and 2, Sam50, CHCHD3, CHCHD6 and DnaJC11 with a potential 
role in protein import (37) have been reported. Hence, interactions of mitofilin with both inner 
and outer membrane proteins have been studied in order to properly understand its role in 
mitochondrial structure and function. 
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Examination of cardiac mitochondria is complicated by the presence of two spatially 
distinct mitochondrial subpopulations; subsarcolemmal mitochondria (SSM) located beneath the 
sarcolemma and interfibrillar mitochondria (IFM) situated between the myofibrils. Mitochondrial 
subpopulation specific interactions of mitofilin have not been studied yet. Hence, the goal of this 
study was to identify novel association of mitofilin in mitochondrial subpopulations and examine 
whether the interaction of mitofilin with the identified proteins are altered during a type 1 
diabetic insult. 
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Materials and Methods 
 
Experimental animals and induction of diabetes 
The animal experiments in this study conformed to the National Institutes of Health 
(NIH) Guidelines for the Care and Use of Laboratory Animals and were approved by the West 
Virginia University Animal Care and Use Committee. Male FVB mice were housed in the West 
Virginia University Health Sciences Center animal facility on a 12-h light/dark cycle in a 
temperature controlled room. Mice were given unlimited access to a standard rodent diet and 
water. Type 1 diabetes mellitus was induced in 6 week old mice following the protocol of the 
Animal Models of Diabetic Complications Consortium utilizing multiple low-dose 
streptozotocin (STZ; Sigma, St. Louis, MO) injections as previously described by our laboratory 
(2-4, 7, 10, 35). Briefly, sodium citrate buffer (pH 4.5) with 50 mg/kg body weight STZ was 
administered to mice for 5 consecutive days via intraperitoneal injections after 6 hours of fasting. 
Vehicle control animals were injected with same volume per body weight sodium citrate buffer. 
Three days following the last injection, hyperglycemia was measured and confirmed (Contour 
Blood Glucose Test Strips, Bayer Healthcare, Mishawaka, IN). Mice with blood glucose levels 
greater than 250 mg/dL were considered diabetic. All of the mice injected with STZ became 
diabetic (values in mg/dL; diabetic 401 ± 81). After diabetic induction, animals were maintained 
for 5 weeks and then euthanized for further experimentation. 
 
Mitochondrial subpopulation isolation 
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 At 5 weeks post-hyperglycemia onset, FVB diabetic and their littermate control mice 
were euthanized and their hearts excised. Hearts were rinsed in phosphate buffered saline (PBS, 
pH 7.4), then blotted dry. SSM and IFM subpopulations were isolated as previously described 
following the methods of Palmer et al. (25) with minor modifications by our laboratory (2-4, 7-
11, 35). Mitochondrial pellets were either resuspended in KME buffer (100 mM KCl, 50 mM 
MOPS, and 0.5 mM EDTA, pH 7.4) for western blot analysis and activity measurements, or in 
1.0 % NP-40 wash/binding buffer (100 mM HEPES (pH 7.4), 1.0 % NP-40, 150 mM NaCl) for 
mitofilin/protein associations. Protein concentrations were determined by the Bradford method 
using bovine serum albumin as a standard (6).  
 
Western blot analyses  
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% gradient gels as 
previously described (21, 35) with equal amounts of protein loaded. Relative amounts of 
mitofilin, cytochrome c oxidase (COX IV), ATP5F1, ATP5A, and CHCHD3  were assessed 
using the following primary antibodies; anti-mitofilin rabbit antibody (product no. ab48139, 
Abcam, Cambridge, MA), anti-COX IV rabbit antibody-mitochondrial loading control (product 
no. ab16056, Abcam, Cambridge, MA), anti-ATP5F1 mouse antibody (product no. ab117991, 
Abcam, Cambridge, MA), anti-ATP5A mouse  antibody (product no. ab110273, Abcam, 
Cambridge, MA), and anti-CHCHD3 rabbit antibody (product no. ab98975, Abcam, Cambridge, 
MA). The secondary antibodies used in the analyses were goat anti-rabbit IgG horseradish 
peroxidase conjugate (product no. 10004301, Cayman Chemical Company, Ann Arbor, MI) for 
mitofilin, COX IV, and CHCHD3, and goat-anti mouse conjugate (product no. 31430; Pierce 
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Biotech, Rockford, IL) was used for ATP5F1, and ATP5A. Detection of signal was performed 
using a Pierce ECL Western blotting substrate detection system according to the manufacturer’s 
directions (Thermo Fisher Scientific Inc., Rockford, IL). Quantification of chemiluminescent 
signals were assessed using a G:Box Bioimaging System (Syngene, Frederick, MD), and data 
were expressed as arbitrary optical density units. Densitometry was measured using Image J 
Software (National Institutes of Health, Bethesda, MD). Protein loading was confirmed using 
COX IV. 
 
Immunoprecipitation analyses 
Dynabeads® protein G (product no 10003D, Life technologies, Grand Island, NY) were 
used to determine protein associations with mitofilin per the manufacturer’s instructions. Briefly, 
100ug of mitochondrial protein resuspended in 1.0 % NP-40 wash/binding buffer was incubated 
with mitofilin antibody overnight. 40ul of protein G beads were then added to the tubes and 
rocked at 4°C for an hour. The antibody binds to the Dynabeads via their Fc-region. The tubes 
were placed in a magnet and beads were washed three times with the wash/binding buffer. The 
supernatant was removed by aspiration and the magnetic beads were eluted with 4X Laemmli 
sample buffer and heated to 70°C. Western blots were performed on the eluted protein and 
probed with protein of interest so as to examine the association with mitofilin. 
 
Protein identification by LC-ESI-MS/MS 
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 In order to identify proteins associated with mitofilin, 1000ug of mitochondrial protein 
was used for immunoprecipitation as described above. After elution of magnetic beads with 4X 
Laemmli sample buffer, it was sent to Protea Biosciences, Inc (Morgantown, WV) for protein 
identification by LC-ESI-MS/MS. Briefly, samples and molecular weight marker were loaded 
onto ProteaGel Mini Precast gel and run in 180v for 30 minutes. After electrophoresis, the gel 
was stained with SYPRO Ruby red stain for overnight and imaged at 550-750 nm. Varying 
molecular weight regions were cut and soaked in 150mM ammonium bicarbonate (AmBic) and 
then acetonitrile. The samples were then dried down on a lyophilizer and treated with 10mM 
dithiothreitol (DTT) in 50mM AmBic followed by an hour incubation at 56°C. After a 30 second 
centrifuge at 4000 RPM, excess DTT was removed and 50ul of 55mM iodoacetamide (IA) in 
50mM AmBic was added to the gels and incubated in the dark for an hour. After drying down 
the samples, trypsin in 50mM AmBic was added and incubated at 37°C overnight. Gel pieces 
after centrifugation were lyophilized and reconstituted in 80ul of acetonitrile/water/formic acid  
for LC-ESI-MS analysis. Liquid chromatography was done using Shimadzu LC-20AD HPLC 
(Tokyo, Japan) and control software was Analyst 1.5. ESI mass spectrometer was performed 
using QTrap 5500 (Ab Sciex, Toronto, Canada) and the ionization method used was electrospray 
ionization in positive ion mode with a voltage at 5.0 kV. Summary of the proteins and peptides 
identified were presented in the Excel data file. 
 
Ingenuity pathway analysis 
After protein identification through mitofilin pull down immunoprecipitation and LC-
ESI-MS/MS, the accession numbers and pull down proteins were tabulated and imported into 
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Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City, CA) for 
canonical pathway analysis. The software was utilized for construction of interacting proteins 
networks associated with mitofilin. IPA contains a database that uses the most current knowledge 
available on genes, proteins, protein interactions, and metabolic pathways needed for protein 
network construction.  
 
Blue native page 
To assess electron transport chain (ETC) complex V content in control and diabetic 
mitochondrial subpopulations, blue native polyacrylamide gel electrophoresis (BN-PAGE) was 
performed as previously described (2, 8) with modifications according to the manufacturer's 
protocol (Invitrogen, Carlsbad, CA) using equal amounts of protein. Briefly, isolated 
mitochondria were solubilized with 1% digitonin on ice. After addition of Coomassie G-250, 
samples were run on 4–16% NativePAGE gels. Following BN-PAGE, gels were placed in a 
fixed solution containing 40% methanol and 10% acetic acid followed by microwaving for 45 
seconds at 1,100 watts. Gels were then washed for 15 minutes at room temperature after which 
the solution was decanted. Destaining was accomplished by addition of 50 ml of an 8% acetic 
acid solution and microwaved a second time for 45 seconds at 1,100 watts. The gel was then 
shaken at room temperature until the desired background was obtained. To control for destaining 
time and enable comparison between gels, each band of interest was expressed per the molecular 
weight marker 480 kDa band. The gel was then scanned and densitometry was measured using 
Image J Software (National Institutes of Health, Bethesda, MD). 
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Statistics 
 Means and SEMs were calculated for all data sets. Data were analyzed using Student’s t-
test (GraphPad Software Inc., La Jolla, CA). Differences between control and diabetic groups 
were considered significant when a P < 0.05 was observed. 
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Results 
Protein identification by LC-ESI-MS/MS analyses 
 Immunoprecipitation with mitofilin followed by gel electrophoresis was performed to 
identify proteins that were pulled down with mitofilin. After gel electrophoresis, the bands were 
cut in different sizes as shown in Figure 2.1. The band sizes cut were 15kDa, 25kDa, 35kDa, 50-
100kDa and 100kDa plus. Further analyses were performed in the cut gels as described in the 
methods section. Finally, LC-ESI-MS/MS analyses were performed to identify the list of 
proteins that were pulled down with mitofilin. 
Canonical pathways 
 Using IPA software-fed proteins pull down with mitofilin, we attempted to predict 
canonical pathways associated with identified proteins within the mitochondrion. Upon analyses 
of the pathways we identified proteins involved in Electron transport chain complexes I, II, III, 
IV and V, proteins involved in mitochondrial structure and protein import (Figure 2.2). 
CHCHD3, pulled down with mitofilin is crucial for maintaining crista integrity and 
mitochondrial function (12). Further, mitofilin with CHCHD3 and Samm50 form a large protein 
complex named mitochondrial intermembrane space bridging complex which is crucial for 
preservation of cristae and in the assembly of respiratory chain complexes (24).  
Mitofilin and CHCHD3 interaction 
 Because of its role in maintaining cristae morphology, we examined association of 
mitofilin with CHCHD3 in control and diabetic mitochondrial subpopulations (Figure 2.3A). Our 
laboratory has previously shown decreased mitofilin content in diabetic IFM (3). Further, we 
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assessed the protein content of CHCHD3 in control and diabetic subpopulations and observed no 
significant changes (Figures 2.3B-C). We conclude that the observed trending decreased 
association of mitofilin with CHCHD3 in diabetic IFM is a function of decreased mitofilin 
content in diabetic IFM. 
Novel interaction of mitofilin with ATP5F1 
 To gain insight into which ATP synthase subunit constituent proteins may be associated 
with mitofilin, we utilized immunoprecipitation pull down with mitofilin and probed with 
ATP5F1. Upon examination of mitofilin association with ATP5F1 in control and diabetic 
mitochondrial subpopulations, we observed a significant decrease in diabetic IFM when 
compared to control (Figure 2.4A). Further, assessment of ATP5F1 protein content in control 
and diabetic mitochondrial subpopulations revealed no significant differences in either group 
(Figures 2.4B-C). We conclude that the significant decrease of ATP5F1 association with 
mitofilin in diabetic IFM is a function of decreased mitofilin content in type 1 diabetic IFM 
subpopulations. 
Blue native page 
 To gain insight into whether decreased association of mitofilin with ATP synthase F0 
subunit complex results in down-regulation of ATP synthase complex component, we utilized a 
BN-PAGE approach. This allowed us to evaluate the complex V expression as a whole. Our data 
indicated no significant differences in complex V content between control and diabetic groups in 
SSM and IFM (Figures 2.5B-C). We conclude that the decreased association of mitofilin with 
ATP5F1 in diabetic IFM does not result in decrement of complex V content. 
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Discussion 
 Interactions of mitofilin with mitochondrial inner as well as outer membrane proteins 
have been widely reported. We are the first group to examine known as well as novel interacting 
partners and associates of mitofilin in mitochondrial subpopulations. No study has examined the 
differential interaction profile of mitofilin in mitochondrial subpopulation during a type 1 
diabetic insult. The following key findings resulted from these studies: 1) Identification of 
proteins pulled down with mitofilin utilizing LC-ESI-MS/MS analyses revealed proteins from 
ETC complexes I, II, III, IV and V, protein import machinery in addition to well established 
structural proteins; 2) Interaction of mitofilin with CHCHD3 is trending towards decreased in 
type 1 diabetic IFM subpopulations; 3) Novel association of mitofilin with ATP5F1 was 
observed in mitochondrial subpopulations and this association is decreased in type 1 diabetic 
IFM when compared with control and; 4) BN-PAGE analyses of Complex V did not reveal any 
significant changes in protein content in control and diabetic mitochondrial subpopulations. 
Taken together, these findings provide novel associating partners of mitofilin and reveal 
decreased interaction of mitofilin in type 1 diabetic IFM. These findings could potentially 
explain mitochondrial dysfunction observed in type 1 diabetic IFM subpopulations. 
 Interaction of mitofilin with CHCHD3 and Sam50 have been shown to form MIB which 
is crucial for cristae preservation and assembly of respiratory complexes (24). Further, others 
have shown existence and requirement of C-terminal domain of mitofilin for interaction with 
Tob55/Sam50 complex which could potentially regulate outer membrane protein import and 
formation of crista junctions (20, 37). Our findings agree with these studies as both CHCHD3 
and Sam50 are pulled down with mitofilin. Further, CHCHD3 along with mitofilin are part of 
MICOS complex which is crucial in regulating cristae morphology and mitochondrial function 
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(16, 18, 28, 33). Previous studies from our laboratory and others have shown morphological 
alterations specifically in the IFM subpopulations during type 1 diabetic insult (10, 31).We have 
also shown down regulation of mitofilin in diabetic IFM subpopulations (3). Our findings in this 
study revealed a trending decreased association of mitofilin with CHCHD3 in diabetic IFM 
which could potentially result in morphological alterations observed during diabetes as 
mentioned above. Further, mitofilin along with CHCHD3 has been shown to cristae morphology 
and integrity (12, 19, 38). 
 Proteins which are not a constituent of the MICOS complex have also been associated 
with regulation of cristae morphology and structure (14, 27).  Of particular interest to this study, 
are findings by Paumard et al. who utilized yeast cells to show the potential role of ATP synthase 
subunits e or g in regulating cristae morphology (27). Further, Rabl et al. showed that deletions 
of ATP subunits e or g resulted in reduction of cristae tip numbers and crista junctions diameter 
enlargement. The authors showed that mitofilin and ATP synthase subunits e or g genetically 
interacted (29). In our current study we identified ATP synthase subunit proteins pulled down 
with mitofilin. Novel association of mitofilin with ATP synthase subunit b (ATPF1) was 
observed in mitochondrial subpopulations. Further, the association was decreased in diabetic 
IFM when compared to control. Previous findings from our laboratory have shown decreased 
ATP synthase activity in diabetic IFM when compared to control (2, 10). Hence, novel 
association of mitofilin with ATPF1 could present a potential mechanism in regulating cristae 
morphology and decreased association observed in diabetic IFM subpopulations could result in 
structural alterations and dysfunctional ATP synthase activity as observed in type 1 diabetes 
mellitus. 
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 ATP synthase also referred to as complex V makes ATP through oxidative 
phosphorylation. Decreased association of mitofilin with ATPF1, as well as decreased synthase 
activity observed during type 1 diabetic insult could result in decrement in complex V. In order 
to examine this, we utilized BN-PAGE technology to assess the protein content. This technology 
has been utilized before to analyze membrane complexes and diagnose oxidative 
phosphorylation defects in mitochondria (8, 30, 32). Analysis of complex V content revealed no 
significant differences between control and diabetic subpopulations. These findings suggest that 
although a decreased association of mitofilin with ATP5F1 is observed in diabetic IFM, the total 
protein content of complex V is not changing. Additional studies examining association of 
mitofilin with other ATP synthase subunits could lend insight into mechanisms contributing to 
observed ATP synthase dysfunction during type 1 diabetes mellitus. 
 In conclusion, we report for the first time, interactions and novel association of mitofilin 
in mitochondrial subpopulations. Further, interaction of mitofilin with CHCHD3 and decreased 
association of ATP5F1 was observed in diabetic IFM when compared with control. Also, pulled 
down with mitofilin were proteins associated with ETC complexes, mitochondrial structure as 
well as protein import which warrants further investigation of role of mitofilin and its 
associations with these proteins in regulating these mechanisms. 
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Figure 2.1 
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Figure 2.1. Protein identification by gel electrophoresis and LC-ESI -MS/MS. Gel 
electrophoresis of proteins pull down with mitofilin. Gels were cut in following band sizes: 
15kDa, 25kDa, 35kDa, 50-100kDa and 100kDa plus. Each band was then separately run through 
LC-ESI-MS/MS so as to identify potential protein targets that associated with mitofilin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
Figure 2.2 
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Figure 2.2.  Canonical pathways analyses using Ingenuity pathway analysis. Identification of 
mitochondrial protein networks involving proteins pulled down with mitofilin. Networks 
involved in ETC complexes, mitochondrial structure, protein import were identified. Red line 
indicates novel association of mitofilin with ATP5F1 presented in this study. 
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Figure 2.3 
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Figure 2.3. CHCHD3 interaction and protein content. A) Interaction of CHCHD3 with 
mitofilin in control and diabetic mitochondrial subpopulations. Control (lanes 1 and 2) and 
diabetic (lanes 3 and 4) for both SSM and IFM. B) Western blot analysis of CHCHD3 protein 
content in control (lanes 1 and 2) and diabetic (lanes 3 and 4) for SSM and IFM subpopulations. 
Bar graph representation of CHCHD3 protein content over COX IV in C) SSM and IFM 
subpopulations. Values are presented as means ± SE. Control for protein loading was confirmed 
with COX IV (mitochondria loading control); n=4 for each group. SSM: subsarlocemmal 
mitochondria, IFM: interfibrillar mitochondria. 
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Figure 2.4 
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Figure 2.4. ATP5F1 novel association with mitofilin and protein content. A) Association of 
ATP5F1 with mitofilin in control and diabetic mitochondrial subpopulations. SSM control (lane 
1), SSM diabetic (lane 2), IFM control (lane 3), and IFM diabetic (lane 4).  B) Western blot 
analysis of ATP5F1 protein content in control (lanes 1 and 2) and diabetic (lanes 3 and 4) for 
SSM and IFM subpopulations. Bar graph representation of ATP5F1 protein content over COX 
IV in C) SSM and IFM subpopulations. Values are presented as means ± SE. Control for protein 
loading was confirmed with COX IV (mitochondria loading control); n=4 for each group. SSM: 
subsarlocemmal mitochondria, IFM: interfibrillar mitochondria. 
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Figure 2.5 
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Figure 2.5. BN-PAGE analysis of ETC complex V. A) IPA pathway showing novel association 
of mitofilin with ATPF1 of ETC complex V. B) ETC complex V expression was examined in 
control (lanes 1 and 2 ) and diabetic (lanes 3 and 4) mitochondrial subpopulations using BN-
PAGE. C) Bar graph representation of ETC complex V assessed for SSM and IFM control and 
diabetic groups. Values are expressed as means ± SE. n=4 for each group. SSM: subsarcolemmal 
mitochondria, IFM: interfibrillar mitochondria. 
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Abstract 
 
Mitofilin, also known as heart muscle protein, is an inner mitochondrial membrane 
structural protein that plays a central role in maintaining cristae morphology and structure. It is a 
critical component of the mitochondrial contact site and cristae organizing system (MICOS) 
complex which is important for mitochondrial architecture and cristae morphology. Our 
laboratory has previously reported alterations in mitochondrial morphology and proteomic make-
up during type 1 diabetes mellitus, with mitofilin being significantly down-regulated in 
interfibrillar mitochondria (IFM). The goal of this study was to investigate whether 
overexpression of mitofilin can limit mitochondrial disruption associated with the diabetic heart 
through restoration of mitochondrial morphology and function. A transgenic mouse line 
overexpressing mitofilin was generated and mice injected intraperitoneally with streptozotocin 
using a multi low-dose approach. Five weeks following diabetes mellitus onset, cardiac 
contractile function was assessed. Restoration of ejection fraction and fractional shortening was 
observed in mitofilin diabetic mice as compared to wild-type controls (P<0.05 for both). 
Decrements observed in electron transport chain (ETC) complexes I, III, IV and V activities, 
state 3 respiration, lipid peroxidation as well as mitochondria membrane potential in type 1 
diabetic IFM were restored in mitofilin diabetic mice (P<0.05 for all). Qualitative analyses of 
electron micrographs revealed restoration of mitochondrial cristae structure in mitofilin diabetic 
mice as compared to wild-type controls. Furthermore measurement of mitochondrial internal 
complexity using flow cytometry displayed significant reduction in internal complexity in 
diabetic IFM which was restored in mitofilin diabetic IFM (P<0.05). Taken together these results 
90 
 
suggest that transgenic overexpression of mitofilin preserves mitochondrial structure, leading to 
restoration of mitochondrial function and attenuation of cardiac contractile dysfunction in the 
diabetic heart. 
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1. Introduction 
Mitochondria are ubiquitous, double membranous organelles with an outer membrane 
and inner membrane. The inner mitochondrial membrane (IMM) of the mitochondria is 
comprised of an inner boundary membrane which is in close proximity with the outer membrane 
and cristae membrane [1, 2]. The regions in between the inner boundary and cristae membranes 
are narrow tubular openings with a fixed diameter and length called crista junctions [1-3]. The 
cristae membrane is composed of large tubular invaginations that protrude into the matrix space 
and house the respiratory chain complexes, as well as the F1F0–ATP synthase, rendering it 
indispensable for proper mitochondrial function [4-7]. Numerous human pathologies have been 
associated with abnormal mitochondrial structure [8, 9]. Thus, proper integrity of mitochondrial 
cristae morphology is crucial for mitochondria structure and function. 
A number of mitochondrial proteins including optic atrophy 1 (OPA1), coiled-coil-helix 
coiled-coil-helix domain 3 (CHCHD3), coiled-coil-helix cristae morphology 1 (CHCM1), and 
ATP synthase subunits have been associated with the regulation of cristae morphology [10-13]. 
One of the recently identified proteins, mitofilin, has been reported to be requisite for the 
maintenance of proper cristae morphology. Mitofilin, also known as heart muscle protein [14] 
due to its high abundance in the heart, is an IMM structural protein specifically localized to the 
cristae junction [15]. Down-regulation of mitofilin in Hela cells results in abnormal 
mitochondrial morphology with concentric layers of inner membrane, reduced cell proliferation, 
increased apoptosis and elevated reactive oxygen species (ROS) production [16]. Moreover, 
mitofilin depletion studies in yeast cells and C. elegans results in curved and stacked 
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mitochondrial cristae tubules, increased ROS production, as well as a reduction in cristae 
junctions which is associated with decreased mitochondrial DNA content [3, 17]. Recently, 
mitofilin was identified as a critical component of the mitochondrial contact site and cristae 
organizing system (MICOS) complex where it functions as a central organizer of mitochondrial 
architecture, cristae junctions and cristae morphology [18-23]. Thus, a number of studies 
substantiate the significant role of mitofilin in maintaining proper mitochondrial structure and 
function. 
Decrements in mitofilin content have been observed in many human diseases such as 
Down’s syndrome [24, 25], Parkinson’s disease [26, 27], Epilepsy [28, 29] and 
Neurodegeneration [30, 31]. Abnormal mitochondrial morphology, significant reduction in 
cristae density, as well as decrements in mitofilin content have been reported in the type 1 
diabetic heart [32, 33]. Our laboratory has reported that following a type 1 diabetic insult, IFM 
exhibit greater dysfunction characterized by enhanced oxidative stress, changes in mitochondrial 
morphology and function as well as altered mitochondrial proteomic signature which is not 
observed in type 1 diabetic subsarcolemmal mitochondria (SSM) [33, 34]. 
The IMM proteomic signature is significantly impacted following type 1 diabetic insult 
and mitofilin is one particular protein that shows significant decrease, specifically in the IFM. 
The impact of mitofilin loss in type 1 diabetic IFM was associated with changes in mitochondrial 
morphology and function. Mitofilin overexpression studies in yeast cells have revealed increased 
diameter as well as branching of cristae and cristae junctions [3]. Nevertheless, overexpression 
of mitofilin in the context of the diabetic heart have not been undertaken. To address this gap in 
knowledge, we generated a novel transgenic mouse model of mitofilin overexpression. The goal 
of the current study was to determine whether mitofilin overexpression provides cardioprotective 
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benefits to the type 1 diabetic heart and if these effects are associated with improved 
mitochondrial structure and function.  
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2.  Materials and Methods 
2.1 Mitofilin Transgenic Mouse Development 
The animal models used in this study conform to the NIH guidelines for the care and use 
of laboratory animals and were approved by the West Virginia University, School of Medicine 
Animal Care and Use Committee. Mitofilin transgenic mouse lines were generated by inserting a 
cDNA encoding the human mitofilin gene into the pCAGGS vector as previously described [35-
38].  Briefly, the pCAGGS vector places the mitofilin gene (RG 201854, Origene) under the 
control of the human cytomegalovirus (CMV) immediate early enhancer and chicken β-actin 
(Ch.β-actin) promoter with first intron. The mitofilin cDNA was inserted into the XhoI cloning 
site of pCAGGS via sticky-end ligation (XhoI/XhoI) and blunt-end ligation of an Sgf1/XbaI 
fragment of approximately 2227 bp (Figure 3.1). The chimeric transgene was cut out of the 
plasmid by SspI and BamH1 digestion, purified, and used to generate transgenic mice. The 
construct was given to the West Virginia University Transgenic Animal Core Facility where the 
pronucleus of fertilized eggs from superovulated FVB female mice crossed with FVB male mice, 
was injected with 1-2 pl of purified DNA fragment at a concentration of 2µg/ml, and transferred 
into the oviducts of pseudopregnant CD-1 mice. All control and transgenic mice were generated 
using an FVB background, and experimental procedures were initiated on animals of 
approximately 5 weeks of age. Animals were maintained in individual microisolator cages within 
the West Virginia University Transgenic Barrier Facility and given food and water ad libitum. 
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2.2 Mitofilin transgenic mouse screening 
Mouse litters were delivered after 19-20 days of gestation. To verify whether the 
chimeric transgene was present in the genome, DNA from 3-week-old mice was isolated from 
tail clips using a Qiagen DNeasy tissue kit (Qiagen, Valencia, CA). Transgene screening was 
performed by qPCR using a mitofilin probe (#hs00272794-m1; Applied Biosystems, Foster City, 
CA). Using this approach, only DNA that contains the exogenous mitofilin cDNA was detected. 
Briefly, isolated tail DNA, probe, and universal master mix were brought up to 25µl and qPCR 
was performed in a 96 well plate using an Applied Biosystems 7900HT Fast Real-Time PCR 
system (Life Technologies, Grand Island, NY). A reaction time versus cycle number 
amplification plot was generated and transgene positive and negative animals were determined.  
 
2.3 Diabetes induction           
Male mice were separated into four groups: 1) control; 2) diabetic; 3) mitofilin 
overexpression; and 4) mitofilin overexpression diabetic. Type 1 diabetes mellitus was induced 
in  diabetic and mitofilin overexpression diabetic mice following the protocol of the Animal 
Models of Diabetic Complications Consortium utilizing multiple low-dose streptozotocin (STZ; 
Sigma, St. Louis, MO) injections as previously described by our laboratory [33, 34, 39-42]. 
Briefly, sodium citrate buffer (pH 4.5) with 50 mg/kg body weight STZ was administered to 
mice for 5 consecutive days via intraperitoneal injections after 6 hours of fasting. Vehicle control 
animals were injected with same volume per body weight sodium citrate buffer. Three days 
following the last injection, hyperglycemia was measured and confirmed (Contour Blood 
Glucose Test Strips, Bayer Healthcare, Mishawaka, IN). Mice with blood glucose levels greater 
97 
 
than 250 mg/dL were considered diabetic. All of the mice injected with STZ became diabetic and 
no differences in degree of hyperglycemia was evident with mitofilin transgene presence (values 
in mg/dL; control diabetic 401 ± 81, mitofilin diabetic 392 ± 91). After diabetic induction, 
animals were maintained for 5 weeks and then euthanized for further experimentation. 
 
2.4 Cardiac contractile function          
Transthoracic echocardiography was performed as previously described by our laboratory 
[39] and others [43]. Briefly, mice were anesthetized with inhalant isofluorane and transferred to 
dorsal recumbency. Using the Vevo 2100 Imaging System (Visual Sonics, Toronto, Canada) and 
a 32- to 55-MHz linear array transducer, micro-ultrasound images were acquired. M-mode 
images were captured via the parasternal short axis at midpapillary level with all images acquired 
at the highest possible frame rate (233-401 frames/s). Left ventricular M-mode images provided 
end-diastolic and end-systolic diameters and volumes, stroke volume, ejection fraction, fractional 
shortening, heart rate and cardiac output measurements. All echocardiographic measurements 
were performed in conjunction with the West Virginia University Animal Models of Imaging 
Core Facility. 
 
2.5 Human patient population 
 The West Virginia University Institutional Review Board (IRB) and Institutional 
Biosafety Committee (IBC) approved all protocols. Individuals undergoing coronary artery 
bypass graft surgery or cardiac valve replacement at Ruby Memorial Hospital in Morgantown, 
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West Virginia, consented to the release of their cardiac tissue to the West Virginia University 
School of Medicine. Consenting individuals were then characterized as non-type 1 diabetic and 
type 1 diabetic based upon previous diagnosis of diabetes mellitus.  
 
2.6 Preparation of individual mitochondrial subpopulations      
At 5 weeks post-hyperglycemia onset, control, diabetic, mitofilin overexpression, and 
mitofilin overexpression diabetic mice were euthanized and their hearts excised. For human 
samples, right atrial appendages were removed from patients, pericardial fat was trimmed and 
the heart tissue was weighed. For both mouse and human samples, hearts were rinsed in PBS (pH 
7.4) and SSM and IFM subpopulations were isolated as previously described following the 
methods of Palmer et al. [44] with minor modifications by our laboratory [33, 34, 38-42, 45, 46]. 
Mitochondrial pellets were resuspended in KME buffer (pH 7.4) for mitochondrial respiration 
analyses, flow cytometric analyses and enzymatic activity measurements. Protein concentrations 
were determined by the Bradford method using bovine serum albumin as a standard [47].  
 
2.7 Mitochondrial respiration rates          
State 3 and state 4 respiration rates were assessed in isolated mitochondrial 
subpopulations as previously described [48-50] with slight modifications [38, 45]. Briefly, 
isolated mitochondria were resuspended in KME buffer and protein content was determined by 
the Bradford method as above [47]. Mitochondria protein was added to respiration buffer and 
loaded into a respiration chamber which was connected to an oxygen probe (OX1LP-1mL 
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Dissolved Oxygen Package, Qubit System, Kingston, ON, Canada). The substrates glutamate 
(5mM) plus malate (5mM) were used to initiate respiration, and measurements of state 3 
(250mM ADP) and state 4 (ADP-limited) respiration were made.  Values were expressed as 
nmol of oxygen consumed/min/mg protein. 
 
2.8 ETC complex activities           
ETC complexes I, III and IV activities were measured spectrophotometrically as 
previously described [34, 38, 46, 51]. Briefly, complex I activity was determined by measuring 
the oxidation of NADH at 340 nm. Complex III activity was determined by measuring the 
reduction of cytochrome c at 550 nm in the presence of reduced decylubiquinone. Complex IV 
activity was determined by measuring the oxidation of cytochrome c at 550 nm. Protein content 
was determined by the Bradford method as described above [47], and ETC activity values were 
expressed as nmol substrate consumed/min/mg protein. ATP synthase activity was measured as 
oligomycin-sensitive ATPase activity using an assay coupled with pyruvate kinase, which 
converts ADP to ATP and produces pyruvate from phosphoenolpyruvate as previously described 
[46, 52-54]. Final values were expressed as nmol of NADH oxidized/min/mg protein. 
 
2.9 Western blot analysis           
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was run on 4-12% gradient gels as 
previously described [42, 55] with equal amounts of protein loaded. Relative amounts of 
mitofilin, cytochrome c oxidase (COX IV), mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), OPA1, 
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CHCHD3, dynamin-related protein 1 (Drp1) and GAPDH were assessed using the following 
primary antibodies; anti-mitofilin rabbit antibody (product no. ab48139, Abcam, Cambridge, 
MA), anti-COX IV rabbit antibody-mitochondrial loading control (product no. ab16056, Abcam, 
Cambridge, MA), anti-Mfn1 rabbit antibody (product no. ab104585, Abcam, Cambridge, MA), 
anti-Mfn2 rabbit antibody (product no. ab50838, Abcam, Cambridge, MA), anti-OPA1 rabbit 
antibody (product no. ab42364, Abcam, Cambridge, MA), anti-CHCHD3 rabbit antibody 
(product no. ab98975, Abcam, Cambridge, MA), anti-Drp1 rabbit antibody (product no. 
sc32898, Santa Cruz  Biotechnology, Dallas, TX), and anti-GAPDH rabbit antibody (product no. 
ab8245, Abcam, Cambridge, MA). The secondary antibody used was goat anti-rabbit IgG 
horseradish peroxidase conjugate (product no. 10004301, Cayman Chemical Company, Ann 
Arbor, MI). Detection of signal was performed using a Pierce ECL Western blotting substrate 
detection system according to the manufacturer’s directions (Thermo Fisher Scientific Inc., 
Rockford, IL). Quantification of chemiluminescent signals were assessed using a G:Box 
Bioimaging System (Syngene, Frederick, MD), and data were expressed as arbitrary optical 
density units. Densitometry was measured using Image J Software (National Institutes of Health, 
Bethesda, MD). Protein loading was further confirmed using Ponceau staining in addition to 
COX IV and GAPDH, where appropriate. 
 
2.10 ETC Complex Protein Expression 
To assess ETC complex abundances, blue native polyacrylamide gel electrophoresis 
(BN-PAGE) was performed as previously described [39, 45] with modifications according to the 
manufacturer's protocol (Invitrogen, Carlsbad, CA) using equal amounts of protein. Briefly, 
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isolated mitochondria were solubilized with 1% digitonin on ice. After addition of Coomassie G-
250, samples were run on 4–16% NativePAGE gels. Following BN-PAGE, gels were placed in a 
fixed solution containing 40% methanol and 10% acetic acid followed by microwaving for 45 
seconds at 1,100 watts. Gels were then washed for 15 minutes at room temperature after which 
the solution was decanted. Destaining was accomplished by addition of 50 ml of an 8% acetic 
acid solution and microwaved a second time for 45 seconds at 1,100 watts. The gel was then 
shaken at room temperature until the desired background was obtained. To control for destaining 
time and enable comparison between gels, each band of interest was expressed per the molecular 
weight marker 480 kDa band. The gel was then scanned and densitometry was measured using 
Image J Software (National Institutes of Health, Bethesda, MD). 
 
2.11 Mitochondrial DNA (mtDNA) content 
Examination of mtDNA content was performed on whole heart lysate from control and 
mitofilin transgenic mice using a NovaQUANTTM mouse mtDNA to nuclear DNA ratio kit that 
compares the levels of nuclear DNA to mtDNA. As per the manufacturers protocol (Millipore, 
Billerica, MA), an RTPCR platform was utilized to compare several nuclear and mitochondrial 
genes and the mtDNA copy number was quantified per diploid nuclear genome.  An Applied 
Biosystems 7900HT Fast Real-Time PCR system (Life Technologies, Grand Island, NY) was 
used for the analyses. 
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2.12 Mitochondrial size, internal complexity and membrane potential     
Mitochondrial size, internal complexity and membrane potential (ΔΨm) were measured 
as previously described by our laboratory with modifications [34, 42, 46]. Briefly, flow 
cytometric analyses were performed using a FACS Calibur equipped with a 15-MW 488-nm 
argon laser and 633-nm red diode laser (Becton Dickinson, San Jose, CA). Each individual 
parameter (gating, size, and complexity) was performed using specific light sources (laser and 
photomultiplier tube) and specific detectors. MitoTracker deep red 633 (Invitrogen, Carlsbad, 
CA), which moves into intact mitochondria due to membrane potential, was used to selectively 
stain intact mitochondria (emission wavelength: 633 nm, fluorescent 633 red diode laser) and 
exclude debris, enabling accurate gating of intact mitochondria. Freshly isolated mitochondria 
were incubated with the MitoTracker dye and subsequently assessed for size and internal 
granularity. Forward scatter (FSC) and side scatter (SSC) detectors were used to examine 
approximate size (FSC; absolute particle size) and approximate internal complexity (SSC; 
refracted and reflected light which is proportional to granularity of the object) in isolated 
mitochondria. Internal complexity or granularity of isolated mitochondria was expressed with 
respect to size (arbitrary unit) of the mitochondria as FSC/SSC ratio. The ratiometric dye 
5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazol carbocyanine iodide (JC-1; Molecular 
Probes, Carlsbad, CA), was used to assess mitochondrial membrane potential. Changes in 
membrane potential were recorded as the ratio between the color shifts from green to orange. All 
flow cytometric measurements were performed in conjunction with the West Virginia University 
Flow Cytometry Core Facility. 
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2.13 Lipid peroxidation            
Lipid peroxidation by-products malondialdehyde (MDA) and 4-hydroxyalkenal (4-HAE), 
stable end products formed from the oxidation of polyunsaturated fatty acids and esters, were 
assessed as previously described [34, 46]. Absorbance was measured on a Molecular Devices 
Flex Station 3 spectrophotometer (Molecular Devices, Sunnyvale, CA), and protein content was 
assessed as described above [47] with final values expressed per milligram of protein. 
 
2.14 Electron microscopy           
A section of left ventricle was cut and fixed for electron microscopy images. Briefly, 
specimens were washed in 0.2M phosphate buffer, post-fixed by incubation for 2 hours with 2% 
osmium tetroxide (Electron Microscopy Science, Hatfield, PA), dehydrated in a graded series of 
ethanol solutions (from 50% to 100%) and propylene oxide, and embedded in Epon resin (SPI 
Supplies, Westchester, PA).  Embedded samples were allowed to polymerize for 48 hours at 
62°C.   Ultrathin sections (50nm) were cut from the resulting blocks with a Leica Ultracut UCT 
ultramicrotome (Leica Biosystems, Buffalo Grove, IL) and then captured on 200 mesh copper 
electron microscopy grids. The sections were observed at 120kV with a Zeiss Libra 120 electron 
microscope (Carl Zeiss NTS, LLC, Peabody, MA, USA) connected to a Gatan Orius SC 1000 
CCD digital camera driven by Digital Micrograph software (Gatan, Pleasanton, CA) for image 
acquisition and analysis. All electron microscopy imaging was performed in conjunction with the 
West Virginia University Tissue Processing and Analysis Core Facility. 
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2.15 Statistics             
Means ± SE were calculated for all data sets. Data were analyzed using a one way 
ANOVA (GraphPad software, La Jolla, CA). A Tukey comparison of all groups was used as the 
post-hoc test to determine the significant differences among means. A Student’s t-test was 
utilized when evaluating mitofilin content in mouse and human mitochondria. P < 0.05 was 
considered significant. 
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3. Results 
3.1 Mitofilin transgenic mouse characterization        
Two mitofilin transgenic mouse lines were created, mitofilin Tg Line 1 and mitofilin Tg 
Line 2. DNA from mitofilin Tg Line 1 displayed average CT values of 26.5, while mitofilin Tg 
Line 2 displayed average CT values of approximately 21, indicating that Line 2 possessed 
greater mitofilin cDNA content. In contrast, DNA from transgenic negative mice of all lines 
displayed CT values of approximately 34-36 which is similar to the CT value of water. As a 
result, we chose to perform all experimentation using mitofilin Tg Line 2 and its associated 
littermate controls. 
To verify increased protein expression in our transgenic mice, mitofilin protein content 
was determined in both whole heart homogenate and isolated mitochondrial subpopulations. 
Transgenic SSM and IFM subpopulations displayed significantly higher levels of mitofilin 
protein content when compared to littermate controls which was not significantly impacted by 
diabetic insult (Figure 3.2 A-D). In addition, mitofilin protein levels were significantly higher in 
transgenic whole heart homogenate as compared to littermate controls (Figure 3.3). Evaluation of 
mitofilin protein content in control and diabetic mitochondria revealed significant decrements in 
type 1 diabetic IFM with no significant decrease in diabetic SSM (Figure 3.4 A-D; P<0.05). 
Because down-regulation of mitofilin has been associated with loss of mtDNA content, we 
determined whether mtDNA levels were influenced by overexpression in our transgenic mouse 
model [3]. Examination of mtDNA content in mitofilin transgenic and littermate controls 
revealed no significant differences (Littermate Control 5319.83 ± 2265.05 copies vs. Mitofilin 
Transgenic 4866.88 ± 1995.13 copies). To determine whether type 1 diabetic patient heart 
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mitochondria displayed similar mitofilin profiles as a result of the pathology, we examined 
mitofilin protein contents in non-diabetic and type 1 diabetic human patient atrial tissue. Our 
data reveal significant decreases in IFM mitofilin protein contents in diabetic patient atrial tissue 
as compared to non-diabetic patients with no significant differences in SSM between diabetic 
and non-diabetic patients (Figure 3.5 A-D).  
 
3.2 Body weight, heart weight and cardiac contractile function      
Significant decreases in heart and body weights were observed in diabetic and mitofilin 
diabetic animals when compared with their respective controls (Table 3.1; P<0.05). However, 
there was no significant differences observed in heart weight to body weight ratios. Cardiac 
contractile dysfunction was observed in diabetic hearts when compared with control hearts. 
Ejection fraction, fractional shortening and cardiac output were significantly decreased in the 
type 1 diabetic heart relative to control (Table 3.1; P<0.05). Overexpression of mitofilin in the 
presence of diabetes mellitus restored ejection fraction and fractional shortening (Table 3.1; 
P<0.05). Further, no significant differences were observed in stroke volume, or volumes at 
systole and diastole between any groups. Finally, no changes in diameter at systole and diastole 
were observed. 
 
3.3 Mitochondrial functional assessment      
Assessment of ETC complexes I, III, IV and V activities revealed significant decrements 
in diabetic IFM as compared with control IFM (Table 3.2; P <0.05), with no significant 
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differences between control and diabetic SSM (Table 3.2). Overexpression of mitofilin preserved 
ETC complexes I, III, IV and V activities in mitofilin diabetic IFM as compared to diabetic IFM 
(Table 3.2; P<0.05). A significant increase in ATP synthase activity was also observed in the 
mitofilin SSM subpopulation as compared to control SSM (Table 3.2; P<0.05). Using complex I 
substrates glutamate/malate, state 3 and state 4 respiration rates were significantly decreased in 
diabetic IFM compared to control IFM (Table 3.2; P<0.05), with no significant differences 
observed between control and diabetic SSM (Table 3.2). Overexpression of mitofilin in the 
diabetic heart restored state 3 respiration rates in the IFM (Table 3.2; P<0.05) with no significant 
effects observed in the SSM (Table 3.2).  
 
3.4 ETC Complex Protein Expression 
 To gain insight into whether the observed decreases in ETC complex activities were the 
result of down-regulation of individual complex contents, we employed a BN-PAGE approach 
(Figure 3.6 A) which enabled evaluation of the expression of each ETC complex as a whole. Our 
data indicated no significant differences in complexes I, III, IV, and V contents between the four 
treatment groups in SSM (Figure 3.7 A-D) and IFM (Figure 3.8 A-D).   
 
3.5 Mitochondrial membrane potential (ΔΨm)        
No significant differences in SSM ΔΨm were observed among the four groups, (Figure 
3.9A), however, there was a significant reduction of ΔΨm in the diabetic IFM subpopulation 
compared with control which was restored with mitofilin overexpression (Figure 3.9B; P<0.05).  
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3.6 Oxidative stress            
Lipid peroxidation by-products 4-HAE and MDA were significantly increased in diabetic 
IFM compared to control IFM (Figure 3.10B; P<0.05), with no significant differences observed 
in diabetic SSM as compared to control SSM (Figure 3.10A). Mitofilin overexpression 
significantly decreased the accumulation of lipid peroxidation by-products in diabetic IFM, 
restoring them back to that of control IFM levels (Figure 3.10B; P<0.05), suggesting an ability of 
mitofilin to attenuate ROS-induced damage to lipids. 
 
3.7 Electron microscopy 
 Qualitative analysis of mitochondrial morphology was performed by electron 
microscopy. Visualization of IFM structure was assessed in control, diabetic, mitofilin control 
and mitofilin diabetic heart. Morphologically altered IFM with damaged cristae structures were 
observed in the diabetic heart when compared to the control heart (Figures 3.11A-B). 
Overexpression of mitofilin restored mitochondrial morphology and cristae structure in the 
mitofilin diabetic IFM (Figure 3.12B), suggesting a potential role for mitofilin in the 
maintenance of cristae morphology following type 1 diabetic insult. 
 
3.8 Mitochondrial internal complexity 
 Because of the improved mitochondrial morphology and cristae structure observed within 
the electron micrographs of mitofilin diabetic IFM, we determined whether internal complexity 
of the mitochondria were affected by mitofilin expression using flow cytometry. FSC and SSC 
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were used to estimate size and internal complexity of mitochondria respectively (Figures 3.13A-
B). The ratio of SSC to FSC was calculated in an effort to determine changes in internal 
complexity with respect to size. Using this approach, diabetic IFM showed significantly 
decreased internal complexity when compared with control (Figure 3.13D; P<0.05) with no 
changes observed in the SSM (Figure 3.13C). Overexpression of mitofilin significantly restored 
mitochondrial internal complexity in mitofilin diabetic IFM (Figure 3.13D; P<0.05). Restoration 
of mitochondrial morphology and cristae structure with mitofilin overexpression could 
potentially account for the improvement in mitochondrial internal complexity in mitofilin 
diabetic IFM. 
 
3.9 Mitochondrial dynamics 
 Because type 1 diabetes mellitus and mitofilin have been associated with mitochondrial 
dynamics and cristae morphological changes, we examined several ancillary proteins involved in 
the regulation of these processes. Western blot analyses indicated no significant differences in 
any of the proteins that we examined (Mfn1, Mfn2, OPA1, CHCHD3, and Drp1) (Figures 3.14 
and 3.15) which are associated with mitochondrial dynamics, suggesting that mitofilin 
overexpression did not alter the levels of these proteins. 
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4. Discussion/Conclusion 
A number of studies corroborate the notion that mitochondrial dysfunction plays a critical 
role in the pathogenesis of the diabetic heart. Previous studies from our laboratory suggest that 
during type 1 diabetic insult mitochondria are spatially impacted with those situated in between 
the myofibrils (IFM) affected to a greater extent [33, 34, 41, 42]. In particular, the IMM are 
disturbed as evidenced by decreased ETC complex activities, ATP synthase activity, protein 
import, cardiolipin content and cardiolipin synthase activity correlating with the manifestation of 
mitochondrial dysfunction [33, 34, 40-42]. Further, mitochondrial morphology including 
changes in size and internal complexity of IFM are also observed. Proteomic alterations during 
type 1 diabetic insult, which are disproportionately realized in the IMM of the IFM 
subpopulation, have been previously reported [33]. These alterations include a decrease in 
mitofilin, a mitochondrial structural protein. Among mitofilin’s primary functions is the 
maintenance of cristae junctions, branching of cristae and preservation of IMM morphology [3, 
17]. Preservation of cristae structure is essential for proper mitochondrial function and health due 
to the presence of ETC complexes vital for ATP production which are contained in the IMM [5, 
6]. The goal of this study was to determine whether preservation of mitofilin provides 
cardioprotective benefits to the type 1 diabetic heart and whether the beneficial effects are 
associated with improved mitochondrial cristae structure. Overexpression of mitofilin in the 
SSM and IFM of transgenic mice revealed significantly higher expression of the protein in IFM 
as compared to SSM. These findings are in agreement with Ferreira et al. who showed a 37 fold 
increase of mitofilin in cardiac tissue IFM when compared with SSM [56].  
Proteomic analyses from our laboratory reveal a significant decrease in mitofilin content 
in IFM during type 1 diabetic insult [33]. Further, morphological alterations are observed 
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primarily in the IFM subpopulation [34, 57]. Thus, it is plausible that the decreased mitofilin 
content observed in the IFM, resulting from type 1 diabetes mellitus may account, in part, for the 
mitochondrial morphological changes observed which could have downstream effects on 
mitochondrial functionality ultimately leading to cardiac contractile dysfunction. Electron 
micrographs from diabetic hearts revealed damaged mitochondrial cristae in mitochondria 
situated between the myofibrils when compared with the control hearts. Moreover, a significant 
decrease in mitochondrial internal complexity and granularity was observed in diabetic IFM. Our 
findings are in agreement with John et al. who investigated the impact of mitofilin down-
regulation in HeLa cells. Their findings revealed a disorganized IMM as well as increased ROS 
production and apoptosis [16]. Moreover, their study revealed that mitofilin-deficient 
mitochondria fail to produce normal tubular cristae and cristae junctions. These author’s 
observations share similarities to the structural abnormalities observed in diabetic IFM in our 
current study. In a similar study, Rabl et al. investigated the down-regulation of Fcj1, a putative 
orthologue of mammalian mitofilin, in yeast cells. The results of these studies revealed a lack of 
cristae junctions which was correlated with abnormal mitochondrial structure. Electron 
microscopy analyses from hearts overexpressing mitofilin revealed preservation of mitochondrial 
morphology and cristae structure in type 1 diabetic IFM. Moreover, restoration of mitochondrial 
internal complexity and granularity was observed in mitofilin diabetic IFM. Our findings are in 
agreement with a study in which overexpression of Fcj1 in yeast cells led to increased cristae 
junction formation and cristae branching, suggesting normal mitochondrial structure [3]. Taken 
together, data from the current study showing abnormal mitochondrial structure as a result of 
decreased mitofilin content in diabetic IFM, which was restored with mitofilin overexpression, 
are in agreement with others [3, 16, 17]. Finally, overexpression of mitofilin led to preservation 
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of ejection fraction and fractional shortening, suggesting improved cardiac contractile function 
which may be the result of improvement in mitochondrial structure and ultimately, function.  
The inner mitochondrial cristae membrane is the principal site for oxidative 
phosphorylation and ATP production [5]. Mitochondrial cristae structure increases the inner 
membrane surface area enabling a greater capacity for oxidative phosphorylation and ATP 
production. In the current study diabetic IFM with disrupted mitochondrial cristae structure and 
decreased internal complexity displayed significant decrements in ETC complexes I, III, IV as 
well as ATP synthase function which are in agreement with previous observations from our 
laboratory [34, 39]. Overexpression of mitofilin restored ETC complexes and ATP synthase 
activities in the mitofilin diabetic IFM which were associated with restoration of cristae 
morphology as well as mitochondrial internal complexity. Though not assessed in the current 
study, these findings may have been the result of an increased surface area leading to an 
enhanced capacity for oxidative phosphorylation and ATP generation. Nevertheless, it should be 
noted that mitofilin overexpression did not lead to changes in the absolute contents of ETC 
complexes. These findings suggest that the benefits imparted by mitofilin overexpression are not 
the result of increased ETC complexes, rather preservation of IMM integrity which could 
enhance stabilization of the ETC complexes. Additional studies designed to determine changes 
in cristae surface area and their impact on ETC stabilization in the face of enhanced mitofilin 
presence would lend insight into the mechanisms contributing to the observed oxidative 
phosphorylation changes. 
Several studies have shown enhanced ROS production from cardiac mitochondria of 
different type 1 diabetic animal models [34, 58]. The oxidative milieu resulting from enhanced 
ROS production promotes damage to mitochondrial membranes and proteins. We have 
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previously observed increased oxidative damage as indexed through nitrotyrosine residues and 
lipid peroxidation in type 1 diabetic IFM [34]. In the current study, we observed similar 
increases in lipid peroxidation of diabetic IFM. Interestingly, overexpression of mitofilin 
attenuated lipid peroxidation in diabetic IFM which could be due to improved mitochondrial 
structure, and preservation of ETC function. Preservation of mitochondrial structure could 
potentially attenuate electron leakage resulting in decreased ROS production and downstream 
oxidative damage. 
In contrast to our study, mitofilin was reported to be increased in pathological cardiac 
hypertrophy and was shown to promote cardiac hypertrophy in response to hypertrophic stimuli. 
In the current study we observed a decrease in heart weight with no change in heart weight/body 
weight ratio as a result of a parallel decrease in body weight following diabetes mellitus 
induction. One potential limitation of our study was the lack of assessment of heart weight/tibia 
length which may have been decreased provided tibia length remained constant which has been 
reported in previous low-dose STZ studies [59]. Moreover, mitofilin overexpression was shown 
to increase ROS generation and lower oxidative phosphorylation activity in animals subjected to 
a cardiac hypertrophy protocol [60]. The differences in the observed results between the two 
studies could be due to a multitude of reasons. Zhang et al. utilized whole tissues for assessing 
oxidative phosphorylation and frozen tissues for their ROS measure in comparison with isolated 
mitochondria used in our studies. Moreover, two different models of cardiomyopathy were being 
studied; diabetic cardiomyopathy and hypertrophy that depict a differential expression of 
mitofilin levels suggesting its distinct role in these pathologies. Furthermore, decrements in 
mitofilin content have also been observed in other human diseases such as Down’s syndrome 
[24, 25] , Parkinson’s disease [26, 27], Epilepsy [28, 29] and Neurodegeneration [30, 31]. Hence, 
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these varied changes of mitofilin observed in different human pathologies as well as different 
cardiac pathologies suggest unique responses and effects of mitofilin under different pathological 
stimuli. 
In conclusion, we report for the first time, that overexpression of mitofilin in a type 1 
diabetic mouse model preserves mitochondrial structure and function, resulting in cardiac 
contractile protection. Mitochondrial functional preservation is associated with the restoration of 
ETC complex activities, ATP synthase activity, state 3 respiration rates, and attenuation of lipid 
peroxidation which are the result of improved mitochondrial morphology, structure and internal 
complexity.  
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Figure 3.1 
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Figure 3.1. Schematic of mitofilin transgenic construct. The generation of mitofilin transgenic 
mice was accomplished by insertion of human mitofilin cDNA into the XbaI and XhoI cloning 
sites of pCAGGS as SgfI and XhoI fragment and released by SspI and BamHI digestion. 
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Figure 3.2 
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Figure 3.2. Mitofilin protein expression in control and transgenic mitochondrial 
subpopulations. Western blot analysis of mitofilin protein expression in isolated (A) SSM and 
IFM mitochondria. Lanes 1-2 are controls, lanes 3-4 are mitofilin transgenic, and lanes 5-6 are 
mitofilin transgenic diabetic samples for both SSM and IFM mitochondria. (B) Bar graph 
representation for SSM and IFM mitochondria protein levels.  COX IV staining was used as 
loading controls for the blots. Values are expressed as means ± SEM. *P <0.05 vs. control; n=4 
per each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar mitochondria. 
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Figure 3.3 
 
 
 
 
 
 
 
 
131 
 
 
Figure 3.3.  Mitofilin protein expression in control and transgenic whole heart. Western blot 
analysis of mitofilin protein expression in total heart mitochondria from control (lanes 1-2) and 
mitofilin transgenic (lanes 3-4) mouse. GAPDH and ponceau staining were used as loading 
controls for the blots. Values are expressed as means ± SEM. *P <0.05 vs. control; n=4 per each 
group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar mitochondria.  
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Figure 3.4 
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Figure 3.4. Mitofilin protein expression analysis in control and diabetic mitochondria 
subpopulations from mouse. (A) Control SSM (lanes 1 and 2) and diabetic SSM (lanes 3 and 4) 
(B) control IFM (lanes 1 and 2) and diabetic IFM (lanes 3 and 4) were analyzed for mitofilin 
protein expression. Bar graph representation of mitofilin protein levels over COX IV in SSM (C) 
and IFM (D) subpopulations. Values are presented as means ± SE; *P <0.05 for control vs. 
diabetic. Control for protein loading was confirmed with COX IV (mitochondria loading 
control); n=5 for each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar 
mitochondria. 
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Figure 3.5 
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Figure 3.5. Mitofilin protein expression analysis in control and diabetic mitochondria 
subpopulations from human samples. Analysis of mitofilin protein content in non-diabetic and 
type 1 diabetic human patient samples in SSM (A) and IFM (B) subpopulations. Bar graph 
representation of mitofilin protein levels over COX IV in SSM (C) and IFM (D) isolated from 
human patient samples. Values are presented as means ± SE; *P <0.05 for control vs. diabetic. 
Control for protein loading was confirmed with COX IV (mitochondria loading control); n=5 for 
each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar mitochondria. 
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Figure 3.6 
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Figure 3.6. Blue Native page analyses. (A) Molecular weight markers in kDa along with ETC 
complexes size are included for two control samples. MW: molecular weight marker. 
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Figure 3.7 
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Figure 3.7. BN-PAGE analysis of ETC Complexes in SSM subpopulations. ETC complexes 
expression was examined in control, diabetic, mitofilin control and mitofilin diabetic 
mitochondrial SSM subpopulations using BN-PAGE. Bar graph representation of ETC 
complexes I, III, IV and V assessed for SSM (A-D). Values are expressed as means ± SEM. n=6 
per each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar mitochondria. 
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Figure 3.8 
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Figure 3.8. BN-PAGE analysis of ETC Complexes in IFM subpopulations. ETC complexes 
expression was examined in control, diabetic, mitofilin control and mitofilin diabetic 
mitochondrial IFM subpopulations using BN-PAGE. Bar graph representation of ETC 
complexes I, III, IV and V assessed for IFM (A-D). Values are expressed as means ± SEM. n=6 
per each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar mitochondria. 
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Figure 3.9 
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Figure 3.9. Mitochondrial membrane potential. Isolated mitochondria from control, diabetic, 
mitofilin control and mitofilin diabetic hearts were incubated with JC-1, and 100,000 gated 
events were analyzed per sample in (A) SSM and (B) IFM subpopulations. Values are expressed 
as means ± SEM. *P < 0.05 for control vs. diabetic and #P < 0.05 for diabetic vs. mitofilin 
diabetic; n=8 per each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar 
mitochondria.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
 
Figure 3.10 
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Figure 3.10.  Lipid peroxidation by-products. Oxidative damage to lipids was assessed in 
control, diabetic, mitofilin control and mitofilin diabetic (A) SSM and (B) IFM subpopulations 
by measuring lipid peroxidation by-products malondialdehyde (MDA) and 4-hydroxyalkenals 
(4-HAE) using a colorimetric assay. Results were compared against a standard curve of known 
4-HAE and MDA concentrations. Values are expressed as means ± SEM. *P < 0.05 for control 
vs. diabetic and #P < 0.05 for diabetic vs. mitofilin diabetic; n=4 per each group. SSM: 
subsarcolemmal mitochondria, IFM: interfibrillar mitochondria. 
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Figure 3.11 
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Figure 3.11.  Mitochondrial structure.  Electron micrographs( x 16.0K) from left ventricle of 
(A) Control, and (B) Diabetic mice hearts showing mitochondrial morphology and cristae 
structures in the IFM subpopulations of type 1 diabetic heart. IFM: interfibrillar mitochondria 
: myofibrils.  
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Figure 3.12 
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B) 
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Figure 3.12.  Mitochondrial structure.  Electron micrographs( x 16.0K) from left ventricle of 
(A) Mitofilin Control, and (B) Mitofilin Diabetic mice hearts showing mitochondrial 
morphology and cristae structures in the IFM subpopulations of type 1 diabetic heart. IFM: 
interfibrillar mitochondria : myofibrils.  
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Figure 3.13 
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Figure 3.13. Mitochondrial Internal Complexity. Mitochondrial internal complexity was 
assessed in control, diabetic, mitofilin control and mitofilin diabetic hearts. Forward scatter and 
side scatter were used to analyze isolated mitochondria as seen by representative histograms of 
(A) SSM and (B) IFM. The ratio of side scatter to forward scatter was used to calculate internal 
complexity of the mitochondria in (C) SSM and (D) IFM mitochondria. Values are expressed as 
means ± SEM. *P < 0.05 for control vs. diabetic and #P < 0.05 for diabetic vs. mitofilin diabetic; 
n=8 per each group. SSM: subsarcolemmal mitochondria, IFM: interfibrillar mitochondria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
Figure 3.14 
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Figure 3.14. Western Blot analyses of mitochondrial dynamics. Protein expression of 
mitochondrial fission, fusion, Chchd3 and Opa1 proteins were analyzed in control, mitofilin, 
mitofilin diabetic, and diabetic cardiac SSM mitochondria. Control for protein loading was 
confirmed with COX IV (mitochondria loading control); n=4 for each group. SSM: 
subsarcolemmal mitochondria. 
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Figure 3.15 
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Figure 3.15. Western Blot analyses of mitochondrial dynamics. Protein expression of 
mitochondrial fission, fusion, Chchd3 and Opa1 proteins were analyzed in control, mitofilin, 
mitofilin diabetic, and diabetic cardiac IFM mitochondria. Control for protein loading was 
confirmed with COX IV (mitochondria loading control); n=4 for each group. IFM: interfibrillar 
mitochondria. 
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Table 3.1 
    
     
Contractile Parameter Control      Diabetic 
Mitofilin 
Control 
Mitofilin 
Diabetic 
BW, g 28.0 ± 0.8 25.5 ± 0.5* 27.1 ± 0.7 24.6 ± 0.4* 
HW, mg 102.7 ± 4.4 94.3 ± 2.5* 103.0 ± 2.1 91.3 ± 1.9* 
HW/BW, mg/g 3.7 ± 0.1 3.7 ± 0.1 3.8 ± 0.1 3.7 ± 0.1 
Ejection fraction, % 70.6 ± 1.4 65.2 ± 0.8* 70.6 ± 1.8 74.7 ± 1.5# 
Fractional shortening, % 39.0 ± 1.1 34.8 ± 0.6* 39.4 ± 1.4 42.4 ± 1.4# 
Cardiac Output, ml/min 18.1 ± 1.2 14.2 ± 1.4* 17.5 ± 1.1 16.0 ± 2.7 
Diameter; s, mm 2.0 ± 0.1 2.1 ± 0.1 2.0 ± 0.2 1.8 ± 0.1 
Diameter; d, mm 3.2 ± 0.1 3.3 ± 0.1 3.4 ± 0.1 3.1 ± 0.1 
Volume; s, µl 13.8 ± 0.6 14.4 ± 1.5 12.8 ± 2.6 10.1 ± 1.0 
Volume; d µl 41.4 ± 4.0 44.7 ± 3.5 47.4 ± 4.3 37.9 ± 2.4 
Stroke volume, µl 32.3 ± 1.9 28.1 ± 2.3 34.6 ± 2.1 28.3 ± 1.7 
Heart rate, bpm 517.0 ±15.7 487.0 ±13.6 506.0 ±14.5 486.0 ± 21.6 
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Table 3.1. Cardiac contractile function. Cardiac contractile measurements were assessed using 
the Vevo 2100 imaging system. Values are means ± SEM. *P < 0.05 diabetics vs. their 
respective control, #P < 0.05 diabetic vs. mitofilin diabetic; n=20 for BW, HW and n=6 for other 
parameters. BW: body weight, HW: heart weight, s: systole, d: diastole, bpm: beats per minute. 
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Table 3.2 
Group Complex I Complex III Complex IV Complex V State 3 State 4 
SSM Control 32.2 ± 4 98.7 ± 17 12.5 ± 2.4 12.1 ± 0.9 16.1 ± 1.1 2.6 ± 0.5 
SSM Diabetic 29.2 ± 2.7 88 ± 7.6 10.7 ± 1.5 12.9 ± 0.9 18.1 ± 0.7 1.9 ± 0.3 
SSM Mitofilin 30.4 ± 3.7 86 ± 11.7 10.4 ± 1.9 16.8 ± 1.4* 17.9 ± 2.1 3.6 ± 0.6 
SSM Mitofilin Diabetic 29.9 ± 1.9 88.4 ± 13.7 12 ± 2.6 14.7 ± 1.2 22.2 ± 2.6 2 ± 0.3 
 
IFM Control 46.8 ± 1.9 197 ± 8.8 39 ± 7 24.5 ± 1.3 21.8 ± 0.9 4.2 ± 0.6Ϯ 
IFM Diabetic 31.3 ± 2.8* 151 ± 6.6* 19.5 ± 2* 20.6 ± 0.6* 14.7 ± 0.6* 2 ± 0.2 
IFM Mitofilin 44.1 ± 6.1 173 ± 13.6 31.9 ± 2.7 23.9 ± 0.7 19.2 ± 1.4 2.4 ± 0.3 
IFM Mitofilin Diabetic 45.9 ± 1.7# 206 ± 11# 37.7 ± 4# 26.6 ± 1.1# 22.3 ± 3.5# 2.2 ± 0.1 
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Table 3.2. Mitochondrial functional assessment. Mitochondrial electron transport chain (ETC) 
complex activities and respiration rates were examined in control, diabetic, mitofilin control and 
mitofilin diabetic mitochondrial subpopulations. ETC complexes I, III, IV and V activities were 
assessed spectrophotometrically by measuring the oxidation of NADH (complex I), reduction of 
cytochrome c (complex III), oxidation of cytochrome c (complex IV) and an assay coupled with 
pyruvvate kinase (complex V). Enzymatic activities for complexes I, III and IV are expressed as 
activity per minute per milligram of protein and complex V is expressed as nmol of NADH per 
minute per milligram of protein. State 3 and state 4 respiration rates were determined in the 
presence of the substrates glutamate-malate, and state 3 respiration was examined upon addition 
of ADP. Values are expressed as means ± SEM.  *P < 0.05 vs. control, #P < 0.05 vs. diabetic and 
ϮP < 0.05 against all groups; n=8 per each group. SSM: subsarcolemmal mitochondria, IFM: 
interfibrillar mitochondria. 
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ABSTRACT 
 
Rationale:
 
 Cardiomyocytes are rich in mitochondria which are situated in spatially-distinct 
subcellular regions including those under the plasma membrane (subsarcolemmal mitochondria; 
SSM), and those between the myofibrils (interfibrillar mitochondria; IFM). Previously, we have 
observed subpopulation-specific differences in mitochondrial proteomes following diabetic 
insult.  
Objective:
 
 Determine whether mitochondrial genome-encoded proteins are regulated by 
microRNAs present in the mitochondrion and whether mitochondrial subcellular spatial location 
or diabetes mellitus influences the dynamics.  
Methods and Results: Using microarray technology coupled with cross-linking 
immunoprecipitation and next generation sequencing, we identified a functional pool of 
mitochondrial microRNAs, termed mitomiRs that are redistributed in spatially-distinct 
mitochondrial subpopulations in an inverse manner following diabetic insult.  Redistributed 
mitomiRs displayed distinct interactions with the mitochondrial genome requiring specific 
stoichiometric associations with RISC constituents argonaute-2 (Ago2) and fragile X mental 
retardation–related protein 1 (FXR1) for translational regulation.  In the presence of Ago2 and 
FXR1, redistribution of mitomiR-378 to the IFM following diabetic insult led to down regulation 
of mitochondrially-encoded F0 component (ATP6). Next generation sequencing analyses 
identified specific transcriptome and mitomiR sequences associated with ATP6 regulation.  
Overexpression of mitomiR-378 in HL-1 cells resulted in its accumulation in the mitochondrion 
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and down-regulation of functional ATP6 protein, while antagomir blockade restored functional 
ATP6 protein and contractile function. 
 
Conclusions:
 
 We propose that mitomiR translational regulation of mitochondrially-encoded 
proteins oscillates in spatially-distinct mitochondrial subpopulations during diabetes mellitus. 
The results reveal the requirement of RISC constituents in the mitochondrion for functional 
mitomiR translational regulation and provide a connecting link between diabetic insult and ATP 
synthase function. 
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ABBREVIATIONS 
 
Ago2 = argonaute-2 
ARE = AU rich elements 
CLIP = cross-linked immunoprecipitation 
FPKM = fragments per kilobase of exon per million 
FXR1 = fragile X mental retardation–related protein 1 
IFM = interfibrillar mitochondria 
miRNA = microRNA 
mitomiR = mitochondrial microRNA 
RISC = RNA-induced silencing complex 
SSM = subsarcolemmal mitochondria 
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INTRODUCTION 
 
Emerging technologies are likely to aid in the discovery of the underlying gene regulation 
linking the mitochondrion to disease initiation and progression. Cardiac tissue is rich in 
mitochondria with spatially-distinct subpopulations which include subsarcolemmal mitochondria 
(SSM), located beneath the cell membrane, and interfibrillar mitochondria (IFM), situated 
between the myofibrils 1, 2. Type 1 diabetes mellitus influences cardiac contractility of which 
mitochondrial dysfunction is central 2-5. The complete mitochondrial genomic sequence has been 
elucidated 6 with each mitochondrion possessing between two and ten copies 7. The 
mitochondrial genome is comprised of 37 genes, 13 of which code for proteins that form parts of 
the oxidative phosphorylation machinery, while the remaining genes code for 22 transfer RNAs 
and two ribosomal RNAs 8. Absence of introns renders the mitochondrial DNA compact while 
lack of histones influences mutation rates and DNA damage repair mechanisms 7. As such, the 
development and progression of many human diseases involves regulation of the mitochondrial 
genome 9, 10. 
  
MicroRNAs (miRNAs) have been shown to play an integral role in regulating gene 
expression through translational repression or degradation of target messenger RNAs (mRNA). 
miRNAs are non-coding RNAs, which influence post-transcriptional gene regulation by binding 
to the 3'-untranslated region (3'-UTR) of target mRNAs. Regulation of gene expression at the 
post-transcriptional level occurs through binding of the miRNA to complementary sites on the 
target mRNA. Association with the RNA-induced silencing complex (RISC) takes place in the 
cytoplasm, thereby regulating translation of the target mRNA 11. Target mRNAs can contain AU 
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rich elements (ARE) which, in conjunction with a given miRNA, will enhance recruitment of the 
RISC components, including argonaute-2 (Ago2) and fragile X mental retardation–related 
protein 1 (FXR1), thereby influencing translation 12. Mature miRNAs have been observed in the 
nucleus and specialized processing bodies13, yet reports identifying mature miRNAs in the 
mitochondrion are limited14, 15. A recent review supporting the existence of miRNAs in the 
mitochondrion have utilized the terminology mitomiR in reference to mitochondrial miRNAs 16. 
Pharmacological inhibition of cardiac-specific miRNA enhances metabolic energy homeostasis 
suggestive of a link between miRNA regulation and the mitochondrion17. Further, mice lacking 
specific miRNAs, including miR-378, exhibit enhanced mitochondrial fatty acid metabolism and 
elevated oxidative capacity18. Though increasing evidence indicates that mitochondrial 
subpopulations are differentially influenced by physiological stressors3, 19-22, no study has 
reported specific enrichment patterns of mitomiRs in spatially-distinct subpopulations or whether 
distribution patterns are influenced by pathological states, including diabetes mellitus. The 
results of our studies suggest a dynamic system requiring the presence of RISC constituents in 
the mitochondrion, which function to regulate the mitochondrial genome during diabetic insult in 
a spatially-distinct manner.  
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METHODS 
 
 
Ethics Statement  
The experiments in this study conformed to the NIH Guide for the Care and Use of 
Laboratory Animals (8th Edition) and were approved by the West Virginia University Animal 
Care and Use Committee. 
 
Experimental Animals and Diabetes Induction  
Male FVB mice (The Jackson Laboratory, Bar Harbor, ME) were housed in the West 
Virginia University Health Sciences Center animal facility and given food and water ad libitum. 
Type 1 diabetes mellitus was induced in 5 week old mice using multiple low-dose streptozotocin 
(STZ; Sigma, St. Louis, MO) injections as previously described 2, 3.  Mice that served as vehicle 
controls were given the same volume per body weight of sodium citrate buffer. One week post-
injections, hyperglycemia was confirmed by measuring fasting blood glucose levels using a 
commercially available kit (Bayer, Mishiwaka, IN).  Blood glucose levels greater than 250 
mg/dL were considered diabetic.  
 
Preparation of Individual Mitochondrial Subpopulations  
At 5 weeks post-hyperglycemia onset, mice were sacrificed and their hearts excised.  
SSM and IFM subpopulations were isolated as previously described 1 with minor modifications 2, 
3, 23-25. Following isolation, SSM and IFM were further purified by percoll gradient (23%, 15%, 
10% and 3% percoll solution) and centrifuged in a Beckman OptimaTM MAX-XP Ultracentrifuge 
(Beckman Coulter, Fullerton, CA) at 32,000 x g for 8 minutes. Mitochondrial subpopulation 
168 
 
pellets were resuspended in a sucrose based SEM buffer (250 mM sucrose, 1 mM EDTA, 10 mM 
MOPS, pH 7.2) or mitochondrial extraction buffer (Biovision, Mountain View, CA) depending 
upon the assay to be performed.  Mitochondrial protein concentrations were determined using the 
Bradford method and bovine serum albumin as a standard 26. 
 
RNA Isolation and Microarray Experimentation  
Total RNA was extracted from isolated mitochondrial subpopulations using a Vantage 
Total RNA Purification Kit (Origene, Rockville, MD). Sample labeling and hybridization was 
performed using an Agilent miRNA Complete Labeling and Hybridization Kit (Agilent 
Technologies, Santa Clara, CA) following the manufacturer’s protocol. Briefly, 80 ng of total 
RNA was labeled and subsequently hybridized overnight (20 hours at 55°C) to an Agilent Mouse 
microRNA Microarray 8x60K v.16 using Agilent’s recommended hybridization chamber and 
oven. The microarrays were washed once with Agilent Gene Expression Wash Buffer 1 (5 
minutes at room temperature) followed by a second wash with preheated Agilent Gene 
Expression Wash Buffer 2 (5 minutes at 37°C). Fluorescence signals were detected using 
Agilent’s Microarray Scanner System (Agilent Technologies, Santa Clara, CA). Differential 
miRNA expression FES derived output data files were analyzed using Gene Spring GX software 
(Agilent Technologies, Santa Clara, CA). Candidate miRNAs were identified and analyzed 
statistically. 
 
Computational Analyses 
To scan the mitochondrial genome for potential miRNA target sites, we used three 
independent algorithms, RNAhybrid, miRWalk and MicroCosm. The algorithmic core of 
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RNAhybrid does not utilize any RNA folding or pairwise sequence alignment code, but rather, 
implements an algorithm that was specifically designed for RNA hybridization 
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/submission.html). The miRWalk algorithm is 
based on a computational approach starting with a heptamer seed miRNA seed, and identifies 
complementation on the complete mitochondrial genome (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/). The MicroCosm target algorithm uses a weighted scoring 
system and rewards complementation at the 5' end of the miRNA (http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/info.html). A probability distribution of random matches for a 
subsequence in the given sequence is calculated. All prediction algorithms were run under 
default parameters. 
 
Network Analyses  
Network analyses were performed on altered miRNAs from the microarray analyses and 
on the predicated targets identified from the Computational Analyses (see above). 
Mitochondrially-encoded genes were mapped to corresponding gene objects in the Ingenuity 
Knowledge Base (http://ingenuity.com/). These mitochondrial genes, called focus genes, were 
overlaid into a global miRNA network developed from the information contained in the 
Ingenuity Pathways Knowledge Base. Networks of focus genes were then algorithmically 
generated based on their connectivity. A network pathway is a graphical representation of the 
molecular relationships between individual miRNAs as well as miRNAs and mitochondrially-
encoded mRNAs.  
 
qRT-PCR of Mature miRNAs  
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Briefly, 50 ng of total RNA was reverse transcribed into cDNA using a First-strand 
cDNA Synthesis Kit for miRNA (Origene, Rockville, MD) as per the manufacturer’s protocol. 
Equal amounts of cDNA from control and diabetic mouse mitochondrial subpopulations were 
subjected to qRT-PCR. For HL-1 and miR-378 overexpressing HL-1 cell lines, isolated 
mitochondria were subjected to qRT-PCR. Custom primers were designed for miR-378 
(Origene, Rockville, MD) and utilized for the quantification of cDNA replicates using QSTAR 
SYBR master mix (Origene, Rockville, MD). qRT-PCR assays were performed in duplicate 
using an Applied Biosystems 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster 
City, CA). All miRNA expression levels were normalized to U6 RNA contents. 
 
Western Blot Analyses 
SDS-PAGE was run on 4–12% gradient gels, as previously described 2, 27, with equal 
amounts of protein loaded for each study treatment. Relative amounts of subpopulation-specific 
mitochondrially-encoded proteins were quantified using antibodies specific for each protein 
(antibody details are indicated in the Supplemental Material section).  Relative amounts of 
subpopulation-specific mitochondrial localized RISC complex proteins, Ago2 and FXR1, as well 
as biotinylated proteins were quantified using the following primary antibodies; anti-Ago2  
rabbit antibody (product #2897, Cell Signaling, Danvers, MA), anti-FXR1 rabbit antibody 
(product #4264S, Cell Signaling, Danvers, MA), anti-GFP mouse monoclonal (product 
#TA150041, Origene, Rockville, MD) and anti-biotin rabbit antibody (product #5571, Cell 
Signaling, Danvers, MA). Mitochondrial loading control was assessed using an anti-COX IV 
rabbit antibody (product #ab16056, Abcam, Cambridge, MA). The secondary antibody used in 
the analyses was a goat anti-rabbit IgG HRP conjugate (product #10004301, Cayman Chemical, 
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Ann Arbor, MI). Detection and quantitation of chemiluminescent signals were performed using a 
G:BOX (Syngene, Frederick, MD), and the data expressed as arbitrary optical density units 
(ODU). Secondary confirmation of protein loading and equal protein transfer was performed 
using Ponceau staining. 
 
ATP Synthase Activity 
 ATP synthase activity was determined by following the decrease in NADH absorption at 
340 nm as previously described 25 and final values expressed as micromoles consumed per 
minute per milligram of protein 26. 
 
UV Cross-Linking Immunoprecipitation (CLIP) 
Mouse heart tissue was minced in a 2 ml volume of ice-cold PBS, transferred to a petri 
dish with a suspension depth of approximately 1 mm. Samples were irradiated 5 times with 
400 mJ/cm2 (∼15 cm distance from the UV source) on ice using a CL-1000 Ultraviolet 
Crosslinker (UVP, Upland, CA), and mixed between each irradiation 28. After irradiation, 
samples were pelleted by centrifugation (2500 rpm for 5 minutes at 4°C) and the supernatant 
removed. SSM and IFM were isolated as described above and resuspended in IP buffer  (20mM 
Tris pH 8.0; 137mM NaCl; 10% Glycerol; 1% Nonidet P-40 (NP-40); 2mM EDTA; 1/100 
protease inhibitor cocktail). Protein concentrations were determined as above. Two hundred μg 
of resuspended protein was added to IP buffer up to 1 ml and the RNA digested by addition of  
10 μl of RNase I (Life Technologies, Grand Island, NY) (1:500 dilution). The complex was 
incubated (3 minutes at 37°C) with constant shaking (1,100 rpm) then transferred to ice.  Fifty μl 
of Dynabeads Protein A (Life Technologies, Grand Island, NY) were washed 3 times with IP 
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buffer and then resuspended in a 100 μl of solution of IP buffer and 5 μl of a specific antibody 
(anti-Ago2 or anti-FXR1). The antibody was allowed to bind to the beads by rotating the tubes (1 
hour at room temperature). The beads were then washed three times with IP buffer, and cross-
linked mitochondrial subpopulation lysates added followed by tube rotation (2 hours at 4°C). 
Beads were then washed three times with IP buffer. A portion of the sample was utilized to 
check antibody specificity using high RNase I (1:50 dilution), while the other portion was used 
for RNA 3'-end biotinylation labeling (Thermo Scientific, Pittsburgh, PA) using T4 RNA ligase 
to attach a single biotinylated nucleotide to the 3' terminus of an RNA strand. Samples were 
incubated overnight at 16°C and then washed with IP buffer.  Thirty μl of loading buffer without 
denaturing agent was added to both the biotinylated and high RNAse I treated beads and heated 
for 10 minutes at 70 °C with shaking (1000 rpm). Samples were submitted to SDS-PAGE as 
described above.  The biotinylated (low RNAse I) sample bands were cut with a clean scalpel 
and the nitrocellulose membrane placed into a microcentrifuge tube. One hundred μl of 
proteinase K solution was added to each tube, incubated for 20 minutes at 37 °C with shaking 
(1000 rpm), and then the RNA extracted using a Vantage Total RNA Purification Kit (Origene, 
Rockville, MD) as above.  qRT-PCR was performed using custom primers designed for targets 
of mouse miR-378 as described above as well as mitochondrially-encoded genome primer 
duplex targets (Origene, Rockville, MD).  Data were normalized to CLIP total RNA input and 
RISC proteins (Ago2 and FXR1). 
 
Next Generation Sequencing 
 Four groups of pooled CLIP-RNA samples (control and diabetic; SSM and IFM; n=5 per 
group) were used for high-throughput sequencing. mRNA and miRNA library preparation was 
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performed using true RNA-seq (Illumina, San Diego, CA) and small RNA-seq kits (Illumina, 
San Diego, CA), respectively. Briefly, as per the manufacturer’s instructions, initial RT–PCR, 
and barcoded products were run on a 2% agarose gel and 200- to 400-bp products purified using 
QiaEx II beads (Qiagen, Valencia, CA). Gel-purified material was amplified for 12 cycles with 
fusion Illumina adaptor primers and the DNA was subjected to next generation sequencing. The 
sequencing of CLIP tags was performed with barcoded libraries using the Illumina Sequencing 
(Mi-Seq) Adaptor primers. Base calling, library sorting by barcode, and mapping to the 
transcriptome were performed, subsequently. 
 
Bioinformatic Analysis of CLIP Tags 
CLIP tags were aligned to the mm10 genome with mitochondrial genome and analyzed 
with Avadis NGS which is an integrated platform that provides tools for extensive workflows for 
alignment, analysis, management and visualization of next-generation sequencing data 
(http://www.avadis-ngs.com/). To crosscheck the Avadis NGS results, we employed several 
other platforms including Galaxy (http://galaxy.psu.edu), the UCSC genome browser 
(http://genome.ucsc.edu/), and miRBASE (http://microrna.sanger.ac.uk). RNA abundance from 
the paired-end RNA-Seq data was expressed as Fragments Per Kilobase of transcript per Million 
mapped reads (FPKM). To assess RISCome enrichment and depletion scores between the 
diabetic and control SSM and IFM, diabetic RISCome FPKM values were normalized to control 
RISCome FPKM values with a cut off ≥1.5.  To estimate the false negative rate, results were 
compared by examining the number of Ago2-mRNA clusters with no predicted seeds in the top 
20 Ago2-miRNAs identified by next generation sequencing. To generate Ago2-mitomiR ternary 
maps, we examined all mitomiR seeds in the Ago2 footprint region analysis. From these data we 
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looked for the greatest enrichment of miRNA seeds in the Ago2-mRNA clusters that were 
present within the top 20 identified miRNAs. We calculated the frequency of conserved mitomiR 
seed matches observed in the Ago2-mRNA footprint regions. 
 
Cell Culture and Stable Cell Line Development 
Cell culture and stable cell line development were carried out using the mouse 
cardiomyocyte cell line (HL-1) which maintains a cardiac-specific phenotype following repeated 
passaging 29.  HL-1 cells were grown at 37°C in a humidified atmosphere of 5% CO2 / 95% air 
and maintained in Claycomb media (Sigma Aldrich, St. Louis, MO) with 10% fetal bovine 
serum (Sigma, St. Louis, MO) and other supplements. miRNA expression plasmid (pCMV-MIR) 
which contains coral GFP for cellular tracking and assessment of transfection efficiency, housing 
the mouse precursor sequence of miR-378 (pre-miR-378) was utilized for stable cell line 
development (Product # sc401025; Origene, Rockville, MD). 
 
The pre-miR-378 precursor sequence was the following: 5′ -AGGGCTCCTG ACTCCAGGTC 
CTGTGTGTTA CCTAGAAATA GCACTGGACT TGGAGTCAGA AGG
 
CCT-3′, where the 
mature sequence is underlined. The pre-miR-378 sequence was situated at the 293 bp – 358 bp of 
a 656 bp insert. The total 656 bp sequence was situated in the multicloning site of the pCMV-
MIR plasmid between Sgf I and Mlu I restriction sites.   
Cells were seeded at a density of ∼1–3 × 105 cells/35-mm dishes and transfected at 60–70% 
confluence using an X-tremeGENE HP DNA Transfection Kit per the manufacturer’s protocol 
(Roche, Indianapolis, IN).  Forty-eight hours post-transfection, stable cell lines were selected in 
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selection media containing G418 (Gibco, Grand Island, NY). After, 4-5 passages cells were 
washed with phosphate-buffered saline (PBS) and harvested in either 1X RIPA Buffer (Sigma, 
St. Louis, MO) for total lysate or purified mitochondria isolated using a mitochondrial isolation 
kit (Thermo scientific, IL) for protein and enzymatic analyses. 
 
In Vivo Antagomir Delivery in the Diabetic Heart 
 To determine whether manipulation of miR-378 in vivo influences ATP6 levels, ATP 
synthase functionality and ultimately, cardiac contractile function, we utilized an antagomir 
delivery approach. Antagomirs are anti-sense oligonucleotide sequences conjugated with 
cholesterol which can be delivered by injection, systemically 30, 31. Antagomirs provide sustained 
miR blockade and are currently in Phase II trials to treat a number of pathologies 32, 33. Linked 
nucleic acid (LNA) antagomirs are unique in that their sugar ring is locked with a methylene 
bridge placing the miR into an optimal end conformation and creating a more stable duplex 
leading to greater specificity for a given nucleic acid target. Four groups were utilized for the 
studies, 1) LNA-miR-378 (Seq: 5’TGACTCCAAGTCCAG3’) (Exiqon, Woburn, MA) which 
was injected with STZ, 2) LNA-scrambled control (Seq: 5’ACGTCTATACGCCCA3’) (Exiqon, 
Woburn, MA) which was injected with STZ, 3) diabetic control which was injected with STZ 
and 4) vehicle control (0.9% NaCl) without STZ. Five week old male FVB mice were imaged by 
echocardiography (described below) as a baseline after which type 1 diabetes mellitus was 
induced using multiple low-dose STZ injections as described above. Antagomir and vehicle 
treatment groups were intraperitoneally-injected once weekly for 4 weeks at a volume of 250 µl 
per injection and a concentration of 25 mg antagomir/kg body weight or . This concentration and 
dosing schedule was chosen based on previous literature using similar LNA-miR compounds 34. 
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One week following the last injection (5 weeks total treatment time; 11 weeks of age) mice were 
reimaged by echocardiography. Mice were then euthanized and cardiac mitochondrial 
subpopulations isolated as described above, for biochemical analyses. 
 
Cardiac Contractile Function 
 Transthoracic echocardiography was performed as previously described by our laboratory 
35, 36 and others 37. Briefly, mice were lightly anesthetized with inhalant isofluorane and 
transferred to dorsal recumbency. Using the Vevo 2100 Imaging System (Visual Sonics, 
Toronto, Canada) and a 32- to 55-MHz linear array transducer, micro-ultrasound images were 
acquired. M-mode images were captured via the parasternal short axis at midpapillary level with 
all images acquired at the highest possible frame rate (233-401 frames/s). Ejection fraction and 
fractional shortening were obtained from the scanned images.  
 
Statistical Analyses 
Means and standard errors (SE) were calculated for all data sets.  Data were analyzed 
with a Student’s t-tests along with a Welch’s Correction non-parametric test (two-tailed) as 
determined by normality of the data (GraphPad Software Inc., La Jolla, CA). For cardiac 
functional parameters in the in vivo antagomir studies, data were analyzed with a two-way 
analysis of variance (ANOVA) method to evaluate the main treatment effects; therapeutic 
intervention and time. Tukey’s post hoc tests were performed to determine significant 
differences among means. P<0.05 was considered significant.  
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RESULTS 
 
The mitochondrial proteome contains nuclear-encoded proteins that are imported from 
the cytoplasm as well proteins translated from its inherent genome 38, which may be subject to 
post-transcriptional regulatory mechanisms.  Recent reports demonstrate that miRNAs are 
associated with the mitochondrion 13-15 however subpopulation-specific miRNA profiles have yet 
to be examined at baseline or during pathological conditions. To determine whether type 1 
diabetes mellitus influences miRNA profiles in spatially-distinct mitochondrial subpopulations, 
we utilized male FVB mice at five weeks post multiple low-dose streptozotocin treatment. This 
procedure renders mice diabetic as assessed by enhanced blood glucose levels as well as reduced 
plasma insulin levels 3, yet limits the toxic effects seen with a single high dose approach 39, 40.  
We isolated and purified SSM and IFM subpopulations from diabetic and control mouse heart 
and confirmed purity by assessing the content by gel electrophoresis of mitochondrial specific 
ribosomal RNAs (16SrRNA and 12SrRNA) (Supplemental Figures S1a-b) as well as the content 
of the cytosolic protein, GAPDH and mitochondrial protein ATP5b (Supplemental Figure S1c). 
 
 
Differential Redistribution of MitomiRs in the Diabetic Heart   
We profiled the expression levels of miRNAs in diabetic and control mouse cardiac SSM 
and IFM using a high-throughput miRNA microarray. Profiling of the mitomiRs, revealed a 
significantly altered inverse expression profile following diabetes mellitus insult for many of the 
mitomiRs when comparing the two subpopulations. The miRNA array analyses indicated that 78 
mitomiRs were differentially regulated in the two mitochondrial subpopulations following type 1 
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diabetic insult relative to control (Figures 4.1 and 4.2). Specifically, we observed an inverse 
distribution pattern between SSM and IFM following diabetic insult such that greater than 54% 
of identified mitomiRs were inversely distributed between the two subpopulations. These 
alterations in expression profiles suggest that mitomiRs may play a role in essential 
mitochondrial processes including the regulation of the mitochondrial genome. Confirmation of 
the microarray analyses was performed by selecting a mitomiR displaying significantly increased 
expression levels in diabetic IFM relative to control (mitomiR-378). The observed change in 
expression levels of this mitomiR was validated in both SSM and IFM by qRT-PCR. MitomiR-
378 was differentially expressed in diabetic cardiac mitochondrial subpopulations as compared 
to controls (Figure 4.2) as well as in whole heart homogenate (miR-378) (Figure 4.2), confirming 
the microarray data. 
 
Differential Expression of Mitochondrial Genome-Encoded Proteins in the Diabetic Heart  
To determine the impact of diabetes mellitus on mitochondrial genome-encoded proteins 
an immunobloting approach was undertaken to determine the subpopulation-specific expression 
profiles of individual mitochondrial genome-encoded proteins. Type 1 diabetic insult was 
associated with changes in 6 of the 13 electron transport chain proteins encoded by the 
mitochondrial genome. Though similar effects on spatially-distinct subpopulation protein 
contents were observed with diabetes mellitus (CO1, ND4), differential effects were also 
observed (ATP6, ATP8, Cyt B, ND6) (Figure 4.3). Of particular interest was the noted decrease 
in ATP6 which was observed exclusively in IFM, suggesting distinct subpopulation-specific 
effects on this F0 component of the ATP synthesis machinery. 
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MitomiR Predicted Mitochondrial Targets and Sequence Specific Motifs 
To determine whether resident mitomiRs were associated with the regulation of 
mitochondrial genome-encoded proteins, we utilized bioinformatic tools to predict potential 
mitomiR interactions with the mitochondrial genome. Using the target-prediction algorithms 
from various miRNA databases (RNAhybrid, MicroCosm and miRWalk), we analyzed the seed 
sequences from each identified mitomiR (7 seed nucleotides) and evaluated their probability of 
interacting with sequences from the mitochondrial genome by assessing the free energy value 
that characterizes the stability of the miRNA/mRNA interaction (greater than -20 kcal/mol) 41.  
Among the 78 mitomiRs identified, 46 were predicted to bind directly to mRNA sequences from 
the mitochondrial genome suggesting potential regulation of translation and/or influence on 
mRNA stability. Using Ingenuity Pathway Analysis software to analyze mitochondrial genome 
targets, we observed potential interactions between all 13 mitochondrial genome-encoded 
electron transport chain proteins (Figure 4.4).  Of the 46 mitomiRs predicted to bind to mRNA 
from the mitochondrial genome, 20 indicated potential binding to a single mitochondrial genome 
target (Figure 4.4; in red with red lines), while 26 displayed the potential to bind to multiple 
mitochondrial genome targets (Figure 4.4; in blue with black lines). Of interest was a predicted 
interaction between mitomiR-378 and ATP6 (orange line). We determined whether any specific 
conserved nucleotide sequence motifs existed among the 46 mitomiRs predicted to bind to 
mRNA from the mitochondrial genome and identified 40 mitomiRs with specific tri-nucleotide 
motifs suggesting sequence commonality among the majority of identified mitomiRs predicted to 
bind to the mitochondrial transcriptome.  Specific enriched motifs included AGG, UGG and 
CCU tri-nucleotide sequences (Figure 4.4). Of particular interest was the observed high 
enrichment of UGG and AGG motifs in the 7 nucleotide seeding region (Figure 4.4). We 
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speculate that the existence of these motifs in a given miRNA may be predictive of its potential 
for distribution in the mitochondrion. Indeed, a similar type of phenomenon based upon the 
possession of specific sequence elements has been reported for the subcellular localization of 
miRNAs into other organelles 42.  
 
Functional Consequences of MitomiR-378 Targeting to the Mitochondrial Genome  
Because it displayed a robust increase in diabetic IFM relative to control IFM and was 
identified as a potential regulator of the ATP synthase, we performed additional analyses on 
mitomiR-378.  miR-378 is of nuclear origin and originates from the first intron between exons 1 
and 2 of the PPARGC1β (PGC-1β) gene which generates a hairpin structure (Figure 4.5) 43. In 
the type 1 diabetic heart PGC-1α mRNA expression was significantly down-regulated while 
PGC-1β remained unchanged (Figure 4.6).  These results are in agreement with a previous report 
18. Bioinformatic analyses indicated that mitomiR-378 was predicted to bind to the mRNA 
sequence of ATP synthase F0 subunit 6 (ATP6), a constituent of the F0 component of the ATP 
synthase, which plays a role in the translocation of protons across in the inner mitochondrial 
membrane. Interestingly, mitomiR-378 was indicated as potentially binding to three different 
regions of the mitochondrial genome at starting positions 8,310, 8,383 and 8,515 on the ATP6 
mRNA with high affinity based upon the minimum free energy (MFE) value characterizing the 
interaction between miRNA and target (Figure 4.6).  Western blot analyses indicated significant 
decreases in diabetic IFM of ATP6 relative to control IFM (Figures 4.3 and 4.6). Evaluation of 
ATP synthase activities indicated a significant decrease in diabetic IFM with no significant effect 
to diabetic SSM, relative to respective controls (Figure 4.6).  These data support the hypothesis 
that enhanced mitomiR-378 expression in diabetic IFM may account for decreases in F0 ATP 
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synthase subunits which lead ultimately to a decreased ability to drive the ATP synthase and 
generate ATP for contractile purposes.   
 
Redistribution of RISC Components in the Mitochondrion  
Small RNAs can interact with the RISC which contains proteins that include Dicer, 
Argonautes, and FXR1, as well as other proteins and cellular factors 44, 45. Assembly of the RISC 
and its subsequent association with a miRNA has been implicated in its biological function 
including regulation of mRNA expression 46, 47.  MiRNA-mediated inhibition of translation 
depends largely upon the degree of complementarity between a specific miRNA or siRNA 
(exogenous mRNA regulators) and its mRNA target 48.  RISC components such as FXR1 and 
Argonautes such as Ago2 interact with miRNAs during pathological conditions suggesting that 
stress-induced activation of the RISC contributes to its assembly 49. Examination of RISC 
components Ago2 and FXR1 in whole heart homogenate revealed no significant differences 
during diabetic insult indicating that the absolute levels of these proteins are not changed as a 
result of the pathology (Figures 4.7a-c). Interestingly, examination of Ago2 and FXR1 protein 
contents in the mitochondrion revealed that both proteins were distributed within the two 
subpopulations (Figures 4.8a-d). Following diabetic insult, both proteins displayed redistributed 
patterns with Ago2 levels decreasing in both subpopulations and FXR1 levels decreasing only in 
the SSM (Figures 4.8a-d).  In contrast, FXR1 protein contents were significantly increased in 
diabetic IFM (Figures 4.8b and 4.8d).  Taken together, these results indicate that RISC 
components Ago2 and FXR1 are present in both mitochondrial subpopulations. Further, 
following diabetic insult, both proteins display subpopulation-specific differential distribution 
patterns.  
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MitomiR and RISC Constituent Interactions Influence Mitochondrial Genome-Encoded 
Protein Abundance 
Based on our broad-scale mitomiR analyses, we determined how a particular mitomiR 
and mRNA target interact. Chi et al. identified Ago2-miRNA-mRNA complexing using high-
throughput sequencing of RNAs isolated by cross-linked immunoprecipitation (HITS-CLIP) 
technology in mouse brain 28. Using a similar approach we determined the endogenous 
interactions between mitomiRs, mRNAs and mitochondrial RISC components Ago2 and FXR1 
in control and diabetic mitochondrial subpopulations. Cross-linked immunoprecipitation (CLIP) 
was utilized to determine the presence of mitomiRs and mRNAs enriched with RISC 
components Ago2 and FXR1 in an effort to identify and detail the presence of a functional 
regulatory complex in the mitochondrion (Figure 4.9). Ago2-RNA and FXR1-RNA complexes 
were identified in both control and diabetic states and displayed molecular weight range shifts 
from 85 kDa to between 95 and 110 kDa indicating binding to the mitomiR-mRNA complex 
(Figure 4.10).  Pull down with IgG followed by immunoblotting for biotin revealed a band in the 
IgG range (40-60 kDa) without bands in the above indicating specificity of the CLIP-Ago2 and 
CLIP-FXR-1 binding. To confirm the interaction between RISC components Ago2 and FXR1, 
the complex was treated with high RNAse I and both RISC components immunoprecipitated 
with one another revealing interaction between the two proteins which was altered by the 
diabetic phenotype. Specifically, diabetic IFM displayed an increased interaction between Ago2 
and FXR1 relative to control in both immunoprecipitation experiments which was not observed 
in diabetic SSM (Figure 4.10b). To determine the specific mitomiR and mRNAs present in the 
CLIP, portions of the membrane in which the protein-RNA complex resided were isolated and 
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RNA extracted after which the reverse transcribed product was utilized for cDNA synthesis.  
cDNA libraries were analyzed to identify enriched quantities of mitomiR-378 by qRT-PCR 
analysis and its association with both Ago2 and FXR1. These analyses indicated that in diabetic 
IFM, both RISC constituents Ago2 and FXR1 were highly associated with mitomiR-378 (Figure 
4.11a). In contrast, SSM diabetic displayed little association between mitomiR-378 and Ago2 yet 
a strong association between mitomiR-378 and FXR1 (Figure 4.11a). These observations 
indicate that in the diabetic IFM, mitomiR-378 is highly associated with components Ago2 and 
FXR1 from the mitochondrial RISC.  In contrast, diabetic SSM display low enrichment of 
mitomiR-378 such that the association of Ago2 with this mitomiR is limited despite the presence 
of FXR1. These data suggest that the regulation of mitochondrial genome-encoded proteins by 
mitomiRs requires the presence of a given mitomiR and the appropriate amount of mitochondrial 
RISC proteins Ago2 and FXR1. In the absence of either protein and/or the mitomiR, regulation 
of mitochondrial gene expression by the mitomiR may be limited.  Complementary analyses 
were carried out by examining the interaction between RISC constituents Ago2 and FXR1 with 
mitochondrially-encoded ATP6 mRNA using qRT-PCR (Figure 4.11b). The analyses indicated 
that mitochondrially-encoded ATP6 mRNA was enriched in the diabetic IFM relative to control 
IFM mitoRISCome regardless of whether immunoprecipitating with Ago2 or FXR1. In contrast 
this phenomenon was not apparent in the diabetic SSM which displayed decreases in ATP6 
mRNA in both Ago2 and FXR1 immunoprecipitated mitoRISComes (Figure 4.11b). These data 
confirm that mitochondrial RISC constituent Ago2 interacts in a ternary complex with both the 
specific mitomiR (mitomiR-378) and targeted mitochondrial genome mRNA (ATP6) providing a 
regulatory platform for the control of mitochondrial gene translation.  
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Next Generation Sequencing of Mitochondrial RISCome Association with Mitochondrial 
mRNA  
 Our assessment of RISC component associations with mitochondrial miRNA and 
mitochondria mRNA revealed differential binding patterns with Ago2 such that functional 
association was lost in the complex with diabetic SSM, while a strong association existed with 
the diabetic IFM. Thus, our analyses suggested that Ago2 presence was requisite for translational 
control of mitochondrial genome protein expression via mitomiR regulatory mechanisms. To 
capture the distinct features of the mitochondrial transcriptome functional complex, we assessed 
CLIP-Ago2 (mitoRISCome)/mRNA complex products utilizing true RNA-seq library 
preparations to establish mitochondrial mRNA transcripts through sequencing with a high-
throughput Mi-seq platform.  Alignment of sequenced reads to the mouse mitochondrial genome, 
revealed that in the non-diabetic condition, differential proportions of the mitochondrial 
transcriptome (mitochondrial mRNA) were associated with the mitoRISCome in SSM (69%) and 
IFM (31%). However, these percent associations were altered with diabetes mellitus treatment 
differentially in SSM and IFM such that a greater portion of the IFM transcriptome (49%) was 
associated with the mitoRISCome, while a lesser portion of the SSM trancriptome (51%) was 
associated with the mitoRISCome (Figure 4.12a and 4.12b). Specific associations between RISC 
component (Ago2) and each of the 13 mitochondrially-encoded proteins under control and 
diabetic conditions are indicated in Figure 4.13. The presence of mitochondrial mRNAs in the 
different groups varied depending upon treatment and subpopulation type. Of particular interest 
was the presence of mRNA encoding ATP6 in the mitoRISCome of diabetic IFM which was not 
present in the control IFM (blue box). This finding was confirmatory of those in the 
mitoRISCome analyses (Figure 4.11b).  Our analyses identified 9 mitochondrially-encoded 
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mRNAs in the diabetic subpopulations which were differentially expressed in the mitoRISCome 
relative to controls (Figure 4.14a).  Further, 6 of the differentially expressed mRNAs displayed 
opposite expression patterns from their subpopulation counterpart (Figure 4.14a). Mapping of the 
mitochondrial mRNAs identified in the mitoRISCome next generation sequencing enabled 
identification of specific cluster regions in each of the 13 mRNA transcripts which were present 
in the mitoRISCome (Figure 4.14b; blocks indicated in red). To gain insight into the relationship 
between these cluster sequences and mRNA binding sites, we performed an unbiased search of 
associated nucleotide sequences in the identified clusters to determine whether specific sequence 
motifs were common within the identified clusters.  Our results indicated that these clusters were 
enriched with a UUCC motif in all 9 mitochondrial transcripts identified, and this motif was 
highly enriched in the ATP6 transcript (Figures 4.15a and 4.15b). 
 
Next Generation Sequencing of Mitochondrial RISCome Association with MitomiRs  
To capture the distinct features of the mitomiR signatures in the mitoRISCome functional 
complex we assessed mitoRISCome/mitomiR complex products utilizing small RNA-seq library 
preparation to establish mitomiR transcripts through sequencing with a high-throughput Mi-seq 
platform.  High throughput sequencing of small RNAs in the mitoRISCome identified 37 
mitomiRs which were differentially regulated as a result of diabetic insult in mitochondrial 
subpopulations (Supplementary Figure 2). Of the 37 mitomiRs identified, 10 (Figure 4.16a) were 
also observed in our initial microarray experiments (Figure 4.1) and underwent prediction 
analyses (Figure 4.4a). Interestingly, our high throughput sequencing of small RNAs in the 
mitoRISCome revealed the presence of a number of mitomiRs that were not identified in our 
initial microarray analyses. Several variables may have accounted for the discrepancy including 
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the lack of miRNA probes on the microarray (miRNA- 3963, -5102, -5105, -5108, -5109, -5112, 
-5115, -5119, and -5131). Thus, our microarray data potentially underestimate the absolute 
number of mitomiRs. As microarray technologies continue to advance, it is probable that a 
greater number will be identified in the mitochondrion in the future. Further, studies suggest 
comparing results from microarray and next generation sequencing shows good correlation 
between expression levels for a given gene between the two platforms, and the use of both can 
provide complementary information. However, issues such as sensitivity, background noise 
interference and hybridization saturation can lead to differences in results 50. Among the 
identified mitomiRs in the mitoRISCome was mitomiR-378 (Figure 4.16a). Of particular interest 
was the observation that the microarray and snapshot mitoRISCome analyses, though identifying 
similar mitomiRs, revealed differential signature patterns, such that the relative ratio of mitomiR 
in the mitochondrion (Figure 4.1) did not necessarily match the data from the mitoRISCome 
analyses (Figure 4.16a).  These data suggest that the presence of the mitomiR in the 
mitochondrion does not necessarily reflect it as possessing a functionally active regulatory role 
on the mitochondrial transcriptome at a given time. Such a phenomenon is in agreement with 
other studies 51, 52. Moreover, our current study revealed that functional miRNA:mRNA 
interactions are not limited to the regulation of nuclear-encoded genes, but may also play a role 
in the regulation of mitochondrially-encoded genes. Diabetic IFM displayed the greatest 
response in terms of increased functional mitomiRs relative to control (Figure 4.16a).  Mapping 
of the mitomiRs identified in the mitoRISCome next generation sequencing which were also 
identified in the microarray analyses enabled identification of specific regions in each of the 10 
mitomiRs present in the mitoRISCome (Figure 4.16b).  As with the mRNA analyses, we 
performed an unbiased search of associated sequences in the 3-22 nucleotide regions of these 10 
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mitomiRs to determine whether specific sequence motifs were common.  Our results revealed 
enriched nucleotide motifs, AGG (in red) and UGG (in yellow) in all 10 mitomiRs, and these 
motifs were highly enriched in mitomiR-378 (Figures 4.16b and 4.16c).  To confirm the presence 
of mitomiR-378 in the mitoRISCome we determined whether the mature mitomiR-378 was 
present.  Mapping of the next generation sequencing indicated the presence of mitomiR-378 
solely in the diabetic IFM of which only the mature transcript was apparent (Figure 4.17a).  
Sequence scanning analysis of the ternary complex revealed mitomiR-378 binding sites were 
present within the footprint region of the ATP6 transcriptome at starting positions 8,310 with a 
secondary binding site at position 8,383 (Figure 4.17b). These results were consistent with the 
previous bioinformatically-predicted targets for mitomiR-378 (Figure 4.6a). 
 
miR-378 Overexpression in a Cellular System 
 To validate the regulatory activity of mitomiR-378 on ATP6, we generated a stable HL-1 
cell line overexpressing the mouse miR-378 which contained a GFP coding sequence to enable 
cellular tracking. To determine whether down-regulation of ATP6 and ATP synthase functional 
decrements were associated with miR-378 presence in the mitochondrion, mitochondria was 
isolated from miR-378 overexpressing HL-1 cells and the presence of mitomiR-378 examined by 
qRT-PCR analyses. Our data revealed an approximately 22 fold increase of mitomiR-378 in 
isolated mitochondria from the stable HL-1 cell line overexpressing miR-378 as compared to 
control HL-1 cells (Figure 4.18a). Western blot analyses revealed a significant decrease in the 
expression of ATP6 in the mitochondrion (Figures 4.18b and 4.19b) with a corresponding 
decrease in ATP synthase activity (Figure 4.19a).  Taken together, these data provide 
complementary evidence that in a model of enhanced miR-378 expression, translocation to the 
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mitochondrion can occur which is associated with a decrease in mitochondrial genome-encoded 
ATP6 and a concomitant reduction in the functionality of the ATP synthase.  
 
Manipulation of miR-378 In Vivo with Targeted Antagomir Delivery 
 To determine whether manipulation of miR-378 in vivo could influence ATP generating 
capacity through ATP6 preservation, we utilized an LNA-linked antagomiR delivery approach 
targeting miR-378 (LNA-miR-378). Repeated injection of LNA-miR-378 over a five week 
period led to preservation of ATP6 protein levels in diabetic IFM which were similar to non-
diabetic controls and significantly higher than diabetic and scrambled miR diabetic groups 
(Figure 4.20b). In contrast, no significant differences in ATP6 protein levels were observed 
among any group in the SSM (Figure 4.20a). To determine whether preservation of ATP6 
protein levels impacted ATP generating capacity, we assessed ATP synthase activities following 
LNA-miR-378 intervention and diabetes mellitus. As with ATP6 protein levels, ATP synthase 
activities displayed similar changes in diabetic IFM, with LNA-miR-378 treatment providing 
restoration of ATP synthase activity which was significantly decreased in diabetic and scrambled 
miR diabetic groups (Figure 4.20d). Further, no significant differences in ATP synthase activities 
were observed among any group in the SSM (Figure 4.20c). Because preservation of ATP 
synthase activity ultimately influences cardiac pump function by providing necessary ATP 
levels, we assessed ejection fraction and fractional shortening changes prior to and following 
LNA-miR-378 intervention and diabetes mellitus. Our results revealed preservation of %ejection 
fraction (Figures 4.21a and 4.21b) and %fractional shortening (Figure 4.21a and 4.21c) in LNA-
miR-378 diabetic hearts which was significantly decreased in diabetic and scrambled miR 
diabetic hearts. Taken together, these findings provide in vivo confirmation of an LNA-miR-378 
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impact on diabetic IFM which manifests as preservation of ATP6 protein content, ATP synthase 
levels and cardiac pump function. 
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DISCUSSION 
 
Our findings indicate for the first time that mitomiRs are differentially distributed in 
spatially-distinct cardiac mitochondrial subpopulations. Upon diabetic insult, cardiac mitomiR 
distribution patterns are dramatically altered and in many cases display opposite/reciprocal 
arrangements. Type 1 diabetes mellitus is associated with cardiac contractile deficits, which may 
result from a decreased ability for cardiac mitochondria to generate ATP. Among the genes 
encoded for by the mitochondrial genome are 13 proteins of the electron transport chain that are 
constituents of complexes I, III, IV, and V. Thus, regulation of the mitochondrial genome by 
mitomiRs may have profound effects on the expression of key components driving ATP 
synthesis and ultimately influencing cardiac contractile function. 
 
Using a number of bioinformatics tools, we identified 46 mitomiRs that were predicted to 
bind to mitochondrial genome-encoded mRNAs. Over half of the identified mitomiRs displayed 
the potential for binding multiple mitochondrial-encoded genome mRNAs. Such a finding is 
intriguing and suggests the potential for an individual mitomiR to regulate the translation of 
multiple mitochondrial genome products. Such a dynamic is consistent with proposed 
mechanisms of action for other miRNAs 53, 54 and as a result mitomiR manipulation for 
therapeutic intervention represents an attractive strategy for addressing pathological conditions, 
such as diabetes mellitus, as it may offer the ability to rectify proteomic loss of multiple 
mitochondrial genome-encoded proteins simultaneously. Additional bioinformatic analyses of 
the nucleotide sequences in the 46 identified mitomiRs indicated that ~ 85% possessed specific 
conserved tri-nucleotide motifs which included AGG, UGG, and CCU.  Of particular interest 
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was an observed concentration of AGG and UGG motifs contained in the 2-7 nucleotide seeding 
region of a number of mitomiRs. We speculate that the existence of these motifs in the mitomiR 
may influence its translocation into mitochondria and that their presence may predict the 
potential for a given miRNA to exist in the mitochondrion. Further investigation is needed to 
determine the relative importance of these particular motifs. 
 
Because it displayed a dynamic change in its content following diabetic insult and a 
reciprocal response in spatially-distinct mitochondrial subpopulations, we chose to examine 
mitomiR-378 for our subsequent studies.  miR-378 plays an important regulatory role in cardiac 
remodeling, cell survival 55, 56 and its complimentary pair, miR-378*, mediates a metabolic shift 
to oxidative phosphorylation 18, 43. Though it displayed a significant increase in the heart 
following diabetic insult, miR-378 was dramatically increased only in the IFM suggesting that its 
enhanced presence may be of particular relevance specifically to the mitochondrion. 
Identification of a mitochondrial genome target for mitomiR-378, ATP6 and the associated 
decrease in ATP synthase activity specifically in the IFM, suggest a coordinated regulatory role 
for mitomiR-378 in type 1 diabetic IFM. Manipulation of this axis may contribute to the 
development of diabetic cardiomyopathy by compromising the generation of ATP. Indeed, 
overexpression of miR-378 in a cell type that maintains a cardiac phenotype revealed increased 
mitochondrial presence and a concomitant decrease in ATP6 content and function in an in vitro 
model. Further, utilization of an antagomir approach directed at miR-378 demonstrated down-
regulation of ATP6, ATP synthase activity, and cardiac pump function confirming this axis in 
vivo. Interestingly, examination of the type 2 diabetic (db/db) heart revealed a similar increase in 
mitomiR-378 presence in the SSM which was associated with its increased presence in the SSM 
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mitoRISCome (Supplementary Figure 3a-b). Though db/db IFM also displayed an increase in 
mitomiR-378 presence, no significant increase in the db/db IFM mitoRISCome was observed 
(Supplementary Figure 3a-b), suggesting lack of a functional interaction with the mitochondrial 
genome in this subpopulation. These findings are in agreement with our previous study revealing 
mitochondrial dysfunction in the db/db heart which was confined primarily to the SSM 
subpopulation 25. Taken together our findings suggest enhanced mitomiR-378 presence in the 
type 1 diabetic IFM and type 2 diabetic SSM, the mitochondrial subpopulations most impacted 
by their associated pathology, may be a common mechanism contributing to bioenergetic deficits 
occurring in the face of the diabetic phenotype. Additional comprehensive studies in the type 2 
diabetic heart are warranted.   
 
Perhaps the most interesting finding in the current study was the identification of RISC 
presence in the mitochondrion which contained key components, Ago2 and FXR1.  It appears 
that the mitochondrial RISC functions similarly to its cytoplasmic counterpart, influencing 
translation. Reports of changes in miRNA expression, has provided indirect evidence for 
translational repression, yet evidence for a direct effect of the miRNA on the mRNA is limited. 
Use of the CLIP experimental approach provides a clear means of identifying direct 
miRNA/mRNA/protein interactions confirming direct association between nucleotide and 
protein components 28.  Following type 1 diabetes mellitus, mitochondrial RISC components 
were differentially expressed in the mitochondrion relative to control and the response was 
subpopulation-specific in nature. Our results indicate that translational regulation of ATP6 of the 
mitochondrial genome by mitomiR-378 requires both Ago2 and FXR1 presence in the RISC, as 
well as the necessary mitomiR (mitomiR-378) as observed in diabetic IFM. When Ago2 content 
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is limiting and the mitomiR (mitomiR-378) is not present, regulation via the mitochondrial RISC 
does not occur, as observed in diabetic SSM (Figure 4.22).  Our results are in agreement with 
literature suggesting the relative importance of FXR1 presence in that its knockout is lethal in 
mice and in zebrafish as a result of cardiomyopathy and muscular dystrophy 57. Reports indicate 
a requirement of both FXR1 and Ago2 in the RISC for translational activation 12, 58-60, via AU-
rich elements.  Our current data extend these findings by identifying a similar phenomenon 
within the mitochondrion that occurs in a subpopulation-specific manner during diabetic insult 
and requires specific sequence motifs (AGG and UGG) in the miRNA sequence. Thus, 
redistribution of mitomiRs and the presence of specific mitochondrial RISC component 
stoichiometry, contributes to the formation of a functional complex which is associated with loss 
of mitochondrially-encoded proteins in the diabetic heart.  
 
Recent crystallographic and NMR structural analyses have indicated that all three 
molecules (mRNA, miRNA and protein) require close proximity and direct interaction to 
facilitate a functional cytoplasmic ternary regulatory complex 28, 51, 61-63. Nevertheless, 
identification of a functional RISC in the mitochondrion is highly challenging. Recent reports 
suggest that RNA can be imported into the mitochondrion 64, 65 which supports our current 
findings. The use of CLIP technology coupled with next generation sequencing offers an 
experimental platform for determining binding maps and sequence motifs necessary for miRNAs 
to exert regulatory influence on mRNA expression/translation. Our CLIP analyses confirmed that 
mitomiR-378 targets two different sites on the ATP6 mRNA, which was bioinformatically 
predicted prior to sequencing analyses. These results were interesting in that miRNAs have been 
identified as binding to the 3'-untranslated region of mRNA to exert regulatory activity. 
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Nevertheless, the mitochondrial genome does not possess 3’-untranslated regions, rather the 
sequence identity from the bioinformatic and next generation sequencing analyses predicted 
binding directly to the coding region. Such a finding is consistent with previous studies 
demonstrating that the mouse Nanog, Oct4 and Sox2 genes were targeted by miRNA in their 
amino acid coding sequence resulting in translational repression 66.  Our results indicate that 
mitomiR-378 targets the ATP6 coding region in a similar manner to control translational activity. 
 
In summary, we propose that mitomiR translational regulation of mitochondrially-
encoded proteins oscillates in spatially-distinct mitochondrial subpopulations in response to type 
1 diabetic insult.  Redistribution of mitomiRs and the presence of a specific mitochondrial RISC 
component stoichiometry, contributes to the formation of a functional ternary complex which is 
associated with loss of mitochondrially-encoded proteins in the diabetic heart.  These results 
suggest a dynamic system that can regulate the mitochondrial proteome during pathological 
states in a spatially-distinct manner. 
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Figure 4.1 
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Figure 4.1. Differential mitomiR expression patterns in cardiac mitochondrial 
subpopulations. (a) Hierarchical clustering heat map for the microarray analysis of mitomiR 
expression profiles in cardiac mitochondrial subpopulations.  DI = diabetic IFM, CI = control 
IFM, DS = diabetic SSM, CS = control SSM; n = 4 for each group.  All mitomiRs reported in the 
heat map are significantly different relative to control. 
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Figure 4.2.  Differential mitomiR expression patterns in cardiac mitochondrial 
subpopulations. (a) Differential distribution (up-regulated or down regulated) patterns of 
mitomiRs in SSM and IFM control and diabetic mitochondrial subpopulations.  (b) qRT-PCR 
analyses of miR-378 in control and diabetic whole heart tissue. Values are represented as mean ± 
SE.  *P < 0.05 for control vs. diabetic. U6 mRNA served as control. (c) qRT-PCR analyses of 
mitomiR-378 in SSM and IFM diabetic mitochondrial subpopulations as compared with control. 
Values are represented as mean ± SE.  U6 mRNA served as control. 
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Figure 4.3 
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Figure 4.3. Mitochondrial genome-encoded proteins in mouse cardiac mitochondrial 
subpopulations. (a) Mitochondrial genome-encoded protein expression in mitochondrial 
subpopulations. Values are represented as mean ± SE of SSM Control, SSM Diabetic, IFM 
Control, and IFM Diabetic; *P < 0.05. 
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Figure 4.4. Predicted mitomiR target networks in mouse cardiac mitochondrial 
subpopulations. (a) Prediction analyses for mitomiR targeting to mitochondrial genome-
encoded mRNAs using bioinformatic databases RNAhybrid, miRWalk and Microcosm. 
Mitochondrial genes (Focus genes) were overlaid into a global mitomiR network developed from 
the information contained in the Ingenuity Pathways Knowledge Base. Focus gene networks 
were algorithmically generated based on their connectivity. The network pathway is a graphical 
representation of the molecular relationships between mitomiR and mitomiR or mitomiR and 
mitochondrial encoded gene.  Those mitomiRs predicted to bind a single mitochondrial genome 
target are indicated in red with red lines, while those mitomiRs predicted to bind multiple 
mitochondrial genome targets are indicated in blue with black lines. MitomiR-378 predicted 
interaction with ATP6 is indicated with an orange line. (b) Conserved sequence specific tri-
nucleotide motifs and their location within the identified mitomiRs. 
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Figure 4.5 
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Figure 4.5. MitomiR-378 and its targeting to the mitochondrial genome. (a) Schematic 
representation of miR-378 location in the PPARGC1b (PGC-1b) gene. It is located in between 
exon 1 and exon 2. (b) qRT-PCR quantification of PGC1α and PGC1β transcripts in control and 
diabetic hearts.  GAPDH served as control. Values are represented as mean ± SE; n=4 for each 
group. *P < 0.05 for Control vs. Diabetic. 
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Figure 4.6. MitomiR-378 and its targeting of ATP6 and ATP6 protein content in control 
and diabetic subpopulations.  (a) Evaluation of the minimum free energy (MFE) value that 
characterizes the stability of mitomiR-378/mRNA interaction, identified by MicroCosm and 
RNAhybrid. (b) Western blot analysis of ATP6 in control and diabetic SSM and IFM. Cox IV 
serves as a loading control. (c) ATP synthase activity expressed in activity/min/mg protein. 
Values are means ± SE; n = 8 for each group. *P < 0.05 for Control IFM vs. Diabetic IFM. 
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Figure 4.7. Redistribution of RISC components in control and diabetic whole heart. (a) 
Western blot analyses of Ago2 and FXR1 in control and diabetic whole heart. GAPDH serves as 
loading control. (b) Quantification of Ago2 protein content in control and diabetic whole heart. 
Values are means ± SE. (c) Quantification of FXR1 protein content in control and diabetic whole 
heart. GAPDH served as loading control. Values are means ± SE. 
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Figure 4.8. Redistribution of RISC components in control and diabetic mitochondrial 
subpopulations. (a) Western blots analyses of Ago2 and FXR1 in Control and Diabetic SSM.  
COX IV serves as a loading control.   (b) Western blots analyses of Ago2 and FXR1 in Control 
and Diabetic IFM.  COX IV serves as a loading control.  (c) Quantification of Ago2 protein 
content in control and diabetic mitochondrial subpopulations. Values are means ± SE. *P < 0.05 
for Control vs. Diabetic.  (d) Quantification of FXR1 protein content in control and diabetic 
mitochondrial subpopulations. Values are means ± SE. *P < 0.05 for Control vs. Diabetic. 
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Figure 4.9 
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Figure 4.9. Crosslinked immunoprecipitation (CLIP) in cardiac mitochondrial 
subpopulations. Schematic representation of CLIP-Ago2 and the CLIP-FXR1 experimental 
designs. The association of mitomRNA and mitomiR requires to be in a complex with both RISC 
components (Ago2 and FXR1). Immunoblotting with biotin is used to pull down protein and 
RNA complex from both CLIP-Ago2 and CLIP-FXR1. RNA isolation is then performed which 
is subjected to next generation sequencing and small RNA seq.  
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Figure 4.10 
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Figure 4.10. Crosslinked immunoprecipitation (CLIP) in cardiac mitochondrial 
subpopulations. (a) Western blots of biotinylated RNA from CLIP-Ago2 and CLIP-FXR1 
reactions illustrating crosslinked protein/RNA and the associated gel shift from 80 kDa to 95-110 
kDa. Pull down with IgG followed by immunoblotting for biotin revealing specificity of the 
CLIP-Ago2 and CLIP-FXR-1 binding. (b) Western blot analyses of CLIP-Ago2 and CLIP-FXR1 
subjected to RNAase I treatment at 1:50 dilution (high RNAase) illustrating interaction between 
the two proteins in the absence of RNA. 
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Figure 4.11 
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Figure 4.11. MitomiR-378 and RISC constituent interactions with the mitochondrial 
genome. (a) CLIP-Ago2 and CLIP-FXR1 associated enrichment analyses of mitomiR-378 
analyzed by qRT-PCR in control and diabetic cardiac mitochondrial subpopulations. Values are 
presented as means ± SE. (b) CLIP-Ago2 and CLIP-FXR1 associated enrichment analysis of 
transcripts for mitochondrial encoded ATP6 mRNA levels as assessed by qRT-PCR analysis in 
control and diabetic cardiac mitochondrial subpopulations. Values are presented as means ± SE. 
  
 228 
 
Figure 4.12 
 
 
 
  
 229 
 
Figure 4.12.  Genomic sequencing analyses of mitochondrial RISCome association with 
mitochondrial mRNA.  Proportion of RNA-seq reads mapping to the mitochondrial 
transcriptome (mitochondrial mRNA) of mitochondrial subpopulations in (a) control and 
following (b) diabetic insult. 
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Figure 4.13 
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Figure 4.13.  Genomic sequencing analyses of mitochondrial RISCome association with 
mitochondrial mRNA.  Genome browser illustration of mitochondrial RNA-seq reads mapping 
to rRNA, tRNA, mRNAs; histogram indicates RNA-seq read distribution which includes the 
transcript region. 
  
 232 
 
Figure 4.14 
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Figure 4.14. Genomic sequencing analyses of mitochondrial RISCome association with 
mitochondrial mRNA.  (a) Mitochondrially-encoded mRNAs in the diabetic subpopulations 
which were differentially expressed in the mitoRISCome relative to controls. (b) Mapping of the 
footprint regions of mitochondrial mRNA sequence identified by next generation sequencing 
which were present in the mitoRISCome. (f) Sequence motif analysis of mitoRISCome 
associated mitochondrial mRNA, identifying a UUCC rich motif.  (g) Distribution of tetra-
nucleotide (UUCC) motifs in the mitoRISCome. 
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Figure 4.15. Genomic sequencing analyses of mitochondrial RISCome association with 
mitochondrial mRNA.  (a) Sequence motif analysis of mitoRISCome associated mitochondrial 
mRNA, identifying a UUCC rich motif.  (b) Distribution of tetra-nucleotide (UUCC) motifs in 
the mitoRISCome. 
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Figure 4.16 
 
 
 
 
  
 237 
 
Figure 4.16.  Genomic sequencing analyses of mitochondrial RISCome association with 
mitomiR. (a) MitomiR heat map derived from next generation sequencing of small RNAs 
identifying enrichment and depletion patterns within the mitoRISCome of diabetic SSM and 
diabetic IFM, relative to respective controls. (b and c) Mapping of the location of the footprint 
regions of mitomiR sequence identified by next generation sequencing which were present in the 
mitoRISCome and were enriched with tri-nucleotide motifs, AGG or UGG.  AGG motifs are 
indicated with red blocks, while UGG motifs are indicated by orange blocks. 
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Figure 4.17. Genomic sequencing analyses of mitochondrial RISCome association with 
mitomiR. (a) Mapping of mitoRISCome associated mitomir-378 enrichment clusters sites in 
control and diabetic SSM and IFM.  (b)  MitoRISCome:mitomiR378 ternary maps for the ATP6 
target in the diabetic IFM. 
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Figure 4.18 
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Figure 4.18. Validation of miR-378 mitochondrial targeting. (a) RTPCR analyses for miR-
378 levels in isolated mitochondria from HL-1 (Control) and miR-378 cells.  (b) Western blot 
analyses of ATP6 protein levels in isolated mitochondria from control HL-1 cells and in a stable 
HL-1 cell line expressing miR-378. COX IV protein expression is utilized as a loading control.  
Values are expressed per COX IV protein levels. Values are means ± SE, n=6. *P < 0.05 for 
Control vs. miR-378. 
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Figure 4.19 
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Figure 4.19. Validation of miR-378 mitochondrial targeting and measurement of ATP 
synthase activity and ATP6 levels. (a) ATP synthase activity in control HL-1 cells and in a 
stable HL-1 cell line expressing miR-378.  Values are means ± SE, n=6. *P < 0.05 for Control 
vs. miR-378. (b) Quantitative analysis of ATP6 protein levels in isolated mitochondria from 
control HL-1 cells and in a stable HL-1 cell line expressing miR-378.  Values are expressed per 
COX IV protein levels. Values are means ± SE, n=6. *P < 0.05 for Control vs. miR-378. 
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Figure 4.20 
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Figure 4.20. ATP6 content and ATP synthase activity with antagomir treatment. 
Quantitative analyses by Western blot of ATP6 protein levels following LNA-miR-378 treatment 
and diabetic induction in (a) SSM and (b) IFM. COX IV protein expression is utilized as a 
loading control and values are expressed per COX IV. ATP synthase activities levels following 
LNA-miR-378 treatment and diabetic induction in (c) SSM and (d) IFM. Values are expressed as 
means ± SE, n=5. *P <0.05 for Control vs. Diabetic and Control vs. Scrambled; #P < 0.05 for 
LNA-miR-378 vs. Diabetic and LNA-miR-378 vs. Scrambled. ScR = Scrambled; miR = LNA-
miR-378. 
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Figure 4.21. 
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Figure 4.21. Validation of in vivo targeting of miR-378 in cardiac contractile function. (a) 
Representative M-mode images of Control, Diabetic, Scrambled and LNA-miR-378 treated 
hearts 5 weeks following diabetes mellitus induction. (b) Quantitative summary of % fractional 
shortening and (c) % ejection fraction prior to (baseline) and 5 weeks following diabetes mellitus 
induction. Values are means ± SE, n=5. *P <0.05 for baseline vs. 5 weeks; #P < 0.05 for LNA-
miR-378 vs. Scrambled. ScR = Scrambled; miR = LNA-miR-378. 
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Figure 4.22 
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Figure 4.22. Translational regulation of mitochondrial genome-encoded ATP6 protein via 
miR-378 interaction. Schematic diagram of miR-378 mechanism of action in the translational 
regulation of mitochondrially-encoded ATP6 and function of the ATP synthase activity during 
diabetic insult, impacting cardiac contractility. 
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General Discussion 
 The overall objective of this dissertation was to determine the mechanisms involved in 
maintaining mitochondrial structure as well as examine alterations of miRNA profile in the 
mitochondrion during type 1 DM. Specifically, we wanted to determine (1) the interaction of 
mitofilin with MINOS components and investigate novel associations of mitofilin with ATP 
synthase F0 subunits, (2) the therapeutic benefit of mitofilin overexpression in mitochondrial 
morphology, dynamics, DNA content, function and ultimately cardiac contractile function and 
(3) miRNA profile in mitochondrial subpopulations and their role in translational regulation of 
the mitochondrial genome during type 1 DM. Our long term goal is to better understand the 
mechanisms involved in the pathogenesis of DM for developing therapeutic interventions to 
protect against diabetic cardiomyopathy. The central hypothesis of this dissertation is that 
alterations in cristae morphology, inner membrane organization and mitochondrial dysfunction 
during a type 1 diabetic insult are associated with decreased mitofilin content and translational 
regulation of mitochondrial genome by mitochondrial miRNAs (mitomiRs) respectively. These 
effects are more pronounced in the diabetic IFM, influencing cardiac contractile processes. Our 
rationale for the proposed research is based on the importance of preserving IMM morphology 
and mitochondrial genome to attenuate mitochondrial dysfunction. We anticipate being able to 
determine morphological alterations, mitochondrial genome regulation in mitochondrial 
subpopulations and investigate areas at risk. The outcomes will provide insight regarding the 
value of improved mitochondrial structure as well as role of miRNAs in regulating mitochondrial 
genome in diabetic cardiomyopathy and will further aid in the development of therapeutic 
interventions that can address mitochondrial subpopulations at risk during type 1 DM. 
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Cardiovascular complications, including diabetic cardiomyopathy, are the leading cause 
of morbidity and mortality in type 1 diabetic patients. Mitochondrial dysfunction is central to the 
pathogenesis of type 1 diabetic heart complications (12, 41, 42, 46). Cardiac mitochondrial 
analyses are further complicated by the presence of two spatially distinct mitochondrial 
subpopulations (Figure 1.1). Previously, locales of mitochondrial subpopulations have shown 
differential effects under a variety of pathological insults including diabetes mellitus (3-5, 12, 24, 
28, 29, 36, 54). A review by our laboratory surmises differential impact of various pathologies 
upon cardiac mitochondrial subpopulations (20).  Our laboratory has reported that following a 
type 1 diabetic insult the IFM exhibit greater dysfunction:  enhanced oxidative stress production, 
decreased size and internal complexity, decreased oxidative phosphorylation, and mitochondrial 
proteomic alterations (4, 12). Majority of proteins altered during a type 1 diabetic insult are 
housed within the inner mitochondrial membrane (IMM) and this mitochondrial proteome 
dysregulation could potentially be associated with the disruption of mitochondrial structure thus 
affecting crucial mitochondrial functions such as oxidative phosphorylation (4). Among the 
proteins altered in type 1 diabetic IFM is structural protein, mitofilin, residing in the inner 
mitochondrial membrane. A list of proteins adapted from proteomic alterations shown by Baseler 
et al. shows selected proteins from mitochondrial respiratory chain as well as structural protein 
mitofilin in Table 5.1 (4). 
Mitofilin is an inner membrane structural protein established for its role in cristae 
morphology (23). Various studies have led to the identification of a large inner membrane multi 
protein complex, critical for inner membrane architecture, mitochondrial functionality, cristae 
morphology and organization, as well as formation of contact sites and protein biogenesis (1, 7, 
19, 21, 47, 51, 57). Mitofilin has been shown to be a critical component of this mitochondrial 
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contact site and cristae organizing system (MICOS) (38). Interaction of mitofilin with CHCHD3 
and Sam50 has been shown to function as mitochondrial intermembrane space bridging complex 
(MIB) for biogenesis of respiratory complexes (35). Presence of mitofilin in a larger complex 
with Sam50, metaxins 1 and 2, CHCHD3, CHCHD6 and DnaJC11 has been shown to potentially 
regulate protein import (56). Hence, interactions of mitofilin with mitochondrial inner and outer 
membrane proteins and their roles in proper functioning of mitochondria have been studied. 
 
Table 5.1. Proteomic alterations in type 1 diabetic IFM (4). 
 With various roles of mitofilin in different protein complexes being reported, we 
examined potential association of mitofilin in mitochondrial subpopulations in Chapter 2. 
Further, mitochondrial subpopulations specific interactions were studied during type 1 diabetes 
mellitus. No study has examined mitochondrial subpopulations specific interaction of mitofilin. 
We for the first time report novel association of mitofilin with ATP5F1 and present our findings 
of mitofilin interaction with CHCHD3 in mitochondrial subpopulations during type 1 diabetic 
insult. Proteins pulled down with mitofilin constituted proteins from ETC complexes I-V, protein 
import machinery and mitochondrial structural proteins. Potential roles of mitofilin in regulating 
respiratory complexes (35), protein import (56) and mitochondrial structure (21, 23, 57) are in 
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agreement to our findings. Further, presence of C-terminal domain of mitofilin has been reported 
as a pre-requisite for interaction of mitofilin with Tob55/Sam50 complex that could potentially 
regulate outer membrane protein import and formation of crista junctions (26).  
 CHCHD3 and mitofilin have been shown to regulate cristae morphology, mitochondrial 
function and are constituents of the MICOS complex (13, 21, 38). Previous studies from our 
laboratory and others have shown decreases in mitochondrial size, internal complexity and 
structural alterations specifically in the IFM subpopulations (12, 42). Further, proteomic studies 
from our laboratory show decreased mitofilin content in T1DM IFM subpopulations (4). These 
findings led us to examine CHCHD3 content and interaction with mitofilin during diabetic insult. 
Assessment of interaction between mitofilin and CHCHD3 in control and diabetic mitochondrial 
subpopulations revealed decreased association of mitofilin with CHCHD3 in diabetic IFM which 
could potentially lead to morphological alterations observed during diabetes. Further, protein 
content of CHCHD3 was not altered in either of the subpopulations during diabetes, 
strengthening the role of mitofilin in cristae morphology and function. With that being said, 
assessment of mitofilin interaction with other constituents of the MICOS complex in 
mitochondrial subpopulations during diabetes mellitus could provide insight into mechanisms 
regulating mitochondrial structure and functions. Further, studies examining MICOS content in 
control and diabetic mitochondrial subpopulations could provide subpopulation specific role of 
the complex in generation of cristae morphology and inner membrane architecture.  
 Other mitochondrial proteins, not reported to be in a multi protein complex with 
mitofilin, have been implicated in regulation of cristae morphology (16, 31, 37, 39). A study by 
Piquereau et al. examining down-regulation of optic atrophy 1 (OPA1) in mouse model reported 
presence of clusters of fused mitochondrial network and altered cristae (39). Study of another 
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structural protein prohibitin present as assembly of two homologous prohibitin subunits, 
prohibitin1 and prohibitin2 have been shown to control cristae morphogenesis and potentially led 
to functional compartmentalization in the inner membrane of the mitochondria (31). Of 
particular interest to our study in Chapter 2 was findings reported by Paumard et al. who utilized 
yeast cells to examine potential role of ATP synthase subunits e or g. These authors present 
potential role of these subunits in regulating cristae morphology (37). Further, another study by 
Rabl et al. showed that deletions of either of these subunits led to reduction in cristae tip numbers 
and crista junctions diameter enlargement. These authors showed genetic interaction of mitofilin 
with ATP synthase subunits e or g (40). Proteins pulled down with mitofilin, presented in 
Chapter 2 did identify proteins of the ATP synthase subunits. These findings of cristae regulation 
by ATP synthase subunits combined with subunits pulled with mitofilin identified in our study 
led us to assess novel subpopulations specific association of mitofilin in control and diabetic 
groups.  
 Novel association of mitofilin with ATP synthase subunit b (ATP5F1) was observed in 
both mitochondrial subpopulations. Association of IFM diabetic was decreased when compared 
to the control. Previous findings from our laboratory have shown decreased ATP synthase 
activity in diabetic IFM (3, 12). Decreased association of mitofilin with ATP5F1 in diabetic IFM 
could potentially alter ATP synthase functionality. Examination of other ATP synthase F0 
subunits pulled down with mitofilin would further aid in understanding subpopulation based 
association of mitofilin. Upon examination of mitofilin association comparing control SSM and 
IFM subpopulations, increased association is observed in IFM, suggesting a possible mechanism 
that could result in increased ATP synthase activity in the IFM. Hence, novel association of 
mitofilin with ATP5F1 could present a different mechanistic phenomenon in regulation or cristae 
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morphology. Differences of mitofilin association present in diabetic IFM could result in 
structural as well as functional decrements observed in diabetic IFM subpopulations during a 
type 1 diabetic insult. 
 Because of decreased association of mitofilin with ATP5F1 in diabetic IFM and a lot of 
proteins of Complex V subunits being pulled with mitofilin, we sought to identify whether this 
decreased association resulted in any alteration of the total complex content in mitochondrial 
subpopulations during diabetes. We utilized BN-PAGE to examine complex V content of SSM 
and IFM in both control and diabetic groups. No significant differences were observed in ATP 
synthase content in SSM and IFM. These findings indicate that decreased association observed 
between mitofilin and ATP5F1 is not sufficient to change the overall protein content. Further, 
examination of other ETC complexes in control and diabetic mitochondrial subpopulations have 
shown no changes in protein content of any complexes (45). 
 It should be noted that all the proteins pulled down with mitofilin do not directly interact 
with it. ATP synthase F1 subunits proteins, residing in the matrix of the mitochondrion were also 
pulled with mitofilin. Association of ATP synthase F0 subunits with F1 subunits could result in 
the pull down of these proteins thus suggesting no direct association of mitofilin with them. 
Indeed, when association of mitofilin with ATP synthase F1 subunit alpha (ATP5A) was 
assessed, no association was observed (data not provided). Hence, careful assessment and 
analyses should be performed in order to examine novel association of mitofilin. One way of 
designing experiment would be to consider location of the protein and utilization of 
immunoprecipitation using both mitofilin and protein of interest vice versa. Also, assessment 
using BN-PAGE would allow examining protein complexes. A clear understanding of protein 
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complexes formed by mitofilin and its potential role in mitochondrial functions greatly aids in 
investigating these novel associations. 
 Taken together, the data compiled in Chapter 2 indicates that examination of novel and 
known mitochondrial subpopulations specific association of mitofilin could potentially regulate 
mitochondrial structure and function during a type 1 diabetic insult. Further, key processes 
involving ETC complexes, protein import as well as mitochondrial structure could be affected 
and potentially dependent upon the association partners of mitofilin.  
 Decrements of mitofilin have been observed in many human diseases such as Down’s 
syndrome (6, 33), Parkinson’s disease (48, 49), Epilepsy (17, 34), Neurodegeneration (52, 55) 
and type 1 diabetes mellitus (4, 9). Studies implementing down-regulation of mitofilin in Hela 
cells have shown abnormal mitochondrial morphology with concentric layers of inner 
membrane. These authors have reported reduced cell proliferation, increased apoptosis and 
elevated reactive oxygen species (ROS) production (23). Similar depletion studies in yeast cells 
and C. elegans have resulted in curved and stacked cristae tubules, increased ROS production 
and reduction in cristae junctions which is associated with decreased DNA content (32, 40). In 
the type 1 diabetic heart, the focus of this study, abnormal mitochondrial morphology with 
decreased cristae density has been reported (9). Studies examining over expression of mitofilin in 
the context of diabetes have not been implemented. Over expression of mitofilin in yeast cells 
resulted in increased diameter as well as branching of cristae and cristae junctions (40). We next 
sought to identify potential effects of mitofilin overexpression in mitochondrial structure, 
function, DNA content, ROS generation and cardiac function, the findings of which are 
presented in Chapter 3 of this dissertation. 
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 In order to examine the role on mitofilin in a STZ induced type 1 diabetes model 
(Chapter 3), we generated a transgenic mouse model overexpressing mitofilin which constituted 
a significantly higher protein expression in IFM as compared to SSM. These findings are in 
agreement with a study by Ferreira et al. who showed a 37 fold higher mitofilin content in 
cardiac IFM than that in SSM subpopulations (15). With mitofilin downregulation shown to alter 
mitochondrial morphology, we utilized electron microscopy to examine structural changes in 
diabetic mitochondria and further analyzed the effects of mitofilin overexpression in our diabetic 
models. Damaged mitochondrial structure was observed in diabetic IFM when compared to 
control. These findings are in agreement to studies by John et al. who observed similar 
morphological alterations with mitofilin down regulation (23). Our transgenic mouse model 
overexpressing mitofilin displayed preservation of mitochondrial morphology and cristae 
structure in the face of diabetes mellitus which corroborate the findings by Rabl et al. who 
showed increased cristae junction formation and branching with mitofilin overexpression in 
yeast cells (40). Decrements in mitochondrial internal complexity and granularity observed in 
type 1 diabetic IFM was also preserved with mitofilin overexpression. Taken together these 
findings further strengthen the role of mitofilin in maintaining cristae morphology and hence 
overall mitochondrial structure. 
 The inner mitochondrial cristae membrane is the principal site for ATP production 
through oxidative phosphorylation (OXPHOS) (18) and improved cristae morphology increases 
the inner membrane surface area thus enabling a greater capacity for OXPHOS and ATP 
production. We next examined ETC complexes and ATP synthase function in our transgenic 
mouse model. Decrements in ETC complexes I, III, IV, and V observed in type 1 diabetic IFM 
was restored with mitofilin overexpression. This restoration in ETC complexes and ATP 
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synthase function could be associated with better mitochondrial structure as well as internal 
complexity observed in our transgenic animals. Though not examined in this dissertation, 
increased inner membrane surface area as a result of improved mitochondrial structure in our 
transgenic diabetic animal models could potentially lead to an enhanced capacity for OXPHOS 
and ATP generation.  
 One potential mechanism that could increase OXPHOS and ATP generation could be due 
to changes in absolute contents of ETC complexes. In order to examine total ETC protein content 
we utilized a BN-PAGE approach. As presented in Chapter 3, we did not observe any changes in 
the absolute contents of ETC complexes. These findings suggest that mitochondrial functional 
benefits observed within our transgenic mouse model are not the result of increased ETC 
complexes but due to preservation of IMM integrity that could enhance stabilization of the ETC 
complexes. Role of mitofilin in maintaining IMM integrity and architecture has been reported 
(19, 21). However, future studies aimed at examining cristae surface area and their impact upon 
IMM architecture, ETC stabilization in the presence of mitofilin overexpression would aid in 
understanding key mechanisms contributing towards observed OXPHOS changes. 
 In an effort to better understand the role of mitofilin overexpression, we next sought to 
examine mitochondrial dynamics and assess if it affects fission and fusion processes. 
Examination of proteins involved in regulation of mitochondrial fission and fusion showed no 
differences in SSM and IFM. Western blot analyses of the proteins examined (mitofusin 1 and 2, 
OPA1, Dynamin- related protein 1) showed no alterations in diabetes and with overexpression of 
mitofilin. These findings are in agreement to a study by John et al. who reported normal 
mitochondrial fission and fusion with mitofilin down regulation (23). These findings suggest that 
no alterations in mitochondrial size and number were observed with overexpression of mitofilin. 
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Further, assessment of mtDNA content in control vs. transgenic mitofilin animals showed similar 
copy numbers. 
 Enhanced ROS production has been reported from cardiac mitochondria of different type 
1 diabetic models (12, 43). The mitochondrial respiratory chain is the major source of ROS 
generation and ETC complexes I and III are culpable of electrons leakage thereby generating 
incompletely reduced forms of oxygen (8, 44). The oxidative milieu resulting from 
mitochondrial ROS can cause cellular damage by oxidation of proteins, conversion of lipids to 
form lipid peroxidation products. Increased oxidative damaged as shown by nitrotyrosine 
residues and lipid peroxidation has been observed in type 1 diabetic IFM (12). Because of 
improvement in mitochondrial cristae structure that houses the complex contributing in ROS 
generation, we examined lipid peroxidation with mitofilin overexpression in control and diabetic 
animals. Our findings as highlighted in Chapter 3 show attenuation of lipid peroxidation in 
diabetic IFM which could potentially be due to preservation of ETC function and mitochondrial 
structure. Further, improved cristae structure could potentially attenuate electron leakage 
resulting in decreased ROS production and downstream oxidative damage. 
 Significant decrements in ejection fraction, fractional shortening, and cardiac output have 
been reported in type 1 diabetic heart (3). Restoration of mitochondrial structure and function by 
mitofilin overexpression led us to examine if cardiac contractile function was affected. Mitofilin 
overexpression led to the preservation of ejection fraction and fractional shortening, suggesting 
improved cardiac contractile function which could be the result of better mitochondrial structure 
and ultimately, function. 
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 Taken together, the results garnered from chapter 3 highlight the novel ability and role of 
mitofilin in restoration of mitochondrial structure, function, and ultimately cardiac contractile 
function during type 1 diabetic insult. Well established role of mitofilin in maintaining cristae 
morphology, IMM architecture and integrity, ETC stabilization, and protein biogenesis (1, 7, 19, 
21, 40, 47, 51, 57) supports our findings in Chapter 3 of this dissertation.  
 The structure of IMM is crucial for proper mitochondrial functioning as it houses the 
ETC and OXPHOS machinery. Role of mitofilin has been reported for proper maintenance of 
IMM architecture, integrity and stability through its role in cristae morphology. However, 
decrements in cristae junctions, altered cristae morphology, decreased mitochondrial size and 
internal complexity and reduced ETC and OXPHOS activities have been reported in diabetic 
IFM (9, 12). Moreover, proteomic alterations specific to the diabetic IFM subpopulations reveal 
decrease in structural as well as proteins of the ETC and OXPHOS complexes (4). Altered 
cristae morphology in conjunction with decrements in proteins of ETC complexes could 
potentially lead to damage in IMM architecture and thus increased ROS generation as observed 
in type 1 diabetic IFM (12). In order to address proteomic alterations in diabetic IFM, we have 
examined protein import in the mitochondrion and reported a decrease in import of nuclear 
encoded proteins in the diabetic IFM (4). In addition to this, utilization of a mitochondria 
phospholipid hydroperoxide glutathione peroxidase 4 (mPHGPX) overexpression mouse model, 
revealed a reversal of proteomic alterations, dysfunctional protein import and ultimately 
mitochondrial function. Further, posttranslational modifications including oxidations and 
deamidations were attenuated in diabetic IFM with mPHGPX overexpression (3). Potential 
regulation of the nuclear encoded proteins with miRNAs has also been examined (5). However, 
these were more geared towards the nuclear encoded proteins. 
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 The mitochondrial genome encodes for 13 proteins constituting ETC complexes I, III, IV, 
and V. Examination of translational regulation of these proteins is crucial to comprehend 
mitochondrial dysfunction observed in type 1 diabetes. Further, development and progression of 
many human diseases involves regulation of mitochondrial genome (27, 30).  In order to address 
potential regulation of the mitochondrial genome during type 1 diabetic insult, we examined 
alterations of miRNAs profile in mitochondrial subpopulation and further assessed its potential 
roles in regulating the mitochondrial genome. The findings of our study are presented in Chapter 
4 of this dissertation. 
 Although presence of miRNAs in the nucleus and processing bodies have been reported 
(22), identification in the mitochondrion are very limited (14). Using prediction analyses 46 
mitochondrial miRNAs (mitomiRs) were predicted to bind to mitochondrial genome-encoded 
mRNAs with over half of the mitomiRs potentially regulating multiple mitochondrial genome-
encoded mRNAs. Further, microarray analyses of mitomiRs in cardiac mitochondrial 
subpopulations revealed dramatically altered and reciprocal patterns. Of the identified mitomiRs, 
mitomiR-378 displayed a reciprocal response in cardiac mitochondrial subpopulations with over 
20 fold increase in diabetic IFM. Examination and assessment of potential roles of mitomiR-378 
during type 1 diabetic insult were performed in our studies. Dramatic increase of mitomiR-378 
only in the IFM might be of particular relevance specifically in the IFM and contribute in its 
functionality. Indeed, ATP6, a mitochondrial genome target mRNA for mitomiR-378 is 
decreased in conjunction with ATP synthase activity thus suggesting a regulatory role for 
mitomiR-378 in type 1 diabetic IFM. 
 In an effort to better understand the regulatory role of mitomiR-378, we conducted both 
in vitro and in vivo experiments. Overexpression of miR-378 in a cardiac HL-1 cell line resulted 
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in decreased ATP6 protein content and ATP synthase activity. Assessment of miR-378 levels in 
mitochondria isolated from over expressed cell lines revealed a 22 fold increase in miR-378 
levels, confirming regulatory role of the miRNA. Multiple intra-peritoneal injections of an LNA-
linked antagomiR targeting miR-378 (LNA-miR-378) were utilized to assess the in vivo efficacy 
of miR-378. Indeed, down-regulation of ATP6 protein content, ATP synthase activity, and 
improved cardiac pump function were observed with LNA-miR-378. These findings suggest the 
potential role of enhanced mitomiR-378 for regulating mitochondrial genome-encoded ATP6 
content and contributing to bioenergetics deficit observed during type 1 diabetes mellitus. 
Regulatory role of miR-378 in cardiac remodeling and cell survival have been reported by other 
studies as well (25).  
 Post-transcriptional gene regulation by miRNA requires binding to complementary sites 
on the target mRNA. Further, association of bound miRNA and mRNA with RNA-induced 
silencing complex (RISC) is crucial for translational regulation of mRNA (2). Recruitment of 
RISC components, including argonaute-2 (Ago2) and fragile X mental retardation-related protein 
1 (FXR1) has been shown to influence translation (50). We next sought to examine and identify 
the presence of RISC components in the mitochondrion. Western blot analyses revealed 
differential expression of Ago2 and FXR1 in the mitochondrion relative to control with the 
response being subpopulation-specific in nature. Significant decrease in Ago2 was observed in 
both subpopulations with diabetic insult whereas FXR1 was decreased in SSM but increased in 
IFM subpopulations. These findings confirm the presence of RISC components in the 
mitochondrion and suggest the potential of RISC formation in the mitochondrion. 
 Cross linked immunoprecipitation (CLIP) experimental approach have been previously 
utilized to identify direct miRNA/mRNA/protein interactions to confirm direct association 
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between nucleotide and protein components (11). Further, direct interaction of these molecules is 
an absolute requirement to facilitate a functional cytoplasmic regulatory complex (10, 11, 53). 
Using similar experimental technique coupled with next generation sequencing we determined 
binding maps and sequence motifs of miRNA-378 binding directly to the coding region of ATp6 
mRNA. Our findings indicate that mitomiR-378 targets ATP6 coding region to control its 
translational activity. Further, translational regulation of ATP6 required the presence of both 
Ago2 and FXR1 presence in the RISC as observed in diabetic IFM. Absence of mitomiR-378 or 
limiting content of Ago2 as observed in diabetic SSM doesn’t result in translational regulation.  
In summary, chapter 4 of this dissertation reports translational regulation of 
mitochondrially-encoded proteins by mitomiRs during type 1 diabetic insult. This regulatory 
mechanism requires the presence of a specific mitochondrial RISC component. These findings 
bring forth an interesting mechanism that can be utilized to study translational regulation of the 
mitochondrial-encoded genome in different pathological insult. 
Findings from these studies clearly implicate mitochondrial structural abnormalities as a 
crucial contributor to mitochondrial dysfunction observed during type 1 diabetic insult. Down-
regulation of mitofilin protein content in type 1 diabetic IFM not only resulted in its decreased 
association with previously reported and novel proteins (Chapter 2), it resulted in altered cristae 
morphology, and decreased internal complexity of the mitochondrion (Chapter 3). Further, 
overexpression of mitofilin maintained cristae structure and functions of mitochondria leading to 
preservation of cardiac contractile function (Chapter 3). Observed proteomic and functional 
dysregulation in ETC complexes of diabetic IFM led us to examine the translational regulation of 
mitochondrial-encoded proteins by mitomiRs (Chapter 4). Mitochondrially-encoded proteins 
constitute ETC complexes I, III, IV, and V. Indeed, antagomir treatment targeted at miR-378 led 
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to preservation of ATP6 protein, ATP synthase activity, and cardiac pump function during type 1 
diabetic insult (Chapter 4). 
The overall summary of this dissertation examines influences of mitochondrial structural 
abnormalities as well as role of mitochondrial miRNAs in regulation of mitochondrial genome 
and hence functions. Examination of ETC and OXPHOS defects in cardiac mitochondria during 
T1DM were assessed by examining two different aspects (Figure 5.1).  Down-regulation of 
mitofilin in diabetic IFM results towards a decreased trend in association of mitofilin with 
CHCHD3 that forms the MICOS complex which has been shown to regulate IMM architecture, 
integrity and mitochondrial cristae morphology. Decreased association of mitofilin could results 
in damaged mitochondrial morphology, decreased internal capacity as well as decreased in ETC 
an OXPHOS activities that are housed in the cristae of the IMM. Decreased ETC and OXPHOS 
machinery results in increased ROS production as observed in type 1 diabetic IFM. Increased 
oxidative milieu causes posttranslational modifications including oxidations and deamidations. 
Increased ROS generation from the ETC complexes was attenuated by mitofilin overexpression 
with preservation of mitochondrial structure and function. One other potential mechanism 
resulting in decreased ETC and OXPHOS machinery could be due to decrements in protein 
constituents of the ETC complexes. Nuclear encoded proteins and their regulation by miRNAs 
have been previously reported. However, translational regulation of mitochondrially-encoded 
proteins that constitute ETC and OXPHOS machinery by miRNAs residing in the mitochondrion 
has not been studied. Examination of this facet of the mitochondrion led to examination of 
miRNAs in the mitochondrion termed as mitomiRs. Indeed, dysregulation of mitomiRs in a 
reciprocal pattern were observed in cardiac SSM and IFM subpopulations. Further, both in vitro 
and in vivo experiments examining miR-378 led to preservation of ATP6 protein and 
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functionality. Studies directed at restoring mitochondrial structure as well as targeted at 
mitomiR-378 regulation led to restoration of mitochondrial function and ultimately cardiac 
contractile function.  
 
 
Figure 5.1: Schematic representation of mitochondrial dysfunction assessment through 
examination of mitochondrial structure and mitochondrial miRNAs. 
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     FUTURE DIRECTIONS  
The findings of this dissertation highlight the importance of mitochondrial structure, 
morphology, architecture and role of IMM for proper mitochondrial functioning. Specifically, as 
it relates to mitochondrial structure, the role of mitofilin, a mitochondrial structural protein 
located at the IMM has been well studied and examined for its role in mitochondrial structure 
and functioning during T1DM. Moreover, overexpression of mitofilin, through a novel 
transgenic mouse model created in our laboratory, led to restoration of mitochondrial structure, 
function and cardiac function during T1DM. Also this dissertation has well established the role 
of miRNAs in regulating mitochondrial genome encoded proteins and their functions. 
Furthermore, utilization of antagomir delivery to regulate miR-378 led to restoration of 
mitochondrial function and ultimately cardiac pump function during T1DM. Taken together 
these findings warrant the assessment of mitofilin as a therapeutic intervention for patients with 
T1DM. This dissertation not only identifies mitofilin as a novel therapeutic target, but also 
presents ways that can be utilized to regulate mitofilin protein levels through miRNAs by 
antagomir treatment. Future studies centered at regulating mitofilin through antagomir delivery 
approach provide a novel platform for T1DM therapeutics. 
 One way to regulate mitofilin levels in the T1DM cardiac mitochondria would be to 
deliver antagomir that are directed towards binding with miRNAs that regulate mitofilin. In 
doing so, potential downregulation of mitofilin content by miRNAs would be attenuated by 
inhibition through antagomirs. miRNAs are 22 nucleotides small non-coding evolutionarily 
conserved RNAs that regulate mRNAs (4, 5, 7). miRNAs regulate mRNA function by binding to 
an 7 base pair complementary seeding region and can either degrade mRNAs or inhibit their 
translation (10, 11). Antagomirs are anti-sense oligonucelotide sequences conjugated with 
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cholesterol that can be systemically delivered by injection. They have a high binding affinity to 
RNA and DNA and have sustained miRNA blockade (13, 15). Further, utilization of antagomirs 
for miRNA blockade is currently under phase II clinical trials for a number of different 
pathologies (14, 24). Hence, utilizing antagomirs to inhibit miRNAs regulating mitofilin in the 
future would provide an ideal therapeutics for improving mitochondrial structure, function and 
ultimately cardiac function in T1DM. 
 Antagomirs currently utilized for miRNA blockade are systemically delivered and are not 
targeted towards a specific organelle. Presence of a mitochondrial targeting sequence in an alpha 
myosin heavy chain driven construct utilized to deliver antagomir would allow its import 
specifically inside the cardiac mitochondrion. Proper import of the antagomir specifically into 
the cardiac mitochondrion would further increase its mitomiR blockade and provide efficient 
therapeutics targeted towards cardiac mitochondrial proteins. Mitochondrial targeting sequence 
are particular amino acid sequences that are essential for proper import of pre-proteins in the 
mitochondria (18, 20). In summary, future research endeavors geared towards delivery of 
antagomirs targeted to the cardiac mitochondria in order to block miRNAs regulating mitofilin 
would provide an ideal therapeutics for T1DM. Restoration of mitochondrial structure through 
mitofilin via antagomir approach  in type 1 diabetic heart would improve mitochondrial function 
and ultimately cardiac function, one of the key findings of this dissertation. 
 Another potential way of site specific antagomir delivery would be the utilization of 
catheters. A catheter system, comprised of distensible penetrating element with a distally located 
chamber for holding therapeutic agent, is used to inject large molecules into the body. This 
delivery system can be tissue specific including the heart, pancreas, stomach, esophagus, large 
intestine and other tissues thus allowing delivery of drugs to the sites where there are more 
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needed (2). Thus, injection of antagomirs to block miRNAs regulating mitofilin utilizing the 
catheter system would also provide an ideal therapeutics for T1DM. 
 Decrements in content of mitofilin have been reported in many human diseases including 
Down’s syndrome (3, 16), Parkinson’s disease (21, 22), epilepsy (6, 17) and neurodegeneration 
(25, 26). With mitofilin providing cardioprotection in type 1 diabetic heart through maintenance 
of mitochondrial morphology and function, it warrants future studies designed to investigate the 
role of mitofilin in the above mentioned pathologies. Further, it invites other investigators to 
examine the role of mitofilin in pathologies like aging (12) where the IFM subpopulation is 
predominantly affected.  
 Mitofilin is a critical component of the MICOS complex comprised of proteins like 
Mio10, Aim5, CHCHD3, and MOMA-1 where it functions as a central organizer of 
mitochondrial architecture and cristae morphology (1, 8, 9, 19, 23, 27).  Studies focused on 
assessing these other proteins of the MICOS complex in diabetic cardiomyopathy as well as 
other pathologies with mitochondrial morphological abnormalities will allow a better 
understanding of the role of mitofilin and the MICOS complex as a whole thus further 
strengthening MICOS and its components as potential therapeutic targets in many mitochondrial 
pathologies.  
 Presence of microRNAs in the mitochondrion provides a novel platform to investigate 
their role in diabetic cardiomyopathy. As reported in chapter 4 of this dissertation miRNAs 
alterations could potentially regulate mitochondrial genome encoded proteins in type 1 diabetic 
heart. Similar studies centered towards assessment of mitochondrial miRNAs in type 2 diabetic 
hearts should be undertaken. Findings from these studies will provide a comprehensive as well as 
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common list of miRNAs that contribute towards the pathogenesis of DM. Not only will this 
allow pinpointing common miRNAs contributing towards both type 1 and type 2 DM, it will 
provide other investigators a novel research area and focus. Findings of chapter 4 with respect to 
the role miR-378 in regulating ATP6 should initiate other key studies focusing on other 
mitochondrial as well as nuclear proteins.  
 In summary, findings derived from the studies in this dissertation has the potential to 
initiate novel research and projects geared towards examining the role of mitofilin and miRNAs  
in proper functioning of mitochondria in various physiological and pathological conditions. Also, 
the reported findings can be highly impactful within the scientific community as it presents novel 
avenues for therapeutic targets in T1DM. 
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